Coronavirus disease 2019 (COVID-19)
References
Reference articles
1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr;5(4):536-44.Full text Abstract
2. World Health Organization. Tracking SARS-CoV-2 variants. 2022 [internet publication].Full text
3. UK Health Security Agency. Investigation of SARS-CoV-2 variants: technical briefing documents on novel SARS-CoV-2 variants. 2022 [internet publication].Full text
4. Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. 2022 [internet publication].Full text
5. Nyberg T, Twohig KA, Harris RJ, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ. 2021 Jun 15;373:n1412.Full text Abstract
6. Bager P, Wohlfahrt J, Fonager J, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis. 2021 Nov;21(11):1507-17.Full text Abstract
7. Patone M, Thomas K, Hatch R, et al. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. Lancet Infect Dis. 2021 Nov;21(11):1518-28.Full text Abstract
8. Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021 May;6(5):e335-45.Full text Abstract
9. Butt AA, Dargham SR, Chemaitelly H, et al. Severity of illness in persons infected with the SARS-CoV-2 Delta variant vs Beta variant in Qatar. JAMA Intern Med. 2022 Feb 1;182(2):197-205.Full text Abstract
10. Mallapaty S. Where did Omicron come from? Three key theories. Nature. 2022 Feb;602(7895):26-8.Full text Abstract
11. World Health Organization. Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member states. January 21 2022 [internet publication].Full text
12. World Health Organization. Statement on Omicron sublineage BA.2. 2022 [internet publication].Full text
13. World Health Organization. Severity of disease associated with Omicron variant as compared with Delta variant in hospitalized patients with suspected or confirmed SARS-CoV-2 infection. 2022 [internet publication].Full text
14. Kozlov M. Omicron’s feeble attack on the lungs could make it less dangerous. 2022 [internet publication].Full text
15. Higdon MM, Baidya A, Walter KK, et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. Lancet Infect Dis. 2022 Jun 22 [Epub ahead of print].Full text Abstract
16. Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022 Jun 22 [Epub ahead of print].Full text Abstract
17. Kozlov M. Omicron overpowers key COVID antibody treatments in early tests. Nature. 2021 Dec 21 [Epub ahead of print].Full text Abstract
18. Roskosky M, Borah BF, DeJonge PM, et al. Notes from the field: SARS-CoV-2 omicron variant infection in 10 persons within 90 days of previous SARS-CoV-2 Delta variant infection - four states, October 2021 – January 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 8;71(14):524-6.Full text Abstract
19. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. 2022 [internet publication].Full text
20. Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021 Jan 11;11(1):e044640.Full text Abstract
21. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021 Feb 1;175(2):143-56.Full text Abstract
22. World Health Organization. COVID-19 disease in children and adolescents: scientific brief, 29 September 2021. 2021 [internet publication].Full text
23. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020 Sep 1;174(9):882-9.Full text Abstract
24. Somekh I, Stein M, Karakis I, et al. Characteristics of SARS-CoV-2 infections in Israeli children during the circulation of different SARS-CoV-2 variants. JAMA Netw Open. 2021 Sep 1;4(9):e2124343.Full text Abstract
25. Chen F, Tian Y, Zhang L, et al. The role of children in household transmission of COVID-19: a systematic review and meta-analysis. Int J Infect Dis. 2022 May 11;122:266-75.Full text Abstract
26. Chou R, Dana T, Buckley DI, et al. Epidemiology of and risk factors for coronavirus infection in health care workers: a living rapid review. Ann Intern Med. 2020 Jul 21;173(2):120-36.Full text Abstract
27. Chou R, Dana T, Buckley DI, et al. Update alert 10: epidemiology of and risk factors for coronavirus infection in health care workers. Ann Intern Med. 2021 Nov 16;M21-4294.Full text Abstract
28. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020 May 5;133(9):1015-24.Full text Abstract
29. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-33.Full text Abstract
30. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-74.Full text Abstract
31. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506.Full text Abstract
32. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13.Full text Abstract
33. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-207.Full text Abstract
34. Roberts DL, Rossman JS, Jarić I. Dating first cases of COVID-19. PLoS Pathog. 2021 Jun;17(6):e1009620.Full text Abstract
35. World Health Organization. WHO-convened global study of the origins of SARS-CoV-2. 2020 [internet publication].Full text
36. Meyerowitz EA, Richterman A, Gandhi RT, et al. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2021 Jan;174(1):69-79.Full text Abstract
37. World Health Organization. Mask use in the context of COVID-19: interim guidance. 2020 [internet publication].Full text
38. Duval D, Palmer JC, Tudge I, et al. Long distance airborne transmission of SARS-CoV-2: rapid systematic review. BMJ. 2022 Jun 29;377:e068743.Full text Abstract
39. Birgand G, Peiffer-Smadja N, Fournier S, et al. Assessment of air contamination by SARS-CoV-2 in hospital settings. JAMA Netw Open. 2020 Dec 1;3(12):e2033232.Full text Abstract
40. Razani N, Malekinejad M, Rutherford GW. Clarification regarding "Outdoor transmission of SARS-CoV-2 and other respiratory viruses: a systematic review". J Infect Dis. 2021 Sep 1;224(5):925-6.Full text Abstract
41. Goldstein KM, Ghadimi K, Mystakelis H, et al. Risk of transmitting coronavirus disease 2019 during nebulizer treatment: a systematic review. J Aerosol Med Pulm Drug Deliv. 2021 Jun;34(3):155-70.Full text Abstract
42. Onakpoya IJ, Heneghan CJ, Spencer EA, et al. SARS-CoV-2 and the role of fomite transmission: a systematic review. F1000Res. 2021 Mar 24;10:233.Full text Abstract
43. Trypsteen W, Van Cleemput J, Snippenberg WV, et al. On the whereabouts of SARS-CoV-2 in the human body: a systematic review. PLoS Pathog. 2020 Oct;16(10):e1009037.Full text Abstract
44. Martinez-Reviejo R, Tejada S, Cipriano A, et al. Solid organ transplantation from donors with recent or current SARS-CoV-2 infection: a systematic review. Anaesth Crit Care Pain Med. 2022 May 6;41(4):101098.Full text Abstract
45. World Health Organization. Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2: scientific brief. 2021 [internet publication].Full text
46. Zhu F, Zozaya C, Zhou Q, et al. SARS-CoV-2 genome and antibodies in breastmilk: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2021 Sep;106(5):514-21.Full text Abstract
47. Zhou Q, Gao Y, Wang X, et al. Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):629.Full text Abstract
48. Centre for Evidence-Based Medicine; Heneghan C, Howdon D, Oke J, et al. The ongoing problem of UK hospital acquired infections. 2020 [internet publication].Full text
49. Read JM, Green CA, Harrison EM, et al. Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave. Lancet. 2021 Sep 18;398(10305):1037-8.Full text Abstract
50. Rhee C, Baker M, Vaidya V, et al. Incidence of nosocomial COVID-19 in patients hospitalized at a large US academic medical center. JAMA Netw Open. 2020 Sep 1;3(9):e2020498.Full text Abstract
51. Subramaniam A, Lim ZJ, Ponnapa Reddy M, et al. SARS-CoV-2 transmission risk to healthcare workers performing tracheostomies: a systematic review. ANZ J Surg. 2022 Jun 2 [Epub ahead of print].Full text Abstract
52. Ge Y, Martinez L, Sun S, et al. COVID-19 transmission dynamics among close contacts of index patients with COVID-19: a population-based cohort study in Zhejiang Province, China. JAMA Intern Med. 2021 Oct 1;181(10):1343-50.Full text Abstract
53. Johnston C, Hughes H, Lingard S, et al. Immunity and infectivity in covid-19. BMJ. 2022 Jul 1;378:e061402.Full text Abstract
54. Jefferson T, Spencer EA, Brassey J, et al. Transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from pre and asymptomatic infected individuals: a systematic review. Clin Microbiol Infect. 2022 Feb;28(2):178-89.Full text Abstract
55. Jefferson T, Spencer EA, Onakpoya IJ, et al. Transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from pre and asymptomatic infected individuals: a systematic review update. Clin Microbiol Infect. 2022 Jun 28 [Epub ahead of print].Full text Abstract
56. Qiu X, Nergiz AI, Maraolo AE, et al. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission: a living systematic review. Clin Microbiol Infect. 2021 Apr;27(4):511-9.Full text Abstract
57. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020 Mar 5;382(10):970-71.Full text Abstract
58. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 May;63(5):706-11.Full text Abstract
59. Luo SH, Liu W, Liu ZJ, et al. A confirmed asymptomatic carrier of 2019 novel coronavirus (SARS-CoV-2). Chin Med J (Engl). 2020 May 5;133(9):1123-5.Full text Abstract
60. Lu S, Lin J, Zhang Z, et al. Alert for non-respiratory symptoms of coronavirus disease 2019 patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients. J Med Virol. 2021 Jan;93(1):518-21.Full text Abstract
61. Li C, Ji F, Wang L, et al. Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China. Emerg Infect Dis. 2020 Mar 31;26(7).Full text Abstract
62. Liu J, Huang J, Xiang D. Large SARS-CoV-2 outbreak caused by asymptomatic traveler, China. Emerg Infect Dis. 2020 Jun 30;29(9).Full text Abstract
63. Jiang XL, Zhang XL, Zhao XN, et al. Transmission potential of asymptomatic and paucisymptomatic severe acute respiratory syndrome coronavirus 2 infections: a three-family cluster study in China. 2020 Jun 11;221(12):1948-52.Full text Abstract
64. Gao M, Yang L, Chen X, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. Respir Med. 2020 May 13;169:106026.Full text Abstract
65. Chen F, Fu D, Yang Q, et al. Low transmission risk of 9 asymptomatic carriers tested positive for both SARS-CoV-2 nucleic acid and serum IgG. J Infect. 2020 Sep;81(3):452-82.Full text Abstract
66. Danis K, Epaulard O, Bénet T, et al. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. Clin Infect Dis. 2020 Jul 28;71(15):825-32.Full text Abstract
67. Cao S, Gan Y, Wang C, et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Nat Commun. 2020 Nov 20;11(1):5917.Full text Abstract
68. Buitrago-Garcia D, Ipekci AM, Heron L, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: update of a living systematic review and meta-analysis. PLoS Med. 2022 May;19(5):e1003987.Full text Abstract
69. Chen X, Huang Z, Wang J, et al. Ratio of asymptomatic COVID-19 cases among ascertained SARS-CoV-2 infections in different regions and population groups in 2020: a systematic review and meta-analysis including 130 123 infections from 241 studies. BMJ Open. 2021 Dec 7;11(12):e049752.Full text Abstract
70. Stubblefield WB, Talbot HK, Feldstein L, et al. Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for patients with COVID-19: Nashville, Tennessee. Clin Infect Dis. 2021 May 4;72(9):1645-8.Full text Abstract
71. Althouse BM, Wenger EA, Miller JC, et al. Superspreading events in the transmission dynamics of SARS-CoV-2: opportunities for interventions and control. PLoS Biol. 2020 Nov 12;18(11):e3000897.Full text Abstract
72. Lopez AS, Hill M, Antezano J, et al. Transmission dynamics of COVID-19 outbreaks associated with child care facilities: Salt Lake City, Utah, April–July 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1319-23.Full text Abstract
73. Wilson E, Donovan CV, Campbell M, et al. Multiple COVID-19 clusters on a university campus: North Carolina, August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 2;69(39):1416-8.Full text Abstract
74. Xu W, Li X, Dong Y, et al. SARS-CoV-2 transmission in schools: an updated living systematic review (version 2; November 2020). J Glob Health. 2021 Jun 10;11:10004.Full text Abstract
75. Caini S, Martinoli C, La Vecchia C, et al. SARS-CoV-2 circulation in the school setting: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022 Apr 28;19(9):5384.Full text Abstract
76. Karki SJ, Joachim A, Heinsohn T, et al. Risk of infection and contribution to transmission of SARS-CoV-2 in school staff: a systematic review. BMJ Open. 2021 Nov 3;11(11):e052690.Full text Abstract
77. Young BC, Eyre DW, Kendrick S, et al. Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial. Lancet. 2021 Oct 2;398(10307):1217-29.Full text Abstract
78. Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis. 2011 Aug;15(8):e510-3.Full text Abstract
79. World Health Organization. Clinical management of COVID-19: living guideline, 23 June 2022. 2022 [internet publication].Full text
80. Xin H, Wong JY, Murphy C, et al. The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Clin Infect Dis. 2021 Dec 16;73(12):2344-52.Full text Abstract
81. Li B, Zhang S, Zhang R, et al. Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis. Front Pediatr. 2020 Nov 2;8:591132.Full text Abstract
82. Ahammed T, Anjum A, Rahman MM, et al. Estimation of novel coronavirus (COVID-19) reproduction number and case fatality rate: a systematic review and meta-analysis. Health Sci Rep. 2021 Jun;4(2):e274.Full text Abstract
83. Centers for Disease Control and Prevention. COVID-19 pandemic planning scenarios. 2021 [internet publication].Full text
84. Hussein M, Toraih E, Elshazli R, et al. Meta-analysis on serial intervals and reproductive rates for SARS-CoV-2. Ann Surg. 2021 Mar 1;273(3):416-23. Abstract
85. Pung R, Mak TM, Kucharski AJ, et al; CMMID COVID-19 working group. Serial intervals in SARS-CoV-2 B.1.617.2 variant cases. Lancet. 2021 Sep 4;398(10303):837-8.Full text Abstract
86. Tian T, Huo X. Secondary attack rates of COVID-19 in diverse contact settings, a meta-analysis. J Infect Dev Ctries. 2020 Dec 31;14(12):1361-7.Full text Abstract
87. Thompson HA, Mousa A, Dighe A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) setting-specific transmission rates: a systematic review and meta-analysis. Clin Infect Dis. 2021 Aug 2;73(3):e754-64.Full text Abstract
88. Madewell ZJ, Yang Y, Longini IM Jr, et al. Factors associated with household transmission of SARS-CoV-2: an updated systematic review and meta-analysis. JAMA Netw Open. 2021 Aug 2;4(8):e2122240.Full text Abstract
89. Silverberg SL, Zhang BY, Li SNJ, et al. Child transmission of SARS-CoV-2: a systematic review and meta-analysis. BMC Pediatr. 2022 Apr 2;22(1):172.Full text Abstract
90. Madewell ZJ, Yang Y, Longini IM Jr, et al. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis. JAMA Netw Open. 2022 Apr 1;5(4):e229317.Full text Abstract
91. Kunasekaran M, Quigley A, Rahman B, et al. Factors associated with SARS-CoV-2 attack rates in aged care: a meta-analysis. Open Forum Infect Dis. 2022 Mar;9(3):ofac033.Full text Abstract
92. Viner R, Waddington C, Mytton O, et al. Transmission of SARS-CoV-2 by children and young people in households and schools: a meta-analysis of population-based and contact-tracing studies. J Infect. 2022 Mar;84(3):361-82.Full text Abstract
93. Jørgensen SB, Nygård K, Kacelnik O, et al. Secondary attack rates for Omicron and Delta variants of SARS-CoV-2 in Norwegian households. JAMA. 2022 Apr 26;327(16):1610-1.Full text Abstract
94. Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021 May;21(5):629-36.Full text Abstract
95. Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021 Jan;2(1):e13-22.Full text Abstract
96. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020 Dec 24;383(26):2586-8.Full text Abstract
97. Stokel-Walker C. How long does SARS-CoV-2 stay in the body? BMJ. 2022 Jun 28;377:o1555.Full text Abstract
98. Widders A, Broom A, Broom J. SARS-CoV-2: the viral shedding vs infectivity dilemma. Infect Dis Health. 2020 Aug;25(3):210-5.Full text Abstract
99. Jung J, Kim JY, Park H, et al. Transmission and infectious SARS-CoV-2 shedding kinetics in vaccinated and unvaccinated individuals. JAMA Netw Open. 2022 May 2;5(5):e2213606.Full text Abstract
100. Killingley B, Mann A, Kalinova M, et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge [preprint]. 2022 [internet publication].Full text
101. Menezes RG, Rizwan T, Saad Ali S, et al. Postmortem findings in COVID-19 fatalities: a systematic review of current evidence. Leg Med (Tokyo). 2021 Dec 7;54:102001.Full text Abstract
102. Lancet Respiratory Medicine. COVID-19: pathophysiology of acute disease. 2021 [internet publication].Full text
103. Peiris S, Mesa H, Aysola A, et al. Pathological findings in organs and tissues of patients with COVID-19: a systematic review. PLoS One. 2021;16(4):e0250708.Full text Abstract
104. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271-80.Full text Abstract
105. Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020 Feb 17;525(1):135-40.Full text Abstract
106. Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020 Feb 10;176:104742. Abstract
107. Piplani S, Singh PK, Winkler DA, et al. In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. Sci Rep. 2021 Jun 24;11(1):13063.Full text Abstract
108. Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021 Apr 30;128(9):1323-6.Full text Abstract
109. Suzuki YJ, Gychka SG. SARS-CoV-2 spike protein elicits cell signaling in human host cells: implications for possible consequences of COVID-19 vaccines. Vaccines (Basel). 2021 Jan 11;9(1):36.Full text Abstract
110. Ramanathan M, Ferguson ID, Miao W, et al. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect Dis. 2021 Aug;21(8):1070.Full text Abstract
111. Sofizan NMFBN, Rahman AFBA, Soon LP, et al. Autopsy findings in COVID-19 infection-related death: a systematic review. Egypt J Forensic Sci. 2022;12(1):22.Full text Abstract
112. Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021 Jun;9(6):622-42.Full text Abstract
113. Milross L, Majo J, Cooper N, et al. Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19. Lancet Respir Med. 2021 Dec 3;10(1):95-106.Full text Abstract
114. Stenton S, McPartland J, Shukla R, et al. SARS-COV2 placentitis and pregnancy outcome: a multicentre experience during the Alpha and early Delta waves of coronavirus pandemic in England. EClinicalMedicine. 2022 May;47:101389.Full text Abstract
115. Severe Covid-19 GWAS Group; Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020 Oct 15;383(16):1522-34.Full text Abstract
116. Downes DJ, Cross AR, Hua P, et al. Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus. Nat Genet. 2021 Nov;53(11):1606-15.Full text Abstract
117. Saengsiwaritt W, Jittikoon J, Chaikledkaew U, et al. Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: a systematic review with meta-analysis. Rev Med Virol. 2022 Jan 8;:e2323.Full text Abstract
118. Kousathanas A, Pairo-Castineira E, Rawlik K, et al. Whole genome sequencing reveals host factors underlying critical Covid-19. Nature. 2022 Mar 7 [Epub ahead of print].Full text Abstract
119. World Health Organization. Public health surveillance for COVID-19: interim guidance. 2022 [internet publication].Full text
120. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): contact tracing. 2022 [internet publication].Full text
121. Romero Starke K, Reissig D, Petereit-Haack G, et al. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021 Dec;6(12):e006434.Full text Abstract
122. Centers for Disease Control and Prevention. Risk for COVID-19 infection, hospitalization, and death by age group. 2022 [internet publication].Full text
123. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020 Sep;20(9):1034-42.Full text Abstract
124. Bonanad C, García-Blas S, Tarazona-Santabalbina F, et al. The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. J Am Med Dir Assoc. 2020 Jul;21(7):915-8.Full text Abstract
125. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19): United States, February 12 - March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-6.Full text Abstract
126. Damayanthi HDWT, Prabani KIP. Nutritional determinants and COVID-19 outcomes of older patients with COVID-19: a systematic review. Arch Gerontol Geriatr. 2021 Mar 31;95:104411.Full text Abstract
127. Pijls BG, Jolani S, Atherley A, et al. Temporal trends of sex differences for COVID-19 infection, hospitalisation, severe disease, intensive care unit (ICU) admission and death: a meta-analysis of 229 studies covering over 10M patients. F1000Res. 2022 Jan 5;11:5.Full text Abstract
128. Abate BB, Kassie AM, Kassaw MW, et al. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020 Oct 6;10(10):e040129.Full text Abstract
129. Baldassarri M, Picchiotti N, Fava F, et al. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. EBioMedicine. 2021 Feb 26;65:103246.Full text Abstract
130. Hu H, Pan H, Li R, et al. Increased circulating cytokines have a role in COVID-19 severity and death with a more pronounced effect in males: a systematic review and meta-analysis. Front Pharmacol. 2022 Feb 14;13:802228.Full text Abstract
131. Sze S, Pan D, Nevill CR, et al. Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2020 Dec;29:100630.Full text Abstract
132. Mackey K, Ayers CK, Kondo KK, et al. Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic review. Ann Intern Med. 2021 Mar;174(3):362-73.Full text Abstract
133. Khanijahani A, Iezadi S, Gholipour K, et al. A systematic review of racial/ethnic and socioeconomic disparities in COVID-19. Int J Equity Health. 2021 Nov 24;20(1):248.Full text Abstract
134. Mathur R, Rentsch CT, Morton CE, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021 May 8;397(10286):1711-24.Full text Abstract
135. Saatci D, Ranger TA, Garriga C, et al. Association between race and COVID-19 outcomes among 2.6 million children in England. JAMA Pediatr. 2021 Sep 1;175(9):928-38.Full text Abstract
136. Acosta AM, Garg S, Pham H, et al. Racial and ethnic disparities in rates of COVID-19–associated hospitalization, intensive care unit admission, and in-hospital death in the United States from March 2020 to February 2021. JAMA Netw Open. 2021 Oct 1;4(10):e2130479.Full text Abstract
137. Magesh S, John D, Li WT, et al. Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis. JAMA Netw Open. 2021 Nov 1;4(11):e2134147.Full text Abstract
138. Agyemang C, Richters A, Jolani S, et al. Ethnic minority status as social determinant for COVID-19 infection, hospitalisation, severity, ICU admission and deaths in the early phase of the pandemic: a meta-analysis. BMJ Glob Health. 2021 Nov;6(11):e007433.Full text Abstract
139. Raharja A, Tamara A, Kok LT. Association between ethnicity and severe COVID-19 disease: a systematic review and meta-analysis. J Racial Ethn Health Disparities. 2021 Sep 1;175(9):928-38.Full text Abstract
140. McMichael TM, Clark S, Pogosjans S, et al. COVID-19 in a long-term care facility: King County, Washington, February 27 – March 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):339-42.Full text Abstract
141. Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19: information for healthcare providers. 2022 [internet publication].Full text
142. Burki T. England and Wales see 20 000 excess deaths in care homes. Lancet. 2020 May 23;395(10237):1602.Full text Abstract
143. Graham N, Junghans C, Downes R, et al. SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes. J Infect. 2020 Sep;81(3):411-9.Full text Abstract
144. Panagiotou OA, Kosar CM, White EM, et al. Risk factors associated with all-cause 30-day mortality in nursing home residents with COVID-19. JAMA Intern Med. 2021 Apr 1;181(4):439-48.Full text Abstract
145. Liu H, Chen S, Liu M, et al. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis. Aging Dis. 2020 May 9;11(3):668-78.Full text Abstract
146. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985.Full text Abstract
147. Norris T, Razieh C, Zaccardi F, et al. Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. Heart. 2021 Dec 15 [Epub ahead of print].Full text Abstract
148. Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020 – March 2021. Prev Chronic Dis. 2021 Jul 1;18:E66.Full text Abstract
149. Adams ML, Katz DL, Grandpre J. Updated estimates of chronic conditions affecting risk for complications from coronavirus disease, United States. Emerg Infect Dis. 2020 Jul 3;26(9).Full text Abstract
150. Adams SH, Park MJ, Schaub JP, et al. Medical vulnerability of young adults to severe COVID-19 illness: data from the National Health Interview Survey. J Adolesc Health. 2020 Jul 9;67(3):362-8.Full text Abstract
151. Ng WH, Tipih T, Makoah NA, et al. Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis. mBio. 2021 Feb 9;12(1):e03647-20.Full text Abstract
152. Zuin M, Rigatelli G, Bilato C, et al. Prognostic role of metabolic syndrome in COVID-19 patients: a systematic review meta-analysis. Viruses. 2021 Sep 27;13(10):1938.Full text Abstract
153. Choi JH, Choi SH, Yun KW. Risk factors for severe COVID-19 in children: a systematic review and meta-analysis. J Korean Med Sci. 2022 Feb 7;37(5):e35.Full text Abstract
154. Cai Z, Yang Y, Zhang J. Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis. BMC Public Health. 2021 Aug 4;21(1):1505.Full text Abstract
155. World Obesity Federation. COVID-19 and obesity: the 2021 atlas. 2021 [internet publication].Full text
156. Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-9.Full text Abstract
157. Kompaniyets L, Goodman AB, Belay B, et al. Body mass index and risk for COVID-19–related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death: United States, March – December 2020. MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):355-61.Full text Abstract
158. Xu J, Xiao W, Liang X, et al. A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity. BMC Public Health. 2021 Aug 11;21(1):1533.Full text Abstract
159. Ehwerhemuepha L, Roth B, Patel AK, et al. Association of congenital and acquired cardiovascular conditions with COVID-19 severity among pediatric patients in the US. JAMA Netw Open. 2022 May 2;5(5):e2211967.Full text Abstract
160. Hessami A, Shamshirian A, Heydari K, et al. Cardiovascular diseases burden in COVID-19: systematic review and meta-analysis. Am J Emerg Med. 2021 Aug;46:382-91.Full text Abstract
161. Zuin M, Rigatelli G, Bilato C, et al. Pre-existing atrial fibrillation is associated with increased mortality in COVID-19 Patients. J Interv Card Electrophysiol. 2021 Nov;62(2):231-8.Full text Abstract
162. Szarpak L, Filipiak KJ, Skwarek A, et al. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19: a systematic review and meta-analysis. Cardiol J. 2022;29(1):33-43. Abstract
163. Liang C, Zhang W, Li S, et al. Coronary heart disease and COVID-19: a meta-analysis. Med Clin (Engl Ed). 2021 Jun 11;156(11):547-54.Full text Abstract
164. Li Y, Pei H, Zhou C, et al. Myocardial injury predicts risk of short-term all-cause mortality in patients with COVID-19: a dose-response meta-analysis. Front Cardiovasc Med. 2022 May 2;9:850447.Full text Abstract
165. Zuin M, Rigatelli G, Bilato MJ, et al. Prevalence of pre-existing peripheral artery disease in COVID-19 patients and relative mortality risk: systematic review and meta-analysis. Vascular. 2022 May 20 [Epub ahead of print].Full text Abstract
166. Bae S, Kim SR, Kim MN, et al. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021 Mar;107(5):373-80.Full text Abstract
167. Pellicori P, Doolub G, Wong CM, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev. 2021 Mar 11;(3):CD013879.Full text Abstract
168. Hartmann-Boyce J, Rees K, Perring JC, et al. Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews. Diabetes Care. 2021 Dec;44(12):2790-811.Full text Abstract
169. Kastora S, Patel M, Carter B, et al. Impact of diabetes on COVID-19 mortality and hospital outcomes from a global perspective: an umbrella systematic review and meta-analysis. Endocrinol Diabetes Metab. 2022 Apr 20:e338.Full text Abstract
170. Chen Y, Yang D, Cheng B, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020 Jul;43(7):1399-407.Full text Abstract
171. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-33.Full text Abstract
172. Pal R, Banerjee M, Yadav U, et al. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes Metab Syndr. 2020 Aug 18;14(6):1563-9.Full text Abstract
173. Papadopoulos VP, Koutroulos MV, Zikoudi DG, et al. Diabetes-related acute metabolic emergencies in COVID-19 patients: a systematic review and meta-analysis. Diabetol Int. 2021 Mar 23;1-15.Full text Abstract
174. Prattichizzo F, de Candia P, Nicolucci A, et al. Impact of pre-infection HbA1c levels on COVID-19 prognosis: systematic review and meta-analysis. Diabetes Metab Res Rev. 2021 May 20:e3476.Full text Abstract
175. Heidarpour M, Abhari AP, Sadeghpour N, et al. Prediabetes and COVID-19 severity, an underestimated risk factor: a systematic review and meta-analysis. Diabetes Metab Syndr. 2021 Oct 9;15(6):102307.Full text Abstract
176. Boden I, Bernabeu MO, Dhillon B, et al. Pre-existing diabetic retinopathy as a prognostic factor for COVID-19 outcomes amongst people with diabetes: a systematic review. Diabetes Res Clin Pract. 2022 Apr 5;187:109869.Full text Abstract
177. Nguyen NN, Ho DS, Nguyen HS, et al. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: a meta-analysis. Metabolism. 2022 Mar 31:155196.Full text Abstract
178. Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-92.Full text Abstract
179. Yin Y, Rohli KE, Shen P, et al. The epidemiology, pathophysiological mechanisms, and management toward COVID-19 patients with type 2 diabetes: a systematic review. Prim Care Diabetes. 2021 Sep 6;15(6):899-909.Full text Abstract
180. Halpin DMG, Faner R, Sibila O, et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020 May;8(5):436-8.Full text Abstract
181. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Otunla A, Drake J, et al. Asthma and COVID-19: risks and management considerations. 2020 [internet publication].Full text
182. Gerayeli FV, Milne S, Cheung C, et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021 Mar;33:100789.Full text Abstract
183. Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021 Jul;9(7):699-711.Full text Abstract
184. Otunla A, Rees K, Dennison P, et al. Risks of infection, hospital and ICU admission, and death from COVID-19 in people with asthma: systematic review and meta-analyses. BMJ Evid Based Med. 2021 Dec 21 [Epub ahead of print].Full text Abstract
185. World Health Organization. Asthma and COVID-19: scientific brief, 19 April 2021. 2021 [internet publication].Full text
186. Hariyanto TI, Kurniawan A. Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Sleep Med. 2021 Apr 1;82:47-53.Full text Abstract
187. Strausz S, Kiiskinen T, Broberg M, et al. Sleep apnoea is a risk factor for severe COVID-19. BMJ Open Respir Res. 2021 Jan;8(1):e000845.Full text Abstract
188. Mathew HR, Choi MY, Parkins MD, et al. Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic. BMC Pulm Med. 2021 May 20;21(1):173.Full text Abstract
189. Wang Y, Feng R, Xu J, et al. An updated meta-analysis on the association between tuberculosis and COVID-19 severity and mortality. J Med Virol. 2021 Oct;93(10):5682-6.Full text Abstract
190. Aggarwal AN, Agarwal R, Dhooria S, et al. Active pulmonary tuberculosis and coronavirus disease 2019: a systematic review and meta-analysis. PLoS One. 2021;16(10):e0259006.Full text Abstract
191. Ouyang L, Gong J, Yu M. Pre-existing interstitial lung disease in patients with coronavirus disease 2019: a meta-analysis. Int Immunopharmacol. 2021 Sep 9;100:108145.Full text Abstract
192. Castro-Rodriguez JA, Forno E. Asthma and COVID-19 in children: a systematic review and call for data. Pediatr Pulmonol. 2020 Sep;55(9):2412-8.Full text Abstract
193. Lin YC, Lai TS, Lin SL, et al. Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:2040622321998860.Full text Abstract
194. Chung EY, Palmer SC, Natale P, et al. Incidence and outcomes of COVID-19 in people with CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2021 Dec;78(6):804-15.Full text Abstract
195. Nopsopon T, Kittrakulrat J, Takkavatakarn K, et al. Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021 Jun 15;15(6):e0009156.Full text Abstract
196. Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020 Jul 10;:1-9.Full text Abstract
197. Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020 Sep;14(5):612-20.Full text Abstract
198. Liu M, Mei K, Tan Z, et al. Liver fibrosis scores and hospitalization, mechanical ventilation, severity, and death in patients with COVID-19: a systematic review and dose-response meta-analysis. Can J Gastroenterol Hepatol. 2022 Mar 29;2022:7235860.Full text Abstract
199. Middleton P, Hsu C, Lythgoe MP. Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies. BMJ Open Gastroenterol. 2021 Oct;8(1):e000739.Full text Abstract
200. Tao Z, Li Y, Cheng B, et al. Risk of severe COVID-19 increased by metabolic dysfunction-associated fatty liver disease: a meta-analysis. J Clin Gastroenterol. 2021 Nov-Dec 01;55(10):830-5.Full text Abstract
201. Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020 Aug;69(8):1545-7.Full text Abstract
202. Zhou YJ, Zheng KI, Wang XB, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020 Sep;73(3):719-21.Full text Abstract
203. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320.Full text Abstract
204. Allotey J, Stallings E, Bonet M, et al. Update to living systematic review on covid-19 in pregnancy. BMJ. 2022 May 30;377:o1205.Full text Abstract
205. Khalil A, Kalafat E, Benlioglu C, et al. SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine. 2020 Aug;25:100446.Full text Abstract
206. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status: United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 6;69(44):1641-7.Full text Abstract
207. Vousden N, Ramakrishnan R, Bunch K, et al. Management and implications of severe COVID-19 in pregnancy in the UK: data from the UK Obstetric Surveillance System national cohort. AActa Obstet Gynecol Scand. 2022 Apr;101(4):461-70.Full text Abstract
208. Gajbhiye RK, Sawant MS, Kuppusamy P, et al. Differential impact of COVID-19 in pregnant women from high-income countries and low- to middle-income countries: a systematic review and meta-analysis. Int J Gynaecol Obstet. 2021 Oct;155(1):48-56.Full text Abstract
209. Zhang H, Ma S, Han T, et al. Association of smoking history with severe and critical outcome in COVID-19 patients: a systemic review and meta-analysis. Eur J Integr Med. 2021 Feb 18:101313.Full text Abstract
210. Patanavanich R, Glantz SA. Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis. BMC Public Health. 2021 Aug 16;21(1):1554.Full text Abstract
211. Salah HM, Sharma T, Mehta J. Smoking doubles the mortality risk in COVID-19: a meta-analysis of recent reports and potential mechanisms. Cureus. 2020 Oct 7;12(10):e10837.Full text Abstract
212. Cai G, Bossé Y, Xiao F, et al. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1557-9.Full text Abstract
213. Patanavanich R, Siripoon T, Amponnavarat S, et al. Active smokers are at higher risk of COVID-19 death: a systematic review and meta-analysis. Nicotine Tob Res. 2022 Apr 1 [Epub ahead of print]. Abstract
214. World Health Organization. Smoking and COVID-19: scientific brief. 2020 [internet publication]Full text
215. Yu J Ouyang W, Chua ML, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020 Mar 25;6(7):1108-10.Full text Abstract
216. Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. JNCI Cancer Spectr. 2021 Feb 24;5(2):pkaa102.Full text Abstract
217. Naimi A, Yashmi I, Jebeleh R, et al. Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: a systematic review and meta-analysis. J Clin Lab Anal. 2022 Apr 6:e24387.Full text Abstract
218. Zarifkar P, Kamath A, Robinson C, et al. Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2021 Mar;33(3):e180-91.Full text Abstract
219. Nadkarni AR, Vijayakumaran SC, Gupta S, et al. Mortality in cancer patients with COVID-19 who are admitted to an ICU or who have severe COVID-19: a systematic review and meta-analysis. JCO Glob Oncol. 2021 Aug;7:1286-305.Full text Abstract
220. Kaur H, Thakur JS, Paika R, et al. Impact of underlying comorbidities on mortality in SARS-COV-2 infected cancer patients: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2021 May 1;22(5):1333-49.Full text Abstract
221. OnCovid Study Group; Pinato DJ, Patel M, Scotti L, et al. Time-dependent COVID-19 mortality in patients with cancer: an updated analysis of the OnCovid registry. JAMA Oncol. 2022 Jan 1;8(1):114-22.Full text Abstract
222. Chavez-MacGregor M, Lei X, Zhao H, et al. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol. 2022 Jan 1;8(1):69-78.Full text Abstract
223. Boulad F, Kamboj M, Bouvier N, et al. COVID-19 in children with cancer in New York City. JAMA Oncol. 2020 Sep 1;6(9):1459-60.Full text Abstract
224. Mukkada S, Bhakta N, Chantada GL, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncol. 2021 Oct;22(10):1416-26.Full text Abstract
225. Dorantes-Acosta E, Ávila-Montiel D, Klünder-Klünder M, et al. Survival and complications in pediatric patients with cancer and COVID-19: a meta-analysis. Front Oncol. 2020 Jan 21;10:608282.Full text Abstract
226. Schlage S, Lehrnbecher T, Berner R, et al. SARS-CoV-2 in pediatric cancer: a systematic review. Eur J Pediatr. 2022 Jan 10;1-15.Full text Abstract
227. Xu J, Xiao W, Liang X, et al. The association of cerebrovascular disease with adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates. J Stroke Cerebrovasc Dis. 2020 Nov;29(11):105283.Full text Abstract
228. Patel U, Malik P, Shah D, et al. Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis. J Neurol. 2021 Jan;268(1):240-7.Full text Abstract
229. Fond G, Nemani K, Etchecopar-Etchart D, et al. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Nov 1;78(11):1208-17.Full text Abstract
230. Ceban F, Nogo D, Carvalho IP, et al. Association between mood disorders and risk of COVID-19 infection, hospitalization, and death: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Oct 1;78(10):1079-91.Full text Abstract
231. Pardamean E, Roan W, Iskandar KTA, et al. Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry. 2022 Feb 4;75:61-7.Full text Abstract
232. Gatti M, Rinaldi M, Bussini L, et al. Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis. Clin Microbiol Infect. 2022 Mar 11 [Epub ahead of print].Full text Abstract
233. Shahzad M, Chaudhary SG, Zafar MU, et al. Impact of COVID-19 in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis. 2022 Jan 14:e13792.Full text Abstract
234. Clift AK, Coupland CAC, Keogh RH, et al. COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann Intern Med. 2021 Apr;174(4):572-6.Full text Abstract
235. Williamson EJ, McDonald HI, Bhaskaran K, et al. Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform. BMJ. 2021 Jul 14;374:n1592.Full text Abstract
236. Bosworth ML, Ayoubkhani D, Nafilyan V, et al. Deaths involving COVID-19 by self-reported disability status during the first two waves of the COVID-19 pandemic in England: a retrospective, population-based cohort study. Lancet Public Health. 2021 Nov;6(11):e817-25.Full text Abstract
237. Hariyanto TI, Putri C, Arisa J, et al. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2020 Nov 19;93:104299.Full text Abstract
238. Saragih ID, Saragih IS, Batubara SO, et al. Dementia as a mortality predictor among older adults with COVID-19: a systematic review and meta-analysis of observational study. Geriatr Nurs. 2021 Sep-Oct;42(5):1230-9.Full text Abstract
239. Office for National Statistics. Deaths involving COVID-19, England and Wales: deaths occurring in June 2020. 2020 [internet publication].Full text
240. Wang Q, Davis PB, Gurney ME, et al. COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 2021 Aug;17(8):1297-306.Full text Abstract
241. Fagni F, Simon D, Tascilar K, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021 Oct;3(10):e724-36.Full text Abstract
242. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859-66.Full text Abstract
243. Nørgård BM, Nielsen J, Knudsen T, et al. Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: a Danish cohort study. Br J Clin Pharmacol. 2021 Apr;87(4):2111-20.Full text Abstract
244. Tassone D, Thompson A, Connell W, et al. Immunosuppression as a risk factor for COVID-19: a meta-analysis. Intern Med J. 2021 Feb;51(2):199-205.Full text Abstract
245. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021 Jan;8(1):e24-32.Full text Abstract
246. Tesoriero JM, Swain CE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021 Feb 1;4(2):e2037069.Full text Abstract
247. Chanda D, Minchella PA, Kampamba D, et al. COVID-19 severity and COVID-19-associated deaths among hospitalized patients with HIV infection: Zambia, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021 Jun 4;70(22):807-10.Full text Abstract
248. Yang X, Sun J, Patel RC, et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV. 2021 Nov;8(11):e690-700.Full text Abstract
249. SeyedAlinaghi S, Karimi A, MohsseniPour M, et al. The clinical outcomes of COVID-19 in HIV-positive patients: a systematic review of current evidence. Immun Inflamm Dis. 2021 Dec;9(4):1160-85.Full text Abstract
250. Lee KW, Yap SF, Ngeow YF, et al. COVID-19 in people living with HIV: a systematic review and meta-analysis. Int J Environ Res Public Health. 2021 Mar 30;18(7):3554.Full text Abstract
251. Mellor MM, Bast AC, Jones NR, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS. 2021 Mar 15;35(4):F1-10.Full text Abstract
252. Hariyanto TI, Rosalind J, Christian K, et al. Human immunodeficiency virus and mortality from coronavirus disease 2019: a systematic review and meta-analysis. South Afr J HIV Med. 2021 Apr 15;22(1):1220.Full text Abstract
253. Danwang C, Noubiap JJ, Robert A, et al. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. AIDS Res Ther. 2022 Jan 14;19(1):3.Full text Abstract
254. Oyelade T, Alqahtani JS, Hjazi AM, et al. Global and regional prevalence and outcomes of COVID-19 in people living with HIV: a systematic review and meta-analysis. Trop Med Infect Dis. 2022 Feb 3;7(2):22.Full text Abstract
255. World Health Organization. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection. 2021 [internet publication].Full text
256. Bertagnolio S, Thwin SS, Silva R, et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 2022 Jul;9(7):e486-95.Full text Abstract
257. Wang H, Jonas KJ. The likelihood of severe COVID-19 outcomes among PLHIV with various comorbidities: a comparative frequentist and Bayesian meta-analysis approach. J Int AIDS Soc. 2021 Nov;24(11):e25841.Full text Abstract
258. Rahmati M, Shamsi MM, Khoramipour K, et al. Baseline physical activity is associated with reduced mortality and disease outcomes in COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2022 Apr 13:e2349.Full text Abstract
259. Centers for Disease Control and Prevention. Brief summary of findings on the association between physical inactivity and severe COVID-19 outcomes. 2022 [internet publication].Full text
260. Sallis R, Young DR, Tartof SY, et al. Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. Br J Sports Med. 2021 Oct;55(19):1099-105.Full text Abstract
261. Lee JX, Chieng WK, Lau SCD, et al. COVID-19 and hemoglobinopathies: a systematic review of clinical presentations, investigations, and outcomes. Front Med (Lausanne). 2021 Oct 13;8:757510.Full text Abstract
262. Clift AK, Saatci D, Coupland CAC, et al. Sickle cell disorders and severe COVID-19 outcomes: a cohort study. Ann Intern Med. 2021 Oct;174(10):1483-7.Full text Abstract
263. Panepinto JA, Brandow A, Mucalo L, et al. Coronavirus disease among persons with sickle cell disease, United States, March 20 – May 21, 2020. Emerg Infect Dis. 2020 Jul 8;26(10).Full text Abstract
264. Hussain FA, Njoku FU, Saraf SL, et al. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020 Jun;189(5):851-2.Full text Abstract
265. Nur E, Gaartman AE, van Tuijn CFJ, et al. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol. 2020 Jun;95(6):725-6.Full text Abstract
266. World Health Organization. Hypertension and COVID-19. 2021 [internet publication].Full text
267. Qian Z, Li Z, Peng J, et al. Association between hypertension and prognosis of patients with COVID-19: a systematic review and meta-analysis. Clin Exp Hypertens. 2022 May 8:1-8. Abstract
268. Pranata R, Lim MA, Huang I, et al. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926899.Full text Abstract
269. de Almeida-Pititto B, Dualib PM, Zajdenverg L, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020 Aug 31;12:75.Full text Abstract
270. Du Y, Zhou N, Zha W, et al. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: a meta-analysis. Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):745-55.Full text Abstract
271. Goldstein MR, Poland GA, Graeber CW. Are certain drugs associated with enhanced mortality in COVID-19? QJM. 2020 Jul 1;113(7):509-10.Full text Abstract
272. Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020 Aug 4;173(3):195-203.Full text Abstract
273. Mackey K, Kansagara D, Vela K. Update alert 7: risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann Intern Med. 2021 Feb;174(2):W25-9.Full text Abstract
274. Baillargeon J, Polychronopoulou E, Kuo YF, et al. The impact of substance use disorder on COVID-19 outcomes. Psychiatr Serv. 2021 May 1;72(5):578-81.Full text Abstract
275. Allen B, El Shahawy O, Rogers ES, et al. Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January-October 2020. J Public Health (Oxf). 2021 Sep 22;43(3):462-5.Full text Abstract
276. Qeadan F, Tingey B, Bern R, et al. Opioid use disorder and health service utilization among COVID-19 patients in the US: a nationwide cohort from the Cerner Real-World Data. EClinicalMedicine. 2021 Jun 4:100938.Full text Abstract
277. Kompaniyets L, Agathis NT, Nelson JM, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open. 2021 Jun 1;4(6):e2111182.Full text Abstract
278. Akbar MR, Wibowo A, Pranata R, et al. Low serum 25-hydroxyvitamin d (vitamin d) level is associated with susceptibility to COVID-19, severity, and mortality: a systematic review and meta-analysis. Front Nutr. 2021 Mar 29;8:660420.Full text Abstract
279. Crafa A, Cannarella R, Condorelli RA, et al. Influence of 25-hydroxy-cholecalciferol levels on SARS-CoV-2 infection and COVID-19 severity: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jul;37:100967.Full text Abstract
280. Szarpak L, Rafique Z, Gasecka A, et al. A systematic review and meta-analysis of effect of vitamin D levels on the incidence of COVID-19. Cardiol J. 2021;28(5):647-54.Full text Abstract
281. Shah K, V P V, Pandya A, et al. Low vitamin D levels and prognosis in a COVID-19 pediatric population: a systematic review. QJM. 2021 Nov 5;114(7):447-53.Full text Abstract
282. Borsche L, Glauner B, von Mendel J. COVID-19 mortality risk correlates inversely with vitamin D3 status, and a mortality rate close to zero could theoretically be achieved at 50 ng/mL 25(OH)D3: results of a systematic review and meta-analysis. Nutrients. 2021 Oct 14;13(10):3596.Full text Abstract
283. Ebrahimzadeh A, Mohseni S, Narimani B, et al. Association between vitamin D status and risk of covid-19 in-hospital mortality: a systematic review and meta-analysis of observational studies. Crit Rev Food Sci Nutr. 2021 Dec 9:1-11. Abstract
284. Dissanayake HA, de Silva NL, Sumanatilleke M, et al. Prognostic and therapeutic role of vitamin D in COVID-19: systematic review and meta-analysis. J Clin Endocrinol Metab. 2022 Apr 19;107(5):1484-502.Full text Abstract
285. Bassatne A, Basbous M, Chakhtoura M, et al. The link between COVID-19 and vitamin D (VIVID): a systematic review and meta-analysis. Metabolism. 2021 Mar 24:154753.Full text Abstract
286. Grove A, Osokogu O, Al-Khudairy L, et al. Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review. BMJ Open. 2021 May 28;11(5):e043737.Full text Abstract
287. Chen J, Mei K, Xie L, et al. Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs. Nutr J. 2021 Oct 31;20(1):89.Full text Abstract
288. Fatima K, Almas T, Lakhani S, et al. The use of proton pump inhibitors and COVID-19: a systematic review and meta-analysis. Trop Med Infect Dis. 2022 Feb 28;7(3):37.Full text Abstract
289. Li GF, An XX, Yu Y, et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut. 2021 Sep;70(9):1806-8.Full text Abstract
290. Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020 Oct 13 [Epub ahead of print].Full text Abstract
291. Conway R, Grimshaw AA, Konig MF, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol. 2022 May;74(5):766-75.Full text Abstract
292. Izadi Z, Brenner EJ, Mahil SK, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021 Oct 1;4(10):e2129639.Full text Abstract
293. Andersen KM, Bates BA, Rashidi ES, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatol. 2022 Jan;4(1):e33-41.Full text Abstract
294. Tripathi K, Godoy Brewer G, Thu Nguyen M, et al. COVID-19 and outcomes in patients with inflammatory bowel disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2021 Oct 27 [Epub ahead of print].Full text Abstract
295. Alrashed F, Battat R, Abdullah I, et al. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2021 Oct;8(1):e000774.Full text Abstract
296. Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020 Jul;69(7):1213-7.Full text Abstract
297. Singh S, Khan A, Chowdhry M, et al. Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the united states: a multicenter research network study. Gastroenterology. 2020 Oct;159(4):1575-8.Full text Abstract
298. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021 Apr;70(4):725-32.Full text Abstract
299. Singh AK, Jena A, Kumar-M P, et al. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. United European Gastroenterol J. 2021 Mar;9(2):159-76.Full text Abstract
300. Sperger J, Shah KS, Lu M, et al. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open. 2021 Nov 12;11(11):e049740.Full text Abstract
301. Sakthiswary R, Chuah HY, Chiang KS, et al. COVID-19 in systemic lupus erythematosus: a pooled analysis and systematic review of case reports and series. Lupus. 2021 Oct;30(12):1946-54.Full text Abstract
302. Rutherford MA, Scott J, Karabayas M, et al. Risk factors for severe outcomes in patients with systemic vasculitis and COVID-19: a binational, registry-based cohort study. Arthritis Rheumatol. 2021 Sep;73(9):1713-9.Full text Abstract
303. Sattui SE, Conway R, Putman MS, et al. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatol. 2021 Dec;3(12):e855-64.Full text Abstract
304. Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020 Sep 1;77(9):1079-88.Full text Abstract
305. Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021 Jun 1;78(6):699-708.Full text Abstract
306. Barzegar M, Mirmosayyeb O, Gajarzadeh M, et al. COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol Neuroinflamm. 2021 Jul;8(4):e1001.Full text Abstract
307. Giovanella L, Ruggeri RM, Ovčariček PP, et al. Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review. Clin Transl Imaging. 2021 Mar 11:1-8.Full text Abstract
308. Malik J, Zaidi SMJ, Waqar AU, et al. Association of hypothyroidism with acute COVID-19: a systematic review. Expert Rev Endocrinol Metab. 2021 Sep;16(5):251-7. Abstract
309. Damara FA, Muchamad GR, Ikhsani R, et al. Thyroid disease and hypothyroidism are associated with poor COVID-19 outcomes: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2021 Oct 22;15(6):102312.Full text Abstract
310. Permana H, Soeriadi EA, Damara FA, et al. The prognostic values of thyroid disorders in predicting COVID-19 composite poor outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr. 2022 Mar 18;16(5):102464.Full text Abstract
311. Putri C, Hariyanto TI, Hananto JE, et al. Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: a systematic review, meta-analysis, and meta-regression. Parkinsonism Relat Disord. 2021 Jun;87:155-61.Full text Abstract
312. Chambergo-Michilot D, Barros-Sevillano S, Rivera-Torrejón O, et al. Factors associated with COVID-19 in people with Parkinson's disease: a systematic review and meta-analysis. Eur J Neurol. 2021 Oct;28(10):3467-77.Full text Abstract
313. Khoshnood RJ, Zali A, Tafreshinejad A, et al. Parkinson's disease and COVID-19: a systematic review and meta-analysis. Neurol Sci. 2022 Feb;43(2):775-83.Full text Abstract
314. Jaiswal V, Alquraish D, Sarfraz Z, et al. The influence of coronavirus disease-2019 (COVID-19) on Parkinson's disease: an updated systematic review. J Prim Care Community Health. 2021 Jan-Dec;12:21501327211039709.Full text Abstract
315. Topless RK, Gaffo A, Stamp LK, et al. Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study. Lancet Rheumatol. 2022 Apr;4(4):e274-81.Full text Abstract
316. Choi GJ, Kim HM, Kang H. The potential role of dyslipidemia in COVID-19 severity: an umbrella review of systematic reviews. J Lipid Atheroscler. 2020 Sep;9(3):435-48.Full text Abstract
317. Zuin M, Rigatelli G, Bilato C, et al. Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis. QJM. 2021 Oct 7;114(6):390-7.Full text Abstract
318. Liu Y, Pan Y, Yin Y, et al. Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis. Virol J. 2021 Jul 27;18(1):157.Full text Abstract
319. Atmosudigdo IS, Pranata R, Lim MA, et al. Dyslipidemia increases the risk of severe COVID-19: a systematic review, meta-analysis, and meta-regression. J Clin Exp Hepatol. 2021 Feb 8 [Epub ahead of print].Full text Abstract
320. Kow CS, Hasan SS. The association between the use of statins and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2022 Mar;22(2):167-81.Full text Abstract
321. Daniels LB, Ren J, Kumar K, et al. Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry. PLoS One. 2021 Jul 15;16(7):e0254635.Full text Abstract
322. Bergqvist R, Ahlqvist VH, Lundberg M, et al. HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: a registry-based cohort study. PLoS Med. 2021 Oct;18(10):e1003820.Full text Abstract
323. Doglietto F, Vezzoli M, Gheza F, et al. Factors associated with surgical mortality and complications among patients with and without coronavirus disease 2019 (COVID-19) in Italy. JAMA Surg. 2020 Jun 12;155(8):1-14.Full text Abstract
324. Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020 Apr 5:100331.Full text Abstract
325. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020 Jul 4;396(10243):27-38.Full text Abstract
326. Liu N, Zhang T, Ma L, et al. The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. Blood Rev. 2020 Dec 8:100785.Full text Abstract
327. Gutiérrez-Valencia M, Leache L, Librero J, et al. ABO blood group and risk of COVID-19 infection and complications: a systematic review and meta-analysis. Transfusion. 2022 Feb;62(2):493-505.Full text Abstract
328. Soo KM, Chung KM, Mohd Azlan MAA, et al. The association of ABO and Rhesus blood type with the risks of developing SARS-CoV-2 infection: a meta-analysis. Trop Biomed. 2022 Mar 1;39(1):126-34.Full text Abstract
329. Franchini M, Cruciani M, Mengoli C, et al. ABO blood group and COVID-19: an updated systematic literature review and meta-analysis. Blood Transfus. 2021 May 12;19(4):317-26.Full text Abstract
330. Wu SC, Arthur CM, Wang J, et al. The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A. Blood Adv. 2021 Mar 9;5(5):1305-1309.Full text Abstract
331. Yamamoto S, Saito M, Tamura A, et al. The human microbiome and COVID-19: a systematic review. PLoS One. 2021 Jun 23;16(6):e0253293.Full text Abstract
332. Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020 May 13;285:198018.Full text Abstract
333. Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020 Sep;159(3):944-55.Full text Abstract
334. Gu S, Chen Y, Wu Z, et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis. 2020 Dec 17;71(10):2669-78.Full text Abstract
335. Yeoh YK, Zuo T, Lui GC, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021 Apr;70(4):698-706.Full text Abstract
336. Zheng HL, Guo ZL, Wang ML, et al. Effects of climate variables on the transmission of COVID-19: a systematic review of 62 ecological studies. Environ Sci Pollut Res Int. 2021 Oct;28(39):54299-316.Full text Abstract
337. Centre for Evidence-Based Medicine; Hoang U, Jones NR. Is there an association between exposure to air pollution and severity of COVID-19 infection? 2020 [internet publication].Full text
338. Copat C, Cristaldi A, Fiore M, et al. The role of air pollution (PM and NO₂) in COVID-19 spread and lethality: a systematic review. Environ Res. 2020 Aug 24;191:110129.Full text Abstract
339. Frontera A, Cianfanelli L, Vlachos K, et al. Severe air pollution links to higher mortality in COVID-19 patients: the “double-hit” hypothesis. J Infect. 2020 Aug;81(2):255-9.Full text Abstract
340. Ogen Y. Assessing nitrogen dioxide (NO2) levels as a contributing factor to coronavirus (COVID-19) fatality. Sci Total Environ. 2020 Apr 11;726:138605.Full text Abstract
341. Yu Z, Bellander T, Bergström A, et al. Association of short-term air pollution exposure with SARS-CoV-2 infection among young adults in Sweden. JAMA Netw Open. 2022 Apr 1;5(4):e228109.Full text Abstract
342. Bowyer RCE, Varsavsky T, Thompson EJ, et al. Geo-social gradients in predicted COVID-19 prevalence in Great Britain: results from 1 960 242 users of the COVID-19 Symptoms Study app. Thorax. 2021 Jul;76(7):723-5.Full text Abstract
343. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-15.Full text Abstract
344. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403-16.Full text Abstract
345. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021 Jun 10;384(23):2187-201.Full text Abstract
346. Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021 Dec 16;385(25):2348-60.Full text Abstract
347. World Health Organization. Interim statement on booster doses for COVID-19 vaccination. 2021 [internet publication].Full text
348. Zeng B, Gao L, Zhou Q, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022 May 23;20(1):200.Full text Abstract
349. World Health Organization. Interim statement on the composition of current COVID-19 vaccines. 2022 [internet publication].Full text
350. World Health Organization. Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines. 2022 [internet publication].Full text
351. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA recommends inclusion of omicron BA.4/5 component for COVID-19 vaccine booster doses. 2022 [internet publication].Full text
352. World Health Organization. Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons. 2021 [internet publication].Full text
353. Centers for Disease Control and Prevention. ACIP evidence to recommendations for use of an additional COVID-19 vaccine dose in immunocompromised people. 2021 [internet publication].Full text
354. European Medicines Agency. Comirnaty and Spikevax: EMA recommendations on extra doses and boosters. 2021 [internet publication].Full text
355. World Health Organization. Interim statement on the use of additional booster doses of emergency use listed mRNA vaccines against COVID-19. 2022 [internet publication].Full text
356. Centers for Disease Control and Prevention. ACIP evidence to recommendations for use of COVID-19 vaccine booster doses. 2021 [internet publication].Full text
357. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021 Oct 7;385(15):1393-400.Full text Abstract
358. Falsey AR, Frenck RW Jr, Walsh EE, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021 Oct 21;385(17):1627-9.Full text Abstract
359. Hause AM, Baggs J, Gee J, et al. Safety monitoring of an additional dose of COVID-19 vaccine: United States, August 12 – September 19, 2021. MMWR Morb Mortal Wkly Rep. 2021 Oct 1;70(39):1379-84.Full text Abstract
360. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021 Dec 4;398(10316):2093-100.Full text Abstract
361. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021 Dec 18;398(10318):2258-76.Full text Abstract
362. Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med. 2021 Dec 23;385(26):2413-20.Full text Abstract
363. Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2 booster across age groups. N Engl J Med. 2021 Dec 23;385(26):2421-30.Full text Abstract
364. Spitzer A, Angel Y, Marudi O, et al. Association of a third dose of BNT162b2 vaccine with incidence of SARS-CoV-2 infection among health care workers in Israel. JAMA. 2022 Jan 25;327(4):341-9.Full text Abstract
365. Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron. N Engl J Med. 2022 Apr 7;386(14):1377-80.Full text Abstract
366. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022 May 5;386(18):1712-20.Full text Abstract
367. Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2022 Apr 28;386(17):1603-14.Full text Abstract
368. World Health Organization. Interim recommendations for heterologous COVID-19 vaccine schedules. 2021 [internet publication].Full text
369. Au WY, Cheung PP. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ. 2022 May 31;377:e069989.Full text Abstract
370. World Health Organization. Coadministration of seasonal inactivated influenza and COVID-19 vaccines. 2021 [internet publication].Full text
371. Lazarus R, Baos S, Cappel-Porter H, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021 Dec 18;398(10318):2277-87.Full text Abstract
372. World Health Organization. Questions and answers: COVID-19 vaccines and pregnancy. 2022 [internet publication].Full text
373. Prasad S, Kalafat E, Blakeway H, et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. Nat Commun. 2022 May 10;13(1):2414.Full text Abstract
374. Carlsen EØ, Magnus MC, Oakley L, et al. Association of COVID-19 vaccination during pregnancy with incidence of SARS-CoV-2 infection in infants. JAMA Intern Med. 2022 Jun 1 [Epub ahead of print].Full text Abstract
375. Halasa NB, Olson SM, Staat MA, et al. Maternal vaccination and risk of hospitalization for Covid-19 among infants. N Engl J Med. 2022 Jun 22 [Epub ahead of print].Full text Abstract
376. World Health Organization. Frequently asked questions: COVID-19 vaccines and breastfeeding based on WHO interim recommendations, 12 August 2021. 2021 [internet publication].Full text
377. Whited N, Cervantes J. Antibodies against SARS-CoV-2 in human breast milk after vaccination: a systematic review and meta-analysis. Breastfeed Med. 2022 Mar 22 [Epub ahead of print].Full text Abstract
378. Golan Y, Prahl M, Cassidy A, et al. Evaluation of messenger RNA from COVID-19 BTN162b2 and mRNA-1273 vaccines in human milk. JAMA Pediatr. 2021 Oct 1;175(10):1069-71.Full text Abstract
379. Du Y, Chen L, Shi Y. Safety, immunogenicity, and efficacy of COVID-19 vaccines in adolescents, children, and infants: a systematic review and meta-analysis. Front Public Health. 2022 Apr 14;10:829176.Full text Abstract
380. Hause AM, Gee J, Baggs J, et al. COVID-19 vaccine safety in adolescents aged 12-17 years: United States, December 14, 2020 – July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1053-8.Full text Abstract
381. Hause AM, Baggs J, Marquez P, et al. COVID-19 vaccine safety in children aged 5-11 years: United States, November 3 – December 19, 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1755-60.Full text Abstract
382. Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022 Mar 2;376:e068632.Full text Abstract
383. Li J, Ayada I, Wang Y, et al. Factors associated with COVID-19 vaccine response in transplant recipients: a systematic review and meta-analysis. Transplantation. 2022 Jun 28 [Epub ahead of print]. Abstract
384. Manothummetha K, Chuleerarux N, Sanguankeo A, et al. Immunogenicity and risk factors associated with poor humoral immune response of SARS-CoV-2 vaccines in recipients of solid organ transplant: a systematic review and meta-analysis. JAMA Netw Open. 2022 Apr 1;5(4):e226822.Full text Abstract
385. Zong K, Peng D, Yang H, et al. Risk factors for weak antibody response of SARS-CoV-2 vaccine in adult solid organ transplant recipients: a systemic review and meta-analysis. Front Immunol. 2022 Jun 14;13:888385.Full text Abstract
386. Abhishek A, Boyton RJ, Peckham N, et al. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respir Med. 2022 Jun 27 [Epub ahead of print].Full text Abstract
387. Jena A, Mishra S, Deepak P, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev. 2021 Aug 30:102927.Full text Abstract
388. Mahil SK, Bechman K, Raharja A, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021 Sep;3(9):e627-37.Full text Abstract
389. Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021 Nov;3(11):e789-97.Full text Abstract
390. Wu X, Wang L, Shen L, et al. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis. EBioMedicine. 2022 Jun 24;81:104102.Full text Abstract
391. Ishay Y, Kenig A, Tsemach-Toren T, et al. Autoimmune phenomena following SARS-CoV-2 vaccination. Int Immunopharmacol. 2021 Jul 10;99:107970.Full text Abstract
392. Cabreira V, Abreu P, Soares-Dos-Reis R, et al. Multiple sclerosis, disease-modifying therapies and COVID-19: a systematic review on immune response and vaccination recommendations. Vaccines (Basel). 2021 Jul 11;9(7):773.Full text Abstract
393. Felten R, Kawka L, Dubois M, et al. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol. 2021 Sep;3(9):e613-5.Full text Abstract
394. Obeid M, Fenwick C, Pantaleo G. Reactivation of IgA vasculitis after COVID-19 vaccination. Lancet Rheumatol. 2021 Sep;3(9):e617.Full text Abstract
395. Gagelmann N, Passamonti F, Wolschke C, et al. Antibody response after vaccination against SARS-CoV-2 in adults with haematological malignancies: a systematic review and meta-analysis. Haematologica. 2021 Dec 16 [Epub ahead of print].Full text Abstract
396. Zhang M, Liang Y, Yu D, et al. A systematic review of vaccine breakthrough infections by SARS-CoV-2 Delta variant. Int J Biol Sci. 2022;18(2):889-900.Full text Abstract
397. Gopinath S, Ishak A, Dhawan N, et al. Characteristics of COVID-19 breakthrough infections among vaccinated individuals and associated risk factors: a systematic review. Trop Med Infect Dis. 2022 May 22;7(5):81.Full text Abstract
398. Juthani PV, Gupta A, Borges KA, et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis. 2021 Nov;21(11):1485-6.Full text Abstract
399. Butt AA, Yan P, Shaikh OS, et al. Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population. EClinicalMedicine. 2021 Aug 28;40:101117.Full text Abstract
400. Lee CJ, Woo W, Kim AY, et al. Clinical manifestations of COVID-19 breakthrough infections: a systematic review and meta-analysis. J Med Virol. 2022 May 19 [Epub ahead of print].Full text Abstract
401. Kampf G. The epidemiological relevance of the COVID-19-vaccinated population is increasing. Lancet Reg Health Eur. 2021 Dec;11:100272.Full text Abstract
402. Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings: Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 6;70(31):1059-62.Full text Abstract
403. Pouwels KB, Pritchard E, Matthews PC, et al. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK [preprint]. 2021 [internet publication].Full text
404. Singanayagam A, Hakki S, Dunning J, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022 Feb;22(2):183-95.Full text Abstract
405. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022 Jan;22(1):43-55.Full text Abstract
406. Sun J, Zheng Q, Madhira V, et al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2022 Feb 1;182(2):153-62.Full text Abstract
407. Song Q, Bates B, Shao YR, et al. Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the National COVID Cohort Collaborative. J Clin Oncol. 2022 May 1;40(13):1414-27.Full text Abstract
408. Wang W, Kaelber DC, Xu R, et al. Breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in vaccinated patients with cancer in the US between December 2020 and November 2021. JAMA Oncol. 2022 Apr 8 [Epub ahead of print].Full text Abstract
409. Wang L, Davis PB, Kaelber DC, et al. COVID-19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021. Alzheimers Dement. 2022 Apr 13 [Epub ahead of print].Full text Abstract
410. Agrawal U, Katikireddi SV, McCowan C, et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir Med. 2021 Dec;9(12):1439-49.Full text Abstract
411. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA. 2021 Nov 16;326(19):1930-9.Full text Abstract
412. Kuhlmann C, Mayer CK, Claassen M, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022 Feb 12;399(10325):625-6.Full text Abstract
413. Fall A, Eldesouki RE, Sachithanandham J, et al. The displacement of the SARS-CoV-2 variant Delta with Omicron: an investigation of hospital admissions and upper respiratory viral loads. EBioMedicine. 2022 Apr 20;79:104008.Full text Abstract
414. Truong DT, Dionne A, Muniz JC, et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults. Circulation. 2022 Feb;145(5):345-56.Full text Abstract
415. Gundry SR. Abstract 10712: MRNA COVID vaccines dramatically increase endothelial inflammatory markers and ACS risk as measured by the PULS cardiac test: a warning. Circulation. 2021 Nov 16;144 (Suppl 1):A10712.Full text
416. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022 Feb;28(2):410-22.Full text Abstract
417. European Medicines Agency. COVID-19 vaccines safety update: 17 June 2022. 2022 [internet publication].Full text
418. Lane S, Yeomans A, Shakir S. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature. BMJ Open. 2022 May 25;12(5):e059223.Full text Abstract
419. Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022 Jan 25;327(4):331-40.Full text Abstract
420. Matta A, Kunadharaju R, Osman M, et al. Clinical presentation and outcomes of myocarditis post mRNA vaccination: a meta-analysis and systematic review. Cureus. 2021 Nov;13(11):e19240.Full text Abstract
421. Wong HL, Hu M, Zhou CK, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. 2022 Jun 11;399(10342):2191-9.Full text Abstract
422. Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents. JAMA Cardiol. 2022 Apr 20 [Epub ahead of print].Full text Abstract
423. Friedensohn L, Levin D, Fadlon-Derai M, et al. Myocarditis following a third BNT162b2 vaccination dose in military recruits in Israel. JAMA. 2022 Apr 26;327(16):1611-2.Full text Abstract
424. Lane S, Yeomans A, Shakir S. Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination. BMJ Open. 2022 Jul 1;12(7):e060425.Full text Abstract
425. UK Health Security Agency. Myocarditis and pericarditis after COVID-19 vaccination: clinical management guidance for healthcare professionals. 2022 [internet publication].Full text
426. Dionne A, Sperotto F, Chamberlain S, et al. Association of myocarditis with BNT162b2 messenger RNA COVID-19 vaccine in a case series of children. JAMA Cardiol. 2021 Dec 1;6(12):1446-50.Full text Abstract
427. Buchan SA, Seo CY, Johnson C, et al. Epidemiology of myocarditis and pericarditis following mrna vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. JAMA Netw Open. 2022 Jun 1;5(6):e2218505.Full text Abstract
428. Shafiq A, Salameh MA, Laswi I, et al. Neurological immune-related adverse events post-COVID-19 vaccination: a systematic review. J Clin Pharmacol. 2022 Mar;62(3):291-303.Full text Abstract
429. Hanson KE, Goddard K, Lewis N, et al. Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the Vaccine Safety Datalink. JAMA Netw Open. 2022 Apr 1;5(4):e228879.Full text Abstract
430. Woo EJ, Mba-Jonas A, Dimova RB, et al. Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barré syndrome, February-July 2021. JAMA. 2021 Oct 26;326(16):1606-13.Full text Abstract
431. Rizk JG, Gupta A, Sardar P, et al. Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review. JAMA Cardiol. 2021 Dec 1;6(12):1451-60.Full text Abstract
432. Hafeez MU, Ikram M, Shafiq Z, et al. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): a systematic review and post hoc analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211048815.Full text Abstract
433. Dag Berild J, Bergstad Larsen V, Myrup Thiesson E, et al. Analysis of thromboembolic and thrombocytopenic events after the AZD1222, BNT162b2, and MRNA-1273 COVID-19 vaccines in 3 Nordic countries. JAMA Netw Open. 2022 Jun 1;5(6):e2217375.Full text Abstract
434. Andrews NJ, Stowe J, Ramsay ME, et al. Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: a national cohort study in England. Lancet Reg Health Eur. 2022 Feb;13:100260.Full text Abstract
435. See I, Lale A, Marquez P, et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: United States, December 2020 to August 2021. Ann Intern Med. 2022 Apr;175(4):513-22.Full text Abstract
436. Mani A, Ojha V. Thromboembolism after COVID-19 vaccination: a systematic review of such events in 286 patients. Ann Vasc Surg. 2022 May 11 [Epub ahead of print].Full text Abstract
437. Warren CM, Snow TT, Lee AS, et al. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system. JAMA Netw Open. 2021 Sep 1;4(9):e2125524.Full text Abstract
438. Greenhawt M, Abrams EM, Shaker M, et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021 Oct;9(10):3546-67.Full text Abstract
439. Alhumaid S, Al Mutair A, Al Alawi Z, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021 Oct 16;17(1):109.Full text Abstract
440. Sobczak M, Pawliczak R. The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis. Clin Mol Allergy. 2022 Jan 17;20(1):1.Full text Abstract
441. Chu DK, Abrams EM, Golden DBK, et al. Risk of second allergic reaction to SARS-CoV-2 vaccines: a systematic review and meta-analysis. JAMA Intern Med. 2022 Apr 1;182(4):376-85.Full text Abstract
442. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 September 2021. 2021 [internet publication].Full text
443. Maroufi SF, Naderi Behdani F, Rezania F, et al. Longitudinally extensive transverse myelitis after Covid-19 vaccination: case report and review of literature. Hum Vaccin Immunother. 2022 Dec 31;18(1):2040239.Full text Abstract
444. Eom H, Kim SW, Kim M, et al. Case reports of acute transverse myelitis associated with mRNA vaccine for COVID-19. J Korean Med Sci. 2022 Feb 21;37(7):e52.Full text Abstract
445. Fazlollahi A, Zahmatyar M, Noori M, et al. Cardiac complications following mRNA COVID-19 vaccines: a systematic review of case reports and case series. Rev Med Virol. 2021 Dec 17:e2318.Full text Abstract
446. Angeli F, Reboldi G, Trapasso M, et al. Blood pressure increase following COVID-19 vaccination: a systematic overview and meta-analysis. J Cardiovasc Dev Dis. 2022 May 9;9(5):150.Full text Abstract
447. EPI-PHARE. Covid-19 vaccines and cardiovascular events in 18-74 year olds [in French]. 2022 [internet publication].Full text
448. European Medicines Agency. COVID-19 vaccines safety update: 17 March 2022. 2022 [internet publication].Full text
449. Elboraey MO, Essa EESF. Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Oct;132(4):e139-42.Full text Abstract
450. Cavalli G, Colafrancesco S, De Luca G, et al. Cutaneous vasculitis following COVID-19 vaccination. Lancet Rheumatol. 2021 Nov;3(11):e743-4.Full text Abstract
451. Askenase PW. Rare skin reactions after mRNA vaccination, similar to Jones-Mote basophil responses. N Engl J Med. 2021 Oct 28;385(18):1720-1.Full text Abstract
452. Birkett L, Singh P, Mosahebi A, et al. Possible associations between alopecia areata and COVID-19 vaccination and infection. Aesthet Surg J. 2022 Jun 20 [Epub ahead of print].Full text Abstract
453. Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two cases of Graves' disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid. 2021 Sep;31(9):1436-9.Full text Abstract
454. Edelman A, Boniface ER, Benhar E, et al. Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: a U.S. cohort. Obstet Gynecol. 2022 Jan 5;139(4):481-9.Full text Abstract
455. Ippolito S, Gallo D, Rossini A, et al. SARS-CoV-2 vaccine-associated subacute thyroiditis: insights from a systematic review. J Endocrinol Invest. 2022 Jan 29;1-12.Full text Abstract
456. Walter T, Connor S, Stedman C, et al. A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine. Br J Clin Pharmacol. 2022 Mar;88(3):1385-6.Full text Abstract
457. Chen Y, Xu Z, Wang P, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022 Apr;165(4):386-401.Full text Abstract
458. Chow KW, Pham NV, Ibrahim BM, et al. Autoimmune hepatitis-like syndrome following COVID-19 vaccination: a systematic review of the literature. Dig Dis Sci. 2022 Apr 29;1-7.Full text Abstract
459. Roy A, Verma N, Singh S, et al. Immune-mediated liver injury following COVID-19 vaccination: a systematic review. Hepatol Commun. 2022 May 4 [Epub ahead of print].Full text Abstract
460. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 April 2022. 2022 [internet publication].Full text
461. Marconi E, Crescioli G, Bonaiuti R, et al. Acute appendicitis in a patient immunised with COVID-19 vaccine: a case report with morphological analysis. Br J Clin Pharmacol. 2022 May 27 [Epub ahead of print].Full text Abstract
462. Leone MC, Canovi S, Pilia A, et al. Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine. Thromb Res. 2022 Mar;211:60-2.Full text Abstract
463. Patone M, Mei XW, Handunnetthi L, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021 Dec;27(12):2144-53.Full text Abstract
464. Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022 Jan;43(1):3-40.Full text Abstract
465. Toljan K, Amin M, Kunchok A, et al. New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure. J Neuroimmunol. 2022 Jan 15;362:577785.Full text Abstract
466. Préta LH, Contejean A, Salvo F, et al. Association study between herpes zoster reporting and mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273). Br J Clin Pharmacol. 2022 Feb 16 [Epub ahead of print].Full text Abstract
467. Yanir Y, Doweck I, Shibli R, et al. Association between the BNT162b2 messenger RNA COVID-19 vaccine and the risk of sudden sensorineural hearing loss. JAMA Otolaryngol Head Neck Surg. 2022 Apr 1;148(4):299-306.Full text Abstract
468. Anamnart C, Tisavipat N, Owattanapanich W, et al. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: case report and systematic review. Mult Scler Relat Disord. 2022 Feb;58:103414. Abstract
469. Sriwastava S, Sharma K, Khalid SH, et al. COVID-19 vaccination and neurological manifestations: a review of case reports and case series. Brain Sci. 2022 Mar 18;12(3):407.Full text Abstract
470. Avasarala J, McLouth CJ, Pettigrew LC, et al. VAERS-reported new-onset seizures following use of COVID-19 vaccinations as compared to influenza vaccinations. Br J Clin Pharmacol. 2022 May 23 [Epub ahead of print].Full text Abstract
471. Wu HHL, Kalra PA, Chinnadurai R. New-onset and relapsed kidney histopathology following COVID-19 vaccination: a systematic review. Vaccines (Basel). 2021 Oct 29;9(11):1252.Full text Abstract
472. Maramattom BV, Philips G, Thomas J, et al. Inflammatory myositis after ChAdOx1 vaccination. Lancet Rheumatol. 2021 Nov;3(11):e747-9.Full text Abstract
473. Leone F, Cerasuolo PG, Bosello SL, et al. Adult-onset Still's disease following COVID-19 vaccination. Lancet Rheumatol. 2021 Oct;3(10):e678-80.Full text Abstract
474. Nguyen B, Lalama MJ, Gamret AC, et al. Cutaneous symptoms of connective tissue diseases after COVID-19 vaccination: a systematic review. Int J Dermatol. 2022 Jul;61(7):e238-41.Full text Abstract
475. Sessa F, Salerno M, Esposito M, et al. Autopsy findings and causality relationship between death and COVID-19 vaccination: a systematic review. J Clin Med. 2021 Dec 15;10(24):5876.Full text Abstract
476. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals. 2021 [internet publication].Full text
477. Medicines and Healthcare products Regulatory Agency. Evusheld approved to prevent COVID-19 in people whose immune response is poor. 2022 [internet publication].Full text
478. European Medicines Agency. EMA recommends authorisation of COVID-19 medicine Evusheld. 2022 [internet publication].Full text
479. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2022 [internet publication].Full text
480. Bhimraj A, Morgan RL, Hirsch Shumaker A, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 infection. 2022 [internet publication].Full text
481. AstraZeneca. Evusheld long-acting antibody combination retains neutralising activity against Omicron variants including BA.2 in new independent studies. 2022 [internet publication].Full text
482. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022 Apr 20 [Epub ahead of print].Full text Abstract
483. Goulenok T, Delaval L, Delory N, et al. Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases. Lancet Rheumatol. 2022 Apr 11 [Epub ahead of print].Full text Abstract
484. World Health Organization. Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed: interim guidance. 2021 [internet publication].Full text
485. World Health Organization. Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline. 2022 [internet publication].Full text
486. Schoberer D, Osmancevic S, Reiter L, et al. Rapid review and meta-analysis of the effectiveness of personal protective equipment for healthcare workers during the COVID-19 pandemic. Public Health Pract (Oxf). 2022 Dec;4:100280.Full text Abstract
487. Razai MS, Doerholt K, Ladhani S, et al. Coronavirus disease 2019 (covid-19): a guide for UK GPs. BMJ. 2020 Mar 5;368:m800.Full text Abstract
488. World Health Organization. Advice for the public: coronavirus disease (COVID-19). 2022 [internet publication].Full text
489. Centers for Disease Control and Prevention. COVID-19: how to protect yourself and others. 2022 [internet publication].Full text
490. Bendavid E, Oh C, Bhattacharya J, et al. Assessing mandatory stay-at-home and business closure effects on the spread of COVID-19. Eur J Clin Invest. 2021 Jan 5:e13484.Full text Abstract
491. Chu IY, Alam P, Larson H, et al. Social consequences of mass quarantine during epidemics: a systematic review with implications for the COVID-19 response. J Travel Med. 2020 Nov 9;27(7):taaa192.Full text Abstract
492. Bundgaard H, Bundgaard JS, Raaschou-Pedersen DET, et al. Effectiveness of adding a mask recommendation to other public health measures to prevent SARS-CoV-2 infection in Danish mask wearers: a randomized controlled trial. Ann Intern Med. 2021 Mar;174(3):335-43.Full text Abstract
493. Nanda A, Hung I, Kwong A, et al. Efficacy of surgical masks or cloth masks in the prevention of viral transmission: systematic review, meta-analysis, and proposal for future trial. J Evid Based Med. 2021 May;14(2):97-111.Full text Abstract
494. Jefferson T, Del Mar CB, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2020 Nov 20;(11):CD006207.Full text Abstract
495. Chou R, Dana T, Jungbauer R, et al. Masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings: a living rapid review. Ann Intern Med. 2020 Oct 6;173(7):542-55.Full text Abstract
496. Chou R, Dana T, Jungbauer R, et al. Update alert 7: masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings. Ann Intern Med. 2022 May;175(5):W58-9.Full text Abstract
497. Sharma SK, Mishra M, Mudgal SK. Efficacy of cloth face mask in prevention of novel coronavirus infection transmission: a systematic review and meta-analysis. J Educ Health Promot. 2020 Jul 28;9:192.Full text Abstract
498. MacIntyre CR, Seale H, Dung TC, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. BMJ Open. 2015 Apr 22;5(4):e006577.Full text Abstract
499. Lazzarino AI, Steptoe A, Hamer M, et al. Covid-19: important potential side effects of wearing face masks that we should bear in mind. BMJ. 2020 May 21;369:m2003.Full text Abstract
500. Bakhit M, Krzyzaniak N, Scott AM, et al. Downsides of face masks and possible mitigation strategies: a systematic review and meta-analysis. BMJ Open. 2021 Feb 22;11(2):e044364.Full text Abstract
501. Burns J, Movsisyan A, Stratil JM, et al. Travel-related control measures to contain the COVID-19 pandemic: a rapid review. Cochrane Database Syst Rev. 2020 Oct 5;(10):CD013717.Full text Abstract
502. Viswanathan M, Kahwati L, Jahn B, et al. Universal screening for SARS-CoV-2 infection: a rapid review. Cochrane Database Syst Rev. 2020 Sep 15;(9):CD013718.Full text Abstract
503. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020 Sep 15;(9):CD013574.Full text Abstract
504. Mahase E. China coronavirus: what do we know so far? BMJ. 2020 Jan 24;368:m308.Full text Abstract
505. Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020 Mar 14;395(10227):912-20.Full text Abstract
506. Ho FK, Celis-Morales CA, Gray SR, et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open. 2020 Nov 19;10(11):e040402.Full text Abstract
507. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2021 Feb 23;(2):CD013665.Full text Abstract
508. World Health Organization. Diagnostic testing for SARS-CoV-2: interim guidance. 2020 [internet publication].Full text
509. Irfan O, Muttalib F, Tang K, et al. Clinical characteristics, treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis. Arch Dis Child. 2021 Feb 16;106(5):440-8.Full text Abstract
510. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19: scientific brief. 2020 [internet publication].Full text
511. British Society of Thoracic Imaging. Thoracic imaging in COVID-19 infection: guidance for the reporting radiologist - version 2. 2020 [internet publication].Full text
512. NHS England. Coronavirus (COVID-19) symptoms in adults. 2022 [internet publication].Full text
513. ZOE COVID Symptom Study. What are the new top 5 COVID symptoms? 2021 [internet publication].Full text
514. ZOE COVID Study. Omicron and cold-like symptoms rapidly taking over in London. 2021 [internet publication].Full text
515. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022 Apr 23;399(10335):1618-24.Full text Abstract
516. Matar R, Alrahmani L, Monzer N, et al. Clinical presentation and outcomes of pregnant women with coronavirus disease 2019: a systematic review and meta-analysis. Clin Infect Dis. 2021 Feb 1;72(3):521-33.Full text Abstract
517. Lechien JR, Chetrit A, Chekkoury-Idrissi Y, et al. Parotitis-like symptoms associated with COVID-19, France, March-April 2020. Emerg Infect Dis. 2020 Jun 3;26(9).Full text Abstract
518. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, et al. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2021 Apr;27 Suppl 3:710-2.Full text Abstract
519. Marinho PM, Marcos AAA, Romano AC, et al. Retinal findings in patients with COVID-19. Lancet. 2020 May 23;395(10237):1610.Full text Abstract
520. Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of hospitalized COVID-19 patients: the "Gabrin sign". J Am Acad Dermatol. 2020 May 21;83(2):680-2.Full text Abstract
521. Giannos P, Katsikas Triantafyllidis K, Geropoulos G, et al. Persistent hiccups as an atypical presentation of SARS-CoV-2 infection: a systematic review of case reports. Front Neurol. 2022 Apr 4;13:819624.Full text Abstract
522. Musuuza JS, Watson L, Parmasad V, et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS One. 2021 May 6;16(5):e0251170.Full text Abstract
523. Wang Y, Xu J, Wang Y, et al. Prevalence of comorbid tuberculosis amongst COVID-19 patients: a rapid review and meta-analysis. Int J Clin Pract. 2021 Nov;75(11):e14867.Full text Abstract
524. Achan J, Serwanga A, Wanzira H, et al. Current malaria infection, previous malaria exposure, and clinical profiles and outcomes of COVID-19 in a setting of high malaria transmission: an exploratory cohort study in Uganda. Lancet Microbe. 2022 Jan;3(1):e62-71.Full text Abstract
525. Dadashi M, Dadashi A, Sameni F, et al. SARS-CoV-2 and HIV co-infection; clinical features, diagnosis, and treatment strategies: a systematic review and meta-analysis. Gene Rep. 2022 Jun;27:101624.Full text Abstract
526. Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids: an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021 Mar 6;:1-8.Full text Abstract
527. Mahase E. Covid-19: Children less likely to report fever, persistent cough, or appetite loss, large UK study finds. BMJ. 2021 Feb 10;372:n408.Full text Abstract
528. Bolia R, Dhanesh Goel A, Badkur M, et al. Gastrointestinal manifestations of pediatric coronavirus disease and their relationship with a severe clinical course: a systematic review and meta-analysis. J Trop Pediatr. 2021 May 17;67(2):fmab051.Full text Abstract
529. Lorenz N, Treptow A, Schmidt S, et al. Neonatal early-onset infection with SARS-CoV-2 in a newborn presenting with encephalitic symptoms. Pediatr Infect Dis J. 2020 Aug;39(8):e212. Abstract
530. Chacón-Aguilar R, Osorio-Cámara JM, Sanjurjo-Jimenez I, et al. COVID-19: fever syndrome and neurological symptoms in a neonate. An Pediatr (Engl Ed). 2020 Apr 27;92(6):373-4.Full text Abstract
531. Sinelli MT, Paterlini G, Citterio M, et al. Early neonatal SARS-CoV-2 infection manifesting with hypoxemia requiring respiratory support. Pediatrics. 2020 Jul;146(1):e20201121.Full text Abstract
532. Rubens JH, Akindele NP, Tschudy MM, et al. Acute covid-19 and multisystem inflammatory syndrome in children. BMJ. 2021 Mar 1;372:n385.Full text Abstract
533. Garazzino S, Montagnani C, Donà D, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill. 2020 May;25(18).Full text Abstract
534. DeBiasi RL, Song X, Delaney M, et al. Severe COVID-19 in children and young adults in the Washington, DC metropolitan region. J Pediatr. 2020 Aug;223:199-203.Full text Abstract
535. Vasudevan RS, Bin Thani K, Aljawder D, et al. The stethoscope: a potential vector for COVID-19? Eur Heart J. 2020 Sep 21;41(36):3393-5.Full text Abstract
536. Ikeuchi K, Saito M, Yamamoto S, et al. Relative bradycardia in patients with mild-to-moderate coronavirus disease, Japan. Emerg Infect Dis. 2020 Jul 1;26(10).Full text Abstract
537. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. 2022 [internet publication].Full text
538. Xie J, Tong Z, Guan X, et al. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020 May;46(5):837-40.Full text Abstract
539. Centers for Disease Control and Prevention. COVID-19: clinical care considerations. 2022 [internet publication].Full text
540. US Food and Drug Administration. Pulse oximeter accuracy and limitations: FDA safety communication. 2022 [internet publication].Full text
541. Royal College of Physicians. NEWS2 and deterioration in COVID-19. 2020 [internet publication].Full text
542. Zhang K, Zhang X, Ding W, et al. The prognostic accuracy of national early warning score 2 on predicting clinical deterioration for patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jul 9;8:699880.Full text Abstract
543. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Jun;92(6):577-83.Full text Abstract
544. Zhu J, Zhong Z, Ji P, et al. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Fam Med Community Health. 2020 Apr;8(2).Full text Abstract
545. Zhang ZL, Hou YL, Li DT, et al. Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Invest. 2020 May 23:1-7.Full text Abstract
546. Wu H, Zhu H, Yuan C, et al. Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China. JAMA Netw Open. 2020 Jun 1;3(6):e2010895.Full text Abstract
547. Henry BM, Benoit SW, de Oliveira MHS, et al. Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): a pooled analysis and review. Clin Biochem. 2020 Jul;81:1-8.Full text Abstract
548. Kronbichler A, Kresse D, Yoon S, et al. Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis. Int J Infect Dis. 2020 Sep;98:180-6.Full text Abstract
549. Peeling RW, Heymann DL, Teo YY, et al. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2021 Dec 20;399(10326):757-68.Full text Abstract
550. World Health Organization. WHO information notice for IVD users 2020/05. 2021 [internet publication].Full text
551. US Food and Drug Administration. SARS-CoV-2 viral mutations: impact on COVID-19 tests. 2021 [internet publication].Full text
552. World Health Organization. Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities: interim guidance. 2021 [internet publication].Full text
553. UK Health Security Agency. Changes to COVID-19 testing in England from 1 April. 2022 [internet publication].Full text
554. NHS England. Living with COVID-19: testing update. 2022 [internet publication].Full text
555. Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2, the virus that causes COVID-19. 2022 [internet publication].Full text
556. Tsang NNY, So HC, Ng KY, et al. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. Lancet Infect Dis. 2021 Apr 12;21(9):1233-45.Full text Abstract
557. Bastos ML, Perlman-Arrow S, Menzies D, et al. The sensitivity and costs of testing for SARS-CoV-2 infection with saliva versus nasopharyngeal swabs: a systematic review and meta-analysis. Ann Intern Med. 2021 Apr;174(4):501-10.Full text Abstract
558. Butler-Laporte G, Lawandi A, Schiller I, et al. Comparison of saliva and nasopharyngeal swab nucleic acid amplification testing for detection of SARS-CoV-2: a systematic review and meta-analysis. JAMA Intern Med. 2021 Mar 1;181(3):353-60.Full text Abstract
559. Cañete MG, Valenzuela IM, Garcés PC, et al. Saliva sample for the massive screening of SARS-CoV-2 infection: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 May;131(5):540-8.Full text Abstract
560. Moreira VM, Mascarenhas P, Machado V, et al. Diagnosis of SARS-Cov-2 infection by RT-PCR using specimens other than naso- and oropharyngeal swabs: a systematic review and meta-analysis. Diagnostics (Basel). 2021 Feb 21;11(2):363.Full text Abstract
561. Atieh MA, Guirguis M, Alsabeeha NHM, et al. The diagnostic accuracy of saliva testing for SARS-CoV-2: a systematic review and meta-analysis. Oral Dis. 2021 Jun 3 [Epub ahead of print].Full text Abstract
562. Ibrahimi N, Delaunay-Moisan A, Hill C, et al. Screening for SARS-CoV-2 by RT-PCR: saliva or nasopharyngeal swab? Rapid review and meta-analysis. PLoS One. 2021 Jun 10;16(6):e0253007.Full text Abstract
563. Centers for Disease Control and Prevention. Interim guidelines for collecting and handling of clinical specimens for COVID-19 testing. 2022 [internet publication].Full text
564. Centers for Disease Control and Prevention. Nucleic acid amplification tests (NAATs). 2021 [internet publication].Full text
565. Zhou Y, O'Leary TJ. Relative sensitivity of anterior nares and nasopharyngeal swabs for initial detection of SARS-CoV-2 in ambulatory patients: Rapid review and meta-analysis. PLoS One. 2021 Jul 20;16(7):e0254559.Full text Abstract
566. Gupta K, Bellino PM, Charness ME. Adverse effects of nasopharyngeal swabs: three-dimensional printed versus commercial swabs. Infect Control Hosp Epidemiol. 2021 May;42(5):641-2.Full text Abstract
567. Koskinen A, Tolvi M, Jauhiainen M, et al. Complications of COVID-19 nasopharyngeal swab test. JAMA Otolaryngol Head Neck Surg. 2021 Jul 1;147(7):672-4.Full text Abstract
568. Sullivan CB, Schwalje AT, Jensen M, et al. Cerebrospinal fluid leak after nasal swab testing for coronavirus disease 2019. JAMA Otolaryngol Head Neck Surg. 2020 Dec 1;146(12):1179-81.Full text Abstract
569. Knížek Z, Michálek R, Vodicka J, et al. Cribriform plate injury after nasal swab testing for COVID-19. JAMA Otolaryngol Head Neck Surg. 2021 Oct 1;147(10):915-7.Full text Abstract
570. Jarrom D, Elston L, Washington J, et al. Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. BMJ Evid Based Med. 2022 Feb;27(1):33-45.Full text Abstract
571. Centre for Evidence-Based Medicine; Jefferson T, Heneghan C, Spencer EA, et al. Are you infectious if you have a positive PCR test result for COVID-19? 2020 [internet publication].Full text
572. Jefferson T, Spencer EA, Brassey J, et al. Viral cultures for coronavirus disease 2019 infectivity assessment: a systematic review. Clin Infect Dis. 2021 Dec 6;73(11):e3884-99.Full text Abstract
573. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. BMJ. 2020 May 12;369:m1808.Full text Abstract
574. Bullard J, Dust K, Funk D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis. 2020 Dec 17;71(10):2663-6.Full text Abstract
575. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-61.Full text Abstract
576. Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results: hidden problems and costs. Lancet Respir Med. 2020 Dec;8(12):1167-8.Full text Abstract
577. Floriano I, Silvinato A, Bernardo WM, et al. Accuracy of the polymerase chain reaction (PCR) test in the diagnosis of acute respiratory syndrome due to coronavirus: a systematic review and meta-analysis. Rev Assoc Med Bras (1992). 2020 Jul;66(7):880-8.Full text Abstract
578. Public Health Laboratory Network. PHLN statement on nucleic acid test false positive results for SARS-CoV-2. 2020 [internet publication].Full text
579. Australian Government Department of Health. COVID-19 testing in Australia: information for health professionals. 2022 [internet publication].Full text
580. US Food and Drug Administration. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. 2020 [internet publication].Full text
581. Government Office for Science; Scientific Advisory Group for Emergencies. Impact of false-positives and false-negatives in the UK’s COVID-19 RT-PCR testing programme. 2020 [internet publication].Full text
582. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. PLoS One. 2020 Dec 10;15(12):e0242958.Full text Abstract
583. Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020 Aug 18;173(4):262-7.Full text Abstract
584. Watson J, Richter A, Deeks J. Testing for SARS-CoV-2 antibodies. BMJ. 2020 Sep 8;370:m3325.Full text Abstract
585. Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing. 2022 [internet publication].Full text
586. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: serologic testing. 2020 [internet publication].Full text
587. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Jun;26(6):845-8.Full text Abstract
588. Qu J, Wu C, Li X, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Nov 19;71(16):2255-8.Full text Abstract
589. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020 Jun 25;(6):CD013652.Full text Abstract
590. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection. 2021 [internet publication].Full text
591. World Health Organization. Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing. 2022 [internet publication].Full text
592. Government of the United Kingdom. Order coronavirus (COVID-19) rapid lateral flow tests. 2022 [internet publication].Full text
593. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: antigen testing. 2021 [internet publication].Full text
594. Centers for Disease Control and Prevention. Guidance for antigen testing for SARS-CoV-2 for healthcare providers testing individuals in the community. 2022 [internet publication].Full text
595. US Food and Drug Administration. Potential for false positive results with antigen tests for rapid detection of SARS-CoV-2: letter to clinical laboratory staff and health care providers. 2020 [internet publication].Full text
596. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021 Mar 24;(3):CD013705.Full text Abstract
597. Mistry DA, Wang JY, Moeser ME, et al. A systematic review of the sensitivity and specificity of lateral flow devices in the detection of SARS-CoV-2. BMC Infect Dis. 2021 Aug 18;21(1):828.Full text Abstract
598. Fujita-Rohwerder N, Beckmann L, Zens Y, et al. Diagnostic accuracy of rapid point-of-care tests for diagnosis of current SARS-CoV-2 infections in children: a systematic review and meta-analysis. BMJ Evid Based Med. 2022 Jan 18 [Epub ahead of print].Full text Abstract
599. García-Fiñana M, Hughes DM, Cheyne CP, et al. Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study. BMJ. 2021 Jul 6;374:n1637.Full text Abstract
600. Wagenhäuser I, Knies K, Rauschenberger V, et al. Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR. EBioMedicine. 2021 Jun 26;69:103455.Full text Abstract
601. Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis. PLoS Med. 2021 Aug;18(8):e1003735.Full text Abstract
602. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief. 2020 [internet publication].Full text
603. Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020 Jul 1;370:m2516.Full text Abstract
604. Poon LC, Yang H, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: information for healthcare professionals. Int J Gynaecol Obstet. 2020 Jun;149(3):273-86.Full text Abstract
605. Sadiq Z, Rana S, Mahfoud Z, et al. Systematic review and meta-analysis of chest radiograph (CXR) findings in COVID-19. Clin Imaging. 2021 Jul 27;80:229-38.Full text Abstract
606. Islam N, Ebrahimzadeh S, Salameh JP, et al. Thoracic imaging tests for the diagnosis of COVID-19. Cochrane Database Syst Rev. 2021 Mar 16;(3):CD013639.Full text Abstract
607. World Health Organization. Use of chest imaging in COVID-19: a rapid advice guide. 2020 [internet publication].Full text
608. Centre for Evidence-Based Medicine; Park JY, Freer R, Stevens R, et al. The accuracy of chest CT in the diagnosis of COVID-19: an umbrella review. 2021 [internet publication].Full text
609. Tavare AN, Braddy A, Brill S, et al. Managing high clinical suspicion COVID-19 inpatients with negative RT-PCR: a pragmatic and limited role for thoracic CT. Thorax. 2020 Jul;75(7):537-8.Full text Abstract
610. American College of Radiology. ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. 2020 [internet publication].Full text
611. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020 Sep;92(9):1518-24.Full text Abstract
612. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Apr;80(4):388-93.Full text Abstract
613. Long C, Xu H, Shen Q, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. 2020 Mar 25;126:108961.Full text Abstract
614. Chen C, Zhu C, Yan D, et al. The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): a systematic review and meta-analysis. Int J Infect Dis. 2021 Mar;104:458-64.Full text Abstract
615. Oshay RR, Chen MYC, Fields BKK, et al. COVID-19 in pregnancy: a systematic review of chest CT findings and associated clinical features in 427 patients. Clin Imaging. 2021 Jan 13;75:75-82.Full text Abstract
616. Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020 Jun;92(6):612-7.Full text Abstract
617. Ojha V, Mani A, Pandey NN, et al. CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients. Eur Radiol. 2020 Nov;30(11):6129-38.Full text Abstract
618. Garg M, Gupta P, Maralakunte M, et al. Diagnostic accuracy of CT and radiographic findings for novel coronavirus 2019 pneumonia: systematic review and meta-analysis. Clin Imaging. 2020 Nov 11;72:75-82.Full text Abstract
619. Hossein H, Ali KM, Hosseini M, et al. Value of chest computed tomography scan in diagnosis of COVID-19: a systematic review and meta-analysis. Clin Transl Imaging. 2020 Oct 12:1-13.Full text Abstract
620. Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020 Jul 28;71(15):756-61.Full text Abstract
621. Wang JG, Mo YF, Su YH, et al. Computed tomography features of COVID-19 in children: a systematic review and meta-analysis. Medicine (Baltimore). 2021 Sep 24;100(38):e22571.Full text Abstract
622. Ghodsi A, Bijari M, Alamdaran SA, et al. Chest computed tomography findings of COVID-19 in children younger than 1 year: a systematic review. World J Pediatr. 2021 Jun;17(3):234-41.Full text Abstract
623. Gil-Rodríguez J, Pérez de Rojas J, Aranda-Laserna P, et al. Ultrasound findings of lung ultrasonography in COVID-19: a systematic review. Eur J Radiol. 2022 Jan 20;148:110156.Full text Abstract
624. Moro F, Buonsenso D, Moruzzi MC, et al. How to perform lung ultrasound in pregnant women with suspected COVID-19 infection. Ultrasound Obstet Gynecol. 2020 May;55(5):593-8.Full text Abstract
625. Denina M, Scolfaro C, Silvestro E, et al. Lung ultrasound in children with COVID-19. Pediatrics. 2020 Jul;146(1):e20201157.Full text Abstract
626. Caroselli C, Blaivas M, Falzetti S. Diagnostic imaging in newborns, children and adolescents infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): is there a realistic alternative to lung high-resolution computed tomography (HRCT) and chest x-rays? A systematic review of the literature. Ultrasound Med Biol. 2021 Nov;47(11):3034-40.Full text Abstract
627. Pillai K, Hewage S, Harky A. The role of the lung ultrasound in coronavirus disease 2019: a systematic review. J Med Ultrasound. 2020 Oct-Dec;28(4):207-12.Full text Abstract
628. Song G, Qiao W, Wang X, et al. Association of lung ultrasound score with mortality and severity of COVID-19: a meta-analysis and trial sequential analysis. Int J Infect Dis. 2021 Jul;108:603-9.Full text Abstract
629. Park GS, Ku K, Baek SH, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2. J Mol Diagn. 2020 Jun;22(6):729-35.Full text Abstract
630. Baek YH, Um J, Antigua KJC, et al. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. Emerg Microbes Infect. 2020 Apr 20:1-31.Full text Abstract
631. Lu R, Wu X, Wan Z, et al. A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2. Int J Mol Sci. 2020 Apr 18;21(8).Full text Abstract
632. Baba MM, Bitew M, Fokam J, et al. Diagnostic performance of a colorimetric RT-LAMP for the identification of SARS-CoV-2: a multicenter prospective clinical evaluation in sub-Saharan Africa. EClinicalMedicine. 2021 Aug 28;40:101101.Full text Abstract
633. Subali AD, Wiyono L. Reverse Transcriptase Loop Mediated Isothermal AmplifiCation (RT-LAMP) for COVID-19 diagnosis: a systematic review and meta-analysis. Pathog Glob Health. 2021 Jun 4:1-11.Full text Abstract
634. Ganbaatar U, Liu C. CRISPR-based COVID-19 testing: toward next-generation point-of-care diagnostics Front Cell Infect Microbiol. 2021 Apr 30;11:663949.Full text Abstract
635. Wang S, Hu J, Sui C, et al. Accuracy of clustered regularly interspaced short palindromic repeats (CRISPR) to diagnose COVID-19, a meta-analysis. Microb Pathog. 2022 Mar 25;165:105498.Full text Abstract
636. Huang PY, Yin X, Huang YT, et al. Evaluation of CRISPR-based assays for rapid detection of SARS-CoV-2: a systematic review and meta-analysis. Yonsei Med J. 2022 May;63(5):480-9.Full text Abstract
637. Abumeeiz M, Elliott L, Olla P. Use of breath analysis for diagnosing COVID-19: opportunities, challenges, and considerations for future pandemic responses. Disaster Med Public Health Prep. 2021 Oct 15:1-4.Full text Abstract
638. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first COVID-19 diagnostic test using breath samples. 2022 [internet publication].Full text
639. Udeh R, Advani S, de Guadiana Romualdo LG, et al. Calprotectin, an emerging biomarker of interest in COVID-19: a systematic review and meta-analysis. J Clin Med. 2021 Feb 15;10(4):775.Full text Abstract
640. Mao Q, Wang C, Wen W, et al. A meta-analysis of the association between calprotectin and the severity of COVID-19. J Infect. 2022 Mar;84(3):e31-3.Full text Abstract
641. Xie Y, Wang Z, Liao H, et al. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis. 2020 Aug 31;20(1):640.Full text Abstract
642. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20.Full text Abstract
643. Islam MA, Kundu S, Alam SS, et al. Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of 17515 patients. PLoS One. 2021;16(4):e0249788.Full text Abstract
644. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020 Apr 23;382(17):1663-5.Full text Abstract
645. Song WJ, Hui CKM, Hull JH, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med. 2021 May;9(5):533-44.Full text Abstract
646. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7;323(11):1061-9.Full text Abstract
647. Grant MC, Geoghegan L, Arbyn M, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020 Jun 23;15(6):e0234765.Full text Abstract
648. Talukder A, Razu SR, Alif SM, et al. Association between symptoms and severity of disease in hospitalised novel coronavirus (COVID-19) patients: a systematic review and meta-analysis. J Multidiscip Healthc. 2022 May 12;15:1101-10.Full text Abstract
649. Cardoso CC, Rossi ÁD, Galliez RM, et al. Olfactory dysfunction in patients with mild COVID-19 during Gamma, Delta, and Omicron waves in Rio de Janeiro, Brazil. JAMA. 2022 Jun 24 [Epub ahead of print].Full text Abstract
650. Hariyanto TI, Rizki NA, Kurniawan A. Anosmia/hyposmia is a good predictor of coronavirus disease 2019 (COVID-19) infection: a meta-analysis. Int Arch Otorhinolaryngol. 2021 Jan;25(1):e170-4.Full text Abstract
651. Esmaeili M, Abdi F, Shafiee G, et al. Olfactory and gustatory dysfunction in 2019 novel coronavirus: an updated systematic review and meta-analysis. Int J Prev Med. 2021 Dec 14;12:170.Full text Abstract
652. Agyeman AA, Chin KL, Landersdorfer CB, et al. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1621-31.Full text Abstract
653. Eliezer M, Hautefort C, Hamel AL, et al. Sudden and complete olfactory loss function as a possible symptom of COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):674-5.Full text Abstract
654. Santos REA, da Silva MG, do Monte Silva MCB, et al. Onset and duration of symptoms of loss of smell/taste in patients with COVID-19: a systematic review. Am J Otolaryngol. 2021 Jan 6;42(2):102889.Full text Abstract
655. Jafar A, Lasso A, Shorr R, et al. Olfactory recovery following infection with COVID-19: a systematic review. PLoS One. 2021 Nov 9;16(11):e0259321.Full text Abstract
656. Renaud M, Thibault C, Le Normand F, et al. Clinical outcomes for patients with anosmia 1 year after COVID-19 diagnosis. JAMA Netw Open. 2021 Jun 1;4(6):e2115352.Full text Abstract
657. Tan HQM, Pendolino AL, Andrews PJ, et al. Prevalence of olfactory dysfunction and quality of life in hospitalised patients 1 year after SARS-CoV-2 infection: a cohort study. BMJ Open. 2022 Jan 25;12(1):e054598.Full text Abstract
658. Walker A, Kelly C, Pottinger G, et al. Parosmia: a common consequence of covid-19. BMJ. 2022 Apr 27;377:e069860.Full text Abstract
659. Ferraro S, Tuccori M, Convertino I, et al. Olfactory and gustatory impairments in COVID-19 patients: role in early diagnosis and interferences by concomitant drugs. Br J Clin Pharmacol. 2021 May;87(5):2186-8.Full text Abstract
660. Yan Q, Qiu D, Liu X, et al. Prevalence of smell or taste dysfunction among children with COVID-19 infection: a systematic review and meta-analysis. Front Pediatr. 2021 Aug 3;9:686600.Full text Abstract
661. Mutiawati E, Syahrul S, Fahriani M, et al. Global prevalence and pathogenesis of headache in COVID-19: a systematic review and meta-analysis. F1000Res. 2020 Nov 12;9:1316.Full text Abstract
662. Parisi S, Borrelli R, Bianchi S, et al. Viral arthritis and COVID-19. Lancet Rheumatol. 2020 Nov;2(11):e655-7.Full text Abstract
663. Chaudhry ZS, Nellessen N, Reis C, et al. The development of inflammatory arthritis following SARS-CoV-2 infection: a systematic review of the literature. Fam Pract. 2022 Apr 8 [Epub ahead of print]. Abstract
664. Tariq R, Saha S, Furqan F, et al. Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1632-48.Full text Abstract
665. Chen A, Agarwal A, Ravindran N, et al. Are gastrointestinal symptoms specific for coronavirus infection? A prospective case-control study from the United States. Gastroenterology. 2020 Sep;159(3):1161-3.Full text Abstract
666. Aziz M, Haghbin H, Lee-Smith W, et al. Gastrointestinal predictors of severe COVID-19: systematic review and meta-analysis. Ann Gastroenterol. 2020 Nov-Dec;33(6):615-30.Full text Abstract
667. Zeng W, Qi K, Ye M, et al. Gastrointestinal symptoms are associated with severity of coronavirus disease 2019: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022 Feb 1;34(2):168-76.Full text Abstract
668. Shehab M, Alrashed F, Shuaibi S, et al. Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: systematic review and meta-analysis. BMJ Open Gastroenterol. 2021 Mar;8(1):e000571.Full text Abstract
669. Wang Y, Li Y, Zhang Y, et al. Are gastrointestinal symptoms associated with higher risk of mortality in COVID-19 patients? A systematic review and meta-analysis. BMC Gastroenterol. 2022 Mar 7;22(1):106.Full text Abstract
670. Guotao L, Xingpeng Z, Zhihui D, et al. SARS-CoV-2 infection presenting with hematochezia. Med Mal Infect. 2020 May;50(3):293-6.Full text Abstract
671. Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y). 2022 Jun 10;3(6):371-87.Full text Abstract
672. Shao SC, Lai CC, Chen YH, et al. Prevalence, incidence and mortality of delirium in patients with COVID-19: A systematic review and meta-analysis. Age Ageing. 2021 Sep 11;50(5):1445-53.Full text Abstract
673. Pun BT, Badenes R, Heras La Calle G, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. Lancet Respir Med. 2021 Mar;9(3):239-50.Full text Abstract
674. Cénat JM, Blais-Rochette C, Kokou-Kpolou CK, et al. Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: a systematic review and meta-analysis. Psychiatry Res. 2020 Nov 26;295:113599.Full text Abstract
675. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020 Oct;7(10):875-82.Full text Abstract
676. Nasiri N, Sharifi H, Bazrafshan A, et al. Ocular manifestations of COVID-19: a systematic review and meta-analysis. J Ophthalmic Vis Res. 2021 Jan-Mar;16(1):103-12.Full text Abstract
677. Inomata T, Kitazawa K, Kuno T, et al. Clinical and prodromal ocular symptoms in coronavirus disease: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):29.Full text Abstract
678. Ma N, Li P, Wang X, et al. Ocular manifestations and clinical characteristics of children with laboratory-confirmed COVID-19 in Wuhan, China. JAMA Ophthalmol. 2020 Oct 1;138(10):1079-86.Full text Abstract
679. Zhong Y, Wang K, Zhu Y, et al. Ocular manifestations in COVID-19 patients: A systematic review and meta-analysis. Travel Med Infect Dis. 2021 Nov-Dec;44:102191.Full text Abstract
680. Sen S, Kannan NB, Kumar J, et al. Retinal manifestations in patients with SARS-CoV-2 infection and pathogenetic implications: a systematic review. Int Ophthalmol. 2022 Jan;42(1):323-36.Full text Abstract
681. Ullah I, Sohail A, Shah MUFA, et al. Central retinal vein occlusion in patients with COVID-19 infection: a systematic review. Ann Med Surg (Lond). 2021 Oct 8:102898.Full text Abstract
682. Modjtahedi BS, Do D, Luong TQ, et al. Changes in the incidence of retinal vascular occlusions after COVID-19 diagnosis. JAMA Ophthalmol. 2022 May 1;140(5):523-7.Full text Abstract
683. Almufarrij I, Munro KJ. One year on: an updated systematic review of SARS-CoV-2, COVID-19 and audio-vestibular symptoms. Int J Audiol. 2021 Mar 22:1-11.Full text Abstract
684. Meng X, Wang J, Sun J, et al. COVID-19 and sudden sensorineural hearing loss: a systematic review. Front Neurol. 2022 Apr 28;13:883749.Full text Abstract
685. Casey K, Iteen A, Nicolini R, et al. COVID-19 pneumonia with hemoptysis: acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med. 2020 Jul;38(7):1544.Full text Abstract
686. Bandhala Rajan M, Kumar-M P, Bhardwaj A. The trend of cutaneous lesions during COVID-19 pandemic: lessons from a meta-analysis and systematic review. Int J Dermatol. 2020 Nov;59(11):1358-70.Full text Abstract
687. Kashetsky N, Mukovozov IM, Bergman J. Chilblain-like lesions (CLL) associated with COVID-19 ("COVID toes"): a systematic review. J Cutan Med Surg. 2021 Nov-Dec;25(6):627-33.Full text Abstract
688. Visconti A, Bataille V, Rossi N, et al. Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection. Br J Dermatol 2021 May;184(5):880-7.Full text
689. Schwartzberg LN, Advani S, Clancy DC, et al. A systematic review of dermatologic manifestations among adult patients with COVID-19 diagnosis. Skin Health Dis. 2021 Jun;1(2):e20.Full text Abstract
690. Shah S, Akhade K, Ganguly S, et al. Cutaneous manifestations associated with COVID-19 in children: A systematic review. J Family Med Prim Care. 2021 Jan;10(1):93-101.Full text Abstract
691. Discepolo V, Catzola A, Pierri L, et al. Bilateral chilblain-like lesions of the toes characterized by microvascular remodeling in adolescents during the COVID-19 pandemic. JAMA Netw Open. 2021 Jun 1;4(6):e2111369.Full text Abstract
692. Gehlhausen JR, Little AJ, Ko CJ, et al. Lack of association between pandemic chilblains and SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2122090119.Full text Abstract
694. Erbaş GS, Botsali A, Erden N, et al. COVID-19-related oral mucosa lesions among confirmed SARS-CoV-2 patients: a systematic review. Int J Dermatol. 2022 Jan;61(1):20-32.Full text Abstract
695. Holcomb ZE, Hussain S, Huang JT, et al. Reactive infectious mucocutaneous eruption associated with SARS-CoV-2 infection. JAMA Dermatol. 2021 May 1;157(5):603-5.Full text Abstract
696. Mashayekhi F, Seirafianpour F, Pour Mohammad A, et al. Severe and life-threatening COVID-19-related mucocutaneous eruptions: a systematic review. Int J Clin Pract. 2021 Aug 19:e14720.Full text Abstract
697. Bhujel N, Zaheer K, Singh RP. Oral mucosal lesions in patients with COVID-19: a systematic review. Br J Oral Maxillofac Surg. 2021 Nov;59(9):1024-30.Full text Abstract
698. Creta M, Sagnelli C, Celentano G, et al. SARS-CoV-2 infection affects the lower urinary tract and male genital system: a systematic review. J Med Virol. 2021 May;93(5):3133-42.Full text Abstract
699. Haghpanah A, Masjedi F, Salehipour M, et al. Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms? A systematic review. Prostate Cancer Prostatic Dis. 2021 May 18;1-12.Full text Abstract
700. Xie Y, Mirzaei M, Kahrizi MS, et al. SARS-CoV-2 effects on sperm parameters: a meta-analysis study. J Assist Reprod Genet. 2022 Jun 18 [Epub ahead of print].Full text Abstract
701. US Food and Drug Administration. Genetic variants of SARS-CoV-2 may lead to false negative results with molecular tests for detection of SARS-CoV-2: letter to clinical laboratory staff and health care providers. 2021 [internet publication].Full text
702. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: molecular diagnostic testing. 2020 [internet publication].Full text
703. Danwang C, Endomba FT, Nkeck JR, et al. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020 Aug 31;8:37.Full text Abstract
704. Zuin M, Rigatelli G, Quadretti L, et al. Prognostic role of anemia in COVID-19 patients: a meta-analysis. Infect Dis Rep. 2021 Oct 31;13(4):930-7.Full text Abstract
705. Foy BH, Carlson JCT, Reinertsen E, et al. Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection. JAMA Netw Open. 2020 Sep 1;3(9):e2022058.Full text Abstract
706. Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry A. 2020 Aug;97(8):772-6.Full text Abstract
707. Chen W, Li Z, Yang B, et al. Delayed-phase thrombocytopenia in patients of coronavirus disease 2019 (COVID-19). Br J Haematol. 2020 Jul;190(2):179-84.Full text Abstract
708. Chen D, Li X, Song Q, et al. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China. JAMA Netw Open. 2020 Jun 1;3(6):e2011122.Full text Abstract
709. Alemzadeh E, Alemzadeh E, Ziaee M, et al. The effect of low serum calcium level on the severity and mortality of Covid patients: a systematic review and meta-analysis. Immun Inflamm Dis. 2021 Dec;9(4):1219-28.Full text Abstract
710. Akbar MR, Pranata R, Wibowo A, et al. The prognostic value of hyponatremia for predicting poor outcome in patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jun 14;8:666949.Full text Abstract
711. Lazarus G, Audrey J, Kharisma Wangsaputra V, et al. High admission blood glucose independently predicts poor prognosis in COVID-19 patients: a systematic review and dose-response meta-analysis. Diabetes Res Clin Pract. 2020 Dec 9:108561.Full text Abstract
712. Handayani DR, Juliastuti H, Nawangsih EN, et al. Prognostic value of fasting hyperglycemia in patients with COVID-19: diagnostic test accuracy meta-analysis. Obes Med. 2021 Apr 4:100333.Full text Abstract
713. Klonoff DC, Messler JC, Umpierrez GE, et al. Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis. Diabetes Care. 2021 Feb;44(2):578-85.Full text Abstract
714. Nugroho J, Wardhana A, Mulia EP, et al. Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: a meta-analysis. Clin Hemorheol Microcirc. 2021;77(2):221-31.Full text Abstract
715. Shah S, Shah K, Patel SB, et al. Elevated D-dimer levels are associated with increased risk of mortality in COVID-19: a systematic review and meta-analysis. Cardiol Rev. 2020 Nov/Dec;28(6):295-302. Abstract
716. Leonard-Lorant I, Delabranche X, Severac F, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiology. 2020 Apr 23:201561.Full text Abstract
717. Mucha SR, Dugar S, McCrae K, et al. Coagulopathy in COVID-19. Cleve Clin J Med. 2020 Jul 31;87(8):461-8.Full text Abstract
718. Zinellu A, Paliogiannis P, Carru C, et al. INR and COVID-19 severity and mortality: a systematic review with meta-analysis and meta-regression. Adv Med Sci. 2021 Jul 21;66(2):372-80.Full text Abstract
719. Rostami M, Mansouritorghabeh H, Parsa-Kondelaji M. High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis. Clin Exp Med. 2021 Nov 6;1-11.Full text Abstract
720. Wungu CDK, Khaerunnisa S, Putri EAC, et al. Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19. Int J Infect Dis. 2021 Mar 9;105:551-9.Full text Abstract
721. Yitbarek GY, Walle Ayehu G, Asnakew S, et al. The role of C-reactive protein in predicting the severity of COVID-19 disease: a systematic review. SAGE Open Med. 2021 Oct 11;9:20503121211050755.Full text Abstract
722. Smilowitz NR, Kunichoff D, Garshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 Jun 14;42(23):2270-9.Full text Abstract
723. Soraya GV, Ulhaq ZS. Interleukin-6 levels in children developing SARS-CoV-2 infection. Pediatr Neonatol. 2020 Jun;61(3):253-4.Full text Abstract
724. Qin R, He L, Yang Z, et al. Identification of parameters representative of immune dysfunction in patients with severe and fatal COVID-19 infection: a systematic review and meta-analysis. Clin Rev Allergy Immunol. 2022 Jan 18;1-33.Full text Abstract
725. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020 May;55(5):1169-74.Full text Abstract
726. Cheng L, Li H, Li L, et al. Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Lab Anal. 2020 Oct 19:e23618.Full text Abstract
727. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-4.Full text Abstract
728. Fu J, Huang PP, Zhang S, et al. The value of serum amyloid A for predicting the severity and recovery of COVID-19. Exp Ther Med. 2020 Oct;20(4):3571-7.Full text Abstract
729. Li Y, Xiaojing H, Zhuanyun L, et al. Prognostic value of serum amyloid A in COVID-19: a meta-analysis. Medicine (Baltimore). 2022 Feb 18;101(7):e28880.Full text Abstract
730. Kumar J, Meena J, Yadav A, et al. Radiological findings of COVID-19 in children: a systematic review and meta-analysis. J Trop Pediatr. 2021 Jul 2;67(3):fmaa045.Full text Abstract
731. Kim H, Hong H, Yoon SH. Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology. 2020 Apr 17:201343.Full text Abstract
732. Lv M, Wang M, Yang N, et al. Chest computed tomography for the diagnosis of patients with coronavirus disease 2019 (COVID-19): a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):622.Full text Abstract
733. Mair MDD, Hussain M, Siddiqui S, et al. A systematic review and meta-analysis comparing the diagnostic accuracy of initial RT-PCR and CT scan in suspected COVID-19 patients. Br J Radiol. 2020 Dec 22:20201039.Full text Abstract
734. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020 Feb 26:200642.Full text Abstract
735. US Food and Drug Administration. Stop using Innova Medical Group SARS-CoV-2 antigen rapid qualitative test: FDA safety communication. 2021 [internet publication].Full text
736. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes antigen test as first over-the-counter fully at-home diagnostic test for COVID-19. 2020 [internet publication].Full text
737. Jari R, Alfuraih AM, McLaughlan JR. The diagnostic performance of lung ultrasound for detecting COVID-19 in emergency departments: a systematic review and meta-analysis. J Clin Ultrasound. 2022 Mar 9 [Epub ahead of print].Full text Abstract
738. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first COVID-19 test for self-testing at home. 2020 [internet publication].Full text
739. Centre for Evidence-Based Medicine; Heneghan C, Pluddemann A, Mahtani KR. Differentiating viral from bacterial pneumonia. 2020 [internet publication].Full text
740. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging. 2020 May;101(5):263-8.Full text Abstract
741. Pormohammad A, Ghorbani S, Khatami A, et al. Comparison of influenza type A and B with COVID-19: a global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev Med Virol. 2020 Oct 9:e2179.Full text Abstract
742. Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 era. JAMA. 2020 Oct 6;324(13):1342-3.Full text Abstract
743. Song X, Delaney M, Shah RK, et al. Comparison of clinical features of COVID-19 vs seasonal influenza A and B in US children. JAMA Netw Open. 2020 Sep 1;3(9):e2020495.Full text Abstract
744. Czubak J, Stolarczyk K, Orzeł A, et al. Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold: a systematic literature review. Adv Clin Exp Med. 2021 Jan;30(1):109-14.Full text Abstract
745. Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles J, et al. Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicenter PCR-based case-control study. Eur J Neurol. 2020 Sep;27(9):1738-41.Full text Abstract
746. Guan Z, Chen C, Li Y, et al. Impact of coinfection with SARS-CoV-2 and influenza on disease severity: a systematic review and meta-analysis. Front Public Health. 2021 Dec 10;9:773130.Full text Abstract
747. Dao TL, Hoang VT, Colson P, et al. Co-infection of SARS-CoV-2 and influenza viruses: a systematic review and meta-analysis. J Clin Virol Plus. 2021 Sep;1(3):100036.Full text Abstract
748. Liu M, Zeng W, Wen Y, et al. COVID-19 pneumonia: CT findings of 122 patients and differentiation from influenza pneumonia. Eur Radiol. 2020 Oct;30(10):5463-9.Full text Abstract
749. Yin Z, Kang Z, Yang D, et al. A comparison of clinical and chest CT findings in patients with influenza A (H1N1) virus infection and coronavirus disease (COVID-19). AJR Am J Roentgenol. 2020 May 26:1-7.Full text Abstract
750. Luo Y, Yuan X, Xue Y, et al. Using the diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus. Int J Infect Dis. 2020 May 1;95:436-40.Full text Abstract
751. Zarei F, Reza J, Sefidbakht S, et al. Aspiration pneumonia or COVID-19 infection: a diagnostic challenge. Acad Radiol. 2020 Jul;27(7):1046.Full text Abstract
752. National Institute for Health and Care Excellence. COVID-19 rapid guideline: delivery of systemic anticancer treatments. 2021 [internet publication].Full text
753. Kaya T, Dilek A, Ozaras R, et al. COVID 19 and febrile neutropenia: case report and systematic review. Travel Med Infect Dis. 2022 Mar 7;47:102305.Full text Abstract
754. Fistera D, Härtl A, Pabst D, et al. What about the others: differential diagnosis of COVID-19 in a German emergency department. BMC Infect Dis. 2021 Sep 17;21(1):969.Full text Abstract
755. World Health Organization. Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022. 2022 [internet publication].Full text
756. UK Health Security Agency. People with symptoms of a respiratory infection including COVID-19. 2022 [internet publication].Full text
757. Centers for Disease Control and Prevention. COVID-19: quarantine and isolation. 2022 [internet publication].Full text
758. Kwon KT, Ko JH, Shin H, et al. Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak. J Korean Med Sci. 2020 Mar 23;35(11):e123.Full text Abstract
759. Medicines and Healthcare products Regulatory Agency. Don’t rely on temperature screening products for detection of coronavirus (COVID-19), says MHRA. 2020 [internet publication].Full text
760. Aggarwal N, Garg M, Dwarakanathan V, et al. Diagnostic accuracy of non-contact infrared thermometers and thermal scanners: a systematic review and meta-analysis. J Travel Med. 2020 Dec 23;27(8):taaa193.Full text Abstract
761. Khan DS, Saultry MB, Adams DS, et al. Comparative accuracy testing of non-contact infrared thermometers and temporal artery thermometers in an adult hospital setting. Am J Infect Control. 2021 May;49(5):597-602.Full text Abstract
762. World Health Organization. Therapeutics and COVID-19: living guideline. 2022 [internet publication].Full text
763. Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020 Sep 4;370:m3379.Full text Abstract
764. Agarwal A, Rochwerg B, Lamontagne F, et al. Update to living WHO guideline on drugs for covid-19. BMJ. 2022 Apr 21;377:o1005.Full text Abstract
765. Mahase E. Covid-19: is it safe to reduce the self-isolation period? BMJ. 2021 Dec 30;375:n3164.Full text Abstract
766. Suter F, Consolaro E, Pedroni S, et al. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: a retrospective observational matched-cohort study. EClinicalMedicine. 2021 Jun 9:100941.Full text Abstract
767. World Health Organization. Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance. 2020 [internet publication].Full text
768. Abuelgasim H, Albury C, Lee J. Effectiveness of honey for symptomatic relief in upper respiratory tract infections: a systematic review and meta-analysis. BMJ Evid Based Med. 2021 Apr;26(2):57-64.Full text Abstract
769. Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA. 2020 Jun 23;323(24):2512-4.Full text Abstract
770. Webster KE, O'Byrne L, MacKeith S, et al. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev. 2021 Jul 22;(7):CD013877.Full text Abstract
771. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the omicron variant. 2022 [internet publication].Full text
772. US Food and Drug Administration. FDA updates sotrovimab emergency use authorization. 2022 [internet publication].Full text
773. McCreary EK, Bariola JR, Wadas RJ, et al. Association of subcutaneous or intravenous administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in adults with COVID-19. JAMA Netw Open. 2022 Apr 1;5(4):e226920.Full text Abstract
774. Kreuzberger N, Hirsch C, Chai KL, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;(9):CD013825.Full text Abstract
775. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA approves first COVID-19 treatment for young children. 2022 [internet publication].Full text
776. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022 Jan 27;386(4):305-15.Full text Abstract
777. Department of Health and Social Care. Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group report. 2022 [internet publication].Full text
778. Zou Y, Han M, Wang J, et al. Predictive value of frailty in the mortality of hospitalized patients with COVID-19: a systematic review and meta-analysis. Ann Transl Med. 2022 Feb;10(4):166.Full text Abstract
779. Pranata R, Henrina J, Lim MA, et al. Clinical frailty scale and mortality in COVID-19: a systematic review and dose-response meta-analysis. Arch Gerontol Geriatr. 2021 Mar-Apr;93:104324.Full text Abstract
780. Rottler M, Ocskay K, Sipos Z, et al. Clinical Frailty Scale (CFS) indicated frailty is associated with increased in-hospital and 30-day mortality in COVID-19 patients: a systematic review and meta-analysis. Ann Intensive Care. 2022 Feb 20;12(1):17.Full text Abstract
781. Subramaniam A, Shekar K, Afroz A, et al. Frailty and mortality associations in patients with COVID-19: a systematic review and meta-analysis. Intern Med J. 2022 May;52(5):724-39.Full text Abstract
782. Cosco TD, Best J, Davis D, et al. What is the relationship between validated frailty scores and mortality for adults with COVID-19 in acute hospital care? A systematic review. Age Ageing. 2021 May 5;50(3):608-16.Full text Abstract
783. Centre for Evidence-Based Medicine; Allsop M, Ziegler L, Fu Y, et al. Is oxygen an effective treatment option to alleviate the symptoms of breathlessness for patients dying with COVID-19 and what are the potential harms? 2020 [internet publication].Full text
784. Alhazzani W, Evans L, Alshamsi F, et al. Surviving Sepsis Campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021 Mar 1;49(3):e219-34.Full text Abstract
785. Ponnapa Reddy M, Subramaniam A, Afroz A, et al. Prone positioning of nonintubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care Med. 2021 Oct 1;49(10):e1001-14.Full text Abstract
786. Chua EX, Zahir SMISM, Ng KT, et al. Effect of prone versus supine position in COVID-19 patients: a systematic review and meta-analysis. J Clin Anesth. 2021 Jun 22;74:110406.Full text Abstract
787. Beran A, Mhanna M, Srour O, et al. Effect of prone positioning on clinical outcomes of non-intubated subjects with COVID-19: a comparative systematic review and meta-analysis. Respir Care. 2022 Apr;67(4):471-9.Full text Abstract
788. Li J, Luo J, Pavlov I, et al. Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis. Lancet Respir Med. 2022 Mar 16 [Epub ahead of print].Full text Abstract
789. Qian ET, Gatto CL, Amusina O, et al. Assessment of awake prone positioning in hospitalized adults with COVID-19: a nonrandomized controlled trial. JAMA Intern Med. 2022 Apr 18 [Epub ahead of print].Full text Abstract
790. Mojoli F, Mongodi S, Orlando A, et al. Our recommendations for acute management of COVID-19. Crit Care. 2020 May 8;24(1):207.Full text Abstract
791. Centre for Evidence-Based Medicine; Jones L, Candy B, Roberts N, et al. How can healthcare workers adapt non-pharmacological treatment – whilst maintaining safety – when treating people with COVID-19 and delirium? 2020 [internet publication].Full text
792. UK Health Security Agency. Mouth care for hospitalised patients with confirmed or suspected COVID-19. 2020 [internet publication].Full text
793. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis. 2020 Jul;50(1):72-81.Full text Abstract
794. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020 Sep;158(3):1143-63.Full text Abstract
795. American Society Of Hematology. COVID-19 and VTE/anticoagulation: frequently asked questions. 2022 [internet publication].Full text
796. Pawlowski C, Venkatakrishnan AJ, Kirkup C, et al. Enoxaparin is associated with lower rates of mortality than unfractionated heparin in hospitalized COVID-19 patients. EClinicalMedicine. 2021 Mar 9:100774.Full text Abstract
797. Lopes RD, de Barros E Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021 Jun 12;397(10291):2253-63.Full text Abstract
798. Kyriakoulis KG, Kollias A, Kyriakoulis IG, et al. Thromboprophylaxis in patients with COVID-19: systematic review of national and international clinical guidance reports. Curr Vasc Pharmacol. 2022;20(1):96-110. Abstract
799. Flumignan RL, Civile VT, Tinôco JDS, et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2022 Mar 4;(3):CD013739.Full text Abstract
800. Zeng J, Liu F, Wang Y, et al. The effect of previous oral anticoagulant use on clinical outcomes in COVID-19: a systematic review and meta-analysis. Am J Emerg Med. 2022 Feb 3;54:107-10.Full text Abstract
801. Wong AY, Tomlinson L, Brown JP, et al. Association between oral anticoagulants and COVID-19-related outcomes: a population-based cohort study. Br J Gen Pract. 2022 Feb 16 [Epub ahead of print].Full text Abstract
802. Li P, Zhao W, Kaatz S, et al. Factors associated with risk of postdischarge thrombosis in patients with COVID-19. JAMA Netw Open. 2021 Nov 1;4(11):e2135397.Full text Abstract
803. Ramacciotti E, Barile Agati L, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022 Jan 1;399(10319):50-9.Full text Abstract
804. Flumignan RL, Tinôco JDS, Pascoal PI, et al. Prophylactic anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2020 Oct 2;(10):CD013739.Full text Abstract
805. Moonla C, Sosothikul D, Chiasakul T, et al. Anticoagulation and in-hospital mortality from coronavirus disease 2019: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211008999.Full text Abstract
806. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334-47.Full text Abstract
807. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021 Apr;27(4):520-31.Full text Abstract
808. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020 Oct 6;324(13):1330-41.Full text Abstract
809. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704.Full text Abstract
810. Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Aug 16;(8):CD014963.Full text Abstract
811. WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19: interim WHO Solidarity trial results. N Engl J Med. 2021 Feb 11;384(6):497-511.Full text Abstract
812. WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022 May 21;399(10339):1941-53.Full text Abstract
813. Ansems K, Grundeis F, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Aug 5;(8):CD014962.Full text Abstract
814. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637-45.Full text Abstract
815. REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021 Apr 22;384(16):1491-502.Full text Abstract
816. Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 Mar 18;(3):CD013881.Full text Abstract
817. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020 Jul 30;370:m2980.Full text Abstract
818. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2021 Mar 31;372:n858.Full text Abstract
819. Zeraatkar D, Cusano E, Martínez JPD, et al. Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis. BMJ Medicine 2022 Mar 2;1:e000036.Full text
820. Patoulias D, Doumas M, Papadopoulos C, et al. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol. 2021 Nov;40(11):4671-4.Full text Abstract
821. Selvaraj V, Finn A, Lal A, et al. Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials. EClinicalMedicine. 2022 Jul;49:101489.Full text Abstract
822. RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022 Feb 12;399(10325):665-76.Full text Abstract
823. Heath L, Carey M, Lowney AC, et al. Pharmacological strategies used to manage symptoms of patients dying of COVID-19: a rapid systematic review. Palliat Med. 2021 Jun;35(6):1099-107.Full text Abstract
824. Abate SM, Ahmed Ali S, Mantfardo B, et al. Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. PLoS One. 2020 Jul 10;15(7):e0235653.Full text Abstract
825. Armstrong RA, Kane AD, Kursumovic E, et al. Mortality in patients admitted to intensive care with COVID-19: an updated systematic review and meta-analysis of observational studies. Anaesthesia. 2021 Apr;76(4):537-48.Full text Abstract
826. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region: case series. N Engl J Med. 2020 May 21;382(21):2012-22.Full text Abstract
827. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020 May 29;369:m1996.Full text Abstract
828. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22;369:m1966.Full text Abstract
829. Chang R, Elhusseiny KM, Yeh YC, et al. COVID-19 ICU and mechanical ventilation patient characteristics and outcomes: a systematic review and meta-analysis. PLoS One. 2021 Feb 11;16(2):e0246318.Full text Abstract
830. Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020 Sep;4(9):653-61.Full text Abstract
831. Williams N, Radia T, Harman K, et al. COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. Eur J Pediatr. 2021 Mar;180(3):689-97.Full text Abstract
832. Schmid B, Griesel M, Fischer AL, et al. Awake prone positioning, high-flow nasal oxygen and non-invasive ventilation as non-invasive respiratory strategies in COVID-19 acute respiratory failure: a systematic review and meta-analysis. J Clin Med. 2022 Jan 13;11(2):391.Full text Abstract
833. Weerakkody S, Arina P, Glenister J, et al. Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research. Lancet Respir Med. 2022 Feb;10(2):199-213.Full text Abstract
834. Schünemann HJ, Khabsa J, Solo K, et al. Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2020 Aug 4;173(3):204-16.Full text Abstract
835. Ute Muti-Schüenemann GE, Szczeklik W, Solo K, et al. Update alert 3: ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2022 Jan;175(1):W6-7.Full text Abstract
836. Glenardi G, Chriestya F, Oetoro BJ, et al. Comparison of high-flow nasal oxygen therapy and noninvasive ventilation in COVID-19 patients: a systematic review and meta-analysis. Acute Crit Care. 2022 Feb;37(1):71-83.Full text Abstract
837. Beran A, Srour O, Malhas SE, et al. High-flow nasal cannula oxygen versus non-invasive ventilation in subjects with COVID-19: a systematic review and meta-analysis of comparative studies. Respir Care. 2022 Mar 22 [Epub ahead of print].Full text Abstract
838. Perkins GD, Ji C, Connolly BA, et al. Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized clinical trial. JAMA. 2022 Feb 8;327(6):546-58.Full text Abstract
839. Ospina-Tascón GA, Calderón-Tapia LE, García AF, et al. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial. JAMA. 2021 Dec 7;326(21):2161-71. Abstract
840. Winslow RL, Zhou J, Windle EF, et al. SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures. Thorax. 2022 Mar;77(3):259-67.Full text Abstract
841. Elsayed HH, Hassaballa AS, Ahmed TA, et al. Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: a systematic review and meta-analysis. PLoS One. 2021;16(6):e0252760.Full text Abstract
842. Xixi NA, Kremmydas P, Xourgia E, et al. Association between timing of intubation and clinical outcomes of critically ill patients: a meta-analysis. J Crit Care. 2022 May 16;71:154062. Abstract
843. Gattinoni L, Coppola S, Cressoni M, et al. Covid-19 does not lead to a "typical" acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020 May 15;201(10):1299-300.Full text Abstract
844. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020 Apr 16;24(1):154.Full text Abstract
845. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020 Jun;46(6):1099-102.Full text Abstract
846. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020 Jun 9;323(22):2329-30.Full text Abstract
847. Rello J, Storti E, Belliato M, et al. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. 2020 May 21;55(5):2001028.Full text Abstract
848. Tsolaki V, Siempos I, Magira E, et al. PEEP levels in COVID-19 pneumonia. Crit Care. 2020 Jun 6;24(1):303.Full text Abstract
849. Bos LD, Paulus F, Vlaar APJ, et al. Subphenotyping acute respiratory distress syndrome in patients with COVID-19: consequences for ventilator management. Ann Am Thorac Soc. 2020 Sep;17(9):1161-3.Full text Abstract
850. Jain A, Doyle DJ. Stages or phenotypes? A critical look at COVID-19 pathophysiology. Intensive Care Med. 2020 May 18;:1-2.Full text Abstract
851. Bos LDJ, Sjoding M, Sinha P, et al. Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts. Lancet Respir Med. 2021 Dec;9(12):1377-86.Full text Abstract
852. Rice TW, Janz DR. In defense of evidence-based medicine for the treatment of COVID-19 ARDS. Ann Am Thorac Soc. 2020 Jul;17(7):787-9.Full text Abstract
853. Dondorp AM, Hayat M, Aryal D, et al. Respiratory support in COVID-19 patients, with a focus on resource-limited settings. Am J Trop Med Hyg. 2020 Jun;102(6):1191-7.Full text Abstract
854. Carsetti A, Damia Paciarini A, Marini B, et al. Prolonged prone position ventilation for SARS-CoV-2 patients is feasible and effective. Crit Care. 2020 May 15;24(1):225.Full text Abstract
855. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020 May;8(5):518-26.Full text Abstract
856. Bertini P, Guarracino F, Falcone M, et al. ECMO in COVID-19 patients: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2021 Nov 12 [Epub ahead of print].Full text Abstract
857. Ling RR, Ramanathan K, Sim JJL, et al. Evolving outcomes of extracorporeal membrane oxygenation during the first 2 years of the COVID-19 pandemic: a systematic review and meta-analysis. Crit Care. 2022 May 23;26(1):147.Full text Abstract
858. Urner M, Barnett AG, Bassi GL, et al. Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study. BMJ. 2022 May 4;377:e068723.Full text Abstract
859. Mustafa AK, Alexander PJ, Joshi DJ, et al. Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure. JAMA Surg. 2020 Aug 11;155(10):990-2.Full text Abstract
860. Kannapadi NV, Jami M, Premraj L, et al. Neurological complications in COVID-19 patients with ECMO support: a systematic review and meta-analysis. Heart Lung Circ. 2022 Feb;31(2):292-8.Full text Abstract
861. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-6.Full text Abstract
862. Zhang S, Li Y, Liu G, et al. Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis. Thromb J. 2021 Nov 24;19(1):91.Full text Abstract
863. Sarfraz A, Sarfraz Z, Razzack AA, et al. Venous thromboembolism, corticosteroids and COVID-19: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029621993573.Full text Abstract
864. Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022 Apr;10(4):327-36.Full text Abstract
865. Chen L, Jiang H, Zhao Y. Pregnancy with Covid-19: management considerations for care of severe and critically ill cases. Am J Reprod Immunol. 2020 Jul 4:e13299.Full text Abstract
866. Girolamo RD, Khalil A, Rizzo G, et al. Systematic review and critical evaluation of quality of clinical practice guidelines on the management of SARS-CoV-2 infection in pregnancy. Am J Obstet Gynecol MFM. 2022 Apr 30 [Epub ahead of print].Full text Abstract
867. Favre G, Pomar L, Qi X, et al. Guidelines for pregnant women with suspected SARS-CoV-2 infection. Lancet Infect Dis. 2020 Jun;20(6):652-3.Full text Abstract
868. Chen D, Yang H, Cao Y, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet. 2020 May;149(2):130-6. Abstract
869. Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection in pregnancy: information for healthcare professionals. 2022 [internet publication].Full text
870. Nana M, Hodson K, Lucas N, et al. Diagnosis and management of covid-19 in pregnancy. BMJ. 2022 Apr 26;377:e069739.Full text Abstract
871. American Academy of Pediatrics. Management of infants born to mothers with suspected or confirmed COVID-19. 2021 [internet publication].Full text
872. Dumitriu D, Emeruwa UN, Hanft E, et al. Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center in New York City. JAMA Pediatr. 2021 Feb 1;175(2):157-67.Full text Abstract
873. World Health Organization. Breastfeeding and COVID-19: scientific brief. 2020 [internet publication].Full text
874. Ronchi A, Pietrasanta C, Zavattoni M, et al. Evaluation of rooming-in practice for neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection in Italy. JAMA Pediatr. 2021 Mar 1;175(3):260-6.Full text Abstract
875. World Health Organization. Clinical management of COVID-19: living guideline, 23 June 2022. 2022 [internet publication]Full text
876. Rottler M, Ocskay K, Sipos Z, et al. Clinical Frailty Scale (CFS) indicated frailty is associated with increased in-hospital and 30-day mortality in COVID-19 patients: a systematic review and meta-analysis. Ann Intensive Care. 2022 Feb 20;12(1):17Full text Abstract
877. National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. 2019 [internet publication]Full text
878. Hsu CY, Ordoñez JD, Chertow GM, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008 Apr 2;74(1):101-7Full text Abstract
879. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. 2022 [internet publication]Full text
880. Center for the Study of Traumatic Stress. Taking care of patients during the coronavirus outbreak: a guide for psychiatrists. 2020 [internet publication]Full text
881. Shore JH, Schneck CD, Mishkind MC. Telepsychiatry and the coronavirus disease 2019 pandemic-current and future outcomes of the rapid virtualization of psychiatric care. JAMA Psychiatry. 2020 Dec 1;77(12):1211-2Full text Abstract
882. Hubley S, Lynch SB, Schneck C, et al. Review of key telepsychiatry outcomes. World J Psychiatry. 2016 Jun 22;6(2):269-82Full text Abstract
883. Fritz Z, Slowther AM, Perkins GD. Resuscitation policy should focus on the patient, not the decision. BMJ. 2017 Feb 28;356:j813Full text Abstract
884. National Institute for Health and Care Excellence. Decision making and mental capacity. 2018 [internet publication]Full text
885. Department of Health. Mental Capacity Act 2005 [internet publication]Full text
886. Social Care Institute for Excellence. Independent mental capacity advocate (IMCA). 2011 [internet publication]Full text
887. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2022 [internet publication]Full text
888. Department of Health and Social Care. Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group. 2022 [internet publication]Full text
889. World Health Organization. COVID-19 clinical care pathway. 2022 [internet publication]Full text
890. Izcovich A, Siemieniuk RA, Bartoszko JJ, et al. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. BMJ Open. 2022 Mar 2;12(3):e048502.Full text Abstract
891. National Institutes of Health. Remdesivir. In: COVID-19 treatment guidelines. 2022 [internet publication]Full text
892. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2022 [internet publication]Full text
893. British Thoracic Society. COPD and COVID-19 for healthcare professionals. 2020 [internet publication]Full text
894. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. 2019 [internet publication]Full text
895. Primary Care Respiratory Society. PCRS pragmatic guidance: diagnosing and managing asthma attacks and people with COPD presenting in crisis during the UK Covid 19 epidemic. 2020 [internet publication]Full text
896. British Thoracic Society. Advice for healthcare professionals treating people with asthma (adults) in relation to COVID-19. 2020 [internet publication]Full text
897. Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018 Mar 19;(3):CD006897Full text Abstract
898. Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020 Aug 4;173(3):195-203Full text Abstract
899. Mackey K, Kansagara D, Vela K. Update alert 7: risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann Intern Med. 2021 Feb;174(2):W25-9Full text Abstract
900. Asiimwe IG, Pushpakom SP, Turner RM, et al. Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022 Mar 24 [Epub ahead of print]Full text Abstract
901. American Heart Association; Heart Failure Society of America; American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. 2020 [internet publication]Full text
902. European Society of Cardiology Council on Hypertension. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. 2020 [internet publication]Full text
903. British Cardiovascular Society; British Society for Heart Failure. BSH & BCS joint statement on ACEi or ARB in relation to COVID-19. 2020 [internet publication]Full text
904. UK Kidney Association. The UK Kidney Association, UK position statement on COVID-19 and ACE inhibitor/angiotensin receptor blocker use. 2020 [internet publication]Full text
905. Clark AL, Kalra PR, Petrie MC, et al. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019 Jun;105(12):904-10 Abstract
906. European Society of Endocrinology. COVID-19 and endocrine diseases: a statement from the European Society of Endocrinology. 2020 [internet publication]Full text
907. American Diabetes Association. COVID-19: if you do get sick, know what to do. 2020 [internet publication]Full text
908. Primary Care Diabetes Society. How to advise on sick day rules. 2020 [internet publication]Full text
909. NHS England. Diabetes COVID-19 key information: sick day rules. 2020 [internet publication]Full text
910. International Diabetes Federation Europe. How to manage diabetes during an illness. 2020 [internet publication]Full text
911. Diabetes Australia; Royal Australian College of General Practitioners. Diabetes management during the coronavirus pandemic: be proactive and prepared. 2020 [internet publication]Full text
912. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Morris E, Goyder C, et al. Managing diabetes during the COVID-19 pandemic. 2020 [internet publication]Full text
913. National Inpatient Diabetes COVID-19 Response Group. Concise advice on inpatient diabetes during COVID-19: front door guidance - version 3.1. 2020 [internet publication]Full text
914. Hartmann-Boyce J, Morris E, Goyder C, et al. Diabetes and COVID-19: risks, management, and learnings from other national disasters. Diabetes Care. 2020 Aug;43(8):1695-703Full text Abstract
915. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Jun 15;38(9):1687-93 Abstract
916. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis. 2016 [internet publication]Full text
917. NHS London Clinical Networks. Sick day rules: how to manage type 2 diabetes if you become unwell with coronavirus and what to do with your medication. 2020 [internet publication]Full text
918. Verbrugge FH, Grieten L, Mullens W. Management of the cardiorenal syndrome in decompensated heart failure. Cardiorenal Med. 2014 Dec;4(3-4):176-88Full text Abstract
919. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010 Dec;6(12):681-94 Abstract
920. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13Full text Abstract
921. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 May 4;47(6):e98-169Full text Abstract
922. Pendlebury ST, Klaus SP, Mather M, et al. Routine cognitive screening in older patients admitted to acute medicine: abbreviated mental test score (AMTS) and subjective memory complaint versus Montreal Cognitive Assessment and IQCODE. Age Ageing. 2015 Nov;44(6):1000-5Full text Abstract
923. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972 Nov;1(4):233-8 Abstract
924. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management. 2019 [internet publication]Full text
925. National Institute for Health and Clinical Excellence. Dementia: assessment, management and support for people living with dementia and their carers. 2018 [internet publication]Full text
926. Scottish Intercollegiate Guidelines Network. Risk reduction and management of delirium: a national clinical guideline. 2019 [internet publication]Full text
927. Nova Scotia Health Authority. This is not my Mom. 2012 [internet publication]Full text
928. Inouye SK, Schlesinger MJ, Lydon TJ. Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Am J Med. 1999 May;106(5):565-73 Abstract
929. Bellelli G, Morandi A, Davis DH, et al. Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalised older people. Age Ageing. 2014 Jul;43(4):496-502Full text Abstract
930. MacLullich AM, Shenkin SD, Goodacre S, et al. The 4 'A's test for detecting delirium in acute medical patients: a diagnostic accuracy study. Health Technol Assess. 2019 Aug;23(40):1-194Full text Abstract
931. British Geriatrics Society. Coronavirus: managing delirium in confirmed and suspected cases. 2020 [internet publication]Full text
932. Medicines and Healthcare products Regulatory Agency. Haloperidol (haldol): reminder of risks when used in elderly patients for the acute treatment of delirium. 2021 [internet publication]Full text
933. Ma H, Huang Y, Cong Z, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42(3):915-37 Abstract
934. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ. 2012 Feb 23;344:e977Full text Abstract
935. Van Leeuwen E, Petrovic M, van Driel ML, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018 Mar 30;(3):CD007726Full text Abstract
936. Centers for Disease Control and Prevention. Clinical questions about COVID-19: questions and answers – patients with asthma. 2022 [internet publication]Full text
937. International Primary Care Respiratory Group. Can we safely use nebulisers during the COVID-19 pandemic in the primary care setting, and if so how? 2021 [internet publication]Full text
938. American Diabetes Association. Diabetes care in the hospital: standards of medical care in diabetes - 2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S244-53Full text Abstract
939. National Inpatient Diabetes COVID-19 Response Group. Concise advice on inpatient diabetes during COVID-19 (COVID:Diabetes): guidance for managing inpatient hyperglycaemia - version 4.2. 2020 [internet publication]Full text
940. Rehman A, Setter SM, Vue MH. Drug-induced glucose alterations part 2: drug-induced hyperglycemia. Diabetes Spect. 2011 Nov;24(4):234-8Full text
941. NHS Digital. National diabetes inpatient audit (NaDIA) - 2019. 2020 [internet publication]Full text
942. Joint British Diabetes Societies for inpatient care. The hospital management of hypoglycaemia in adults with diabetes mellitus. March 2022 [internet publication]Full text
943. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. 2019 [internet publication]Full text
944. Rayman G, Vas PR, Baker N, et al. The Ipswich Touch Test: a simple and novel method to identify inpatients with diabetes at risk of foot ulceration. Diabetes Care. 2011 Jul;34(7):1517-8Full text Abstract
945. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13Full text Abstract
946. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011 May;106(5):906-14 Abstract
947. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015 May;29(5):459-525Full text Abstract
948. National Institute for Health and Care Excellence. Depression in adults with a chronic physical health problem: recognition and management. 2009 [internet publication]Full text
949. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th edition. Chichester: Wiley-Blackwell; 2021
950. Flowers L. Nicotine replacement therapy. Am J Psychiatry Resid J. 2016 Jun;11(6):4-7Full text
951. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469-94 Abstract
952. Oliveira P, Ribeiro J, Donato H, et al. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 2017 Mar 6;16:17Full text Abstract
953. National Centre for Smoking Cessation and Training. Smoking cessation and mental health: a briefing for front-line staff. 2014 [internet publication]Full text
954. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112-20Full text Abstract
955. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014 Feb 19;348:g1626 Abstract
956. National Institute for Health and Care Excellence. Liaison psychiatry. In: Emergency acute medical care in over 16s: service delivery and organisation. 2018 [internet publication]Full text
957. National Confidential Enquiry into Patient Outcome and Death. Treat as one: bridging the gap between mental and physical healthcare in general hospitals. 2017 [internet publication]Full text
958. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000 Jul 24;160(14):2101-7Full text Abstract
959. Prina AM, Cosco TD, Dening T, et al. The association between depressive symptoms in the community, non-psychiatric hospital admission and hospital outcomes: a systematic review. J Psychosom Res. 2015 Jan;78(1):25-33Full text Abstract
960. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009 Apr 6;190(s7):S54-60 Abstract
961. World Health Organization. Excess mortality in persons with severe mental disorders. 2016 [internet publication]Full text
962. National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence. 2021 [internet publication]Full text
963. O'Driscoll BR, Howard LS, Earis J, et al; British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(suppl 1):ii1-90 Abstract
964. Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018 Apr 28;391(10131):1693-705 Abstract
965. Siemieniuk RAC, Chu DK, Kim LH, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ. 2018 Oct 24;363:k4169 Abstract
966. National Institute for Health and Care Excellence. Intravenous fluid therapy in adults in hospital. 2017 [internet publication]Full text
967. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972 Nov;1(4):233-8 Abstract
968. Chowdhury TA, Cheston H, Claydon A. Managing adults with diabetes in hospital during an acute illness. BMJ. 2017 Jun 22;357:j2551 Abstract
969. Karslioglu French E, Donihi AC, Korytkowski MT. Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients. BMJ. 2019 May 29;365:l1114Full text Abstract
970. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Sep;38(9):1687-93Full text Abstract
971. Law JP, Pickup L, Townend JN, et al. Anticoagulant strategies for the patient with chronic kidney disease. Clin Med (Lond). 2020 Mar;20(2):151-5Full text Abstract
972. National Inpatient Diabetes COVID-19 Response Group. Concise advice on inpatient diabetes during COVID-19 (COVID:Diabetes): dexamethasone/glucocorticosteroid therapy in COVID-19 patients – implications and guidance for the management of blood glucose in people with and without diabetes - version 2.3. 2020 [internet publication]Full text
973. Joint British Diabetes Societies for inpatient care. Management of hyperglycaemia and steroid (glucocorticosteroid) therapy. 2022 [internet publication]Full text
974. Judd LL, Schettler PJ, Brown ES, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014 Oct;171(10):1045-51Full text Abstract
975. Kenna HA, Poon AW, de los Angeles CP, et al. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011 Oct;65(6):549-60Full text Abstract
976. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006 Oct;81(10):1361-7Full text Abstract
977. Fardet L, Nazareth I, Whitaker HJ, et al. Severe neuropsychiatric outcomes following discontinuation of long-term glucocorticoid therapy: a cohort study. J Clin Psychiatry. 2013 Apr;74(4):e281-6 Abstract
978. US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021 [internet publication].Full text
979. World Health Organization. Therapeutics and COVID-19: living guideline. 2022 [internet publication]Full text
980. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011 Apr;21(2):69-72 Abstract
981. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J. 2020 May 14;55(5):2000892.Full text Abstract
982. Centers for Disease Control and Prevention. COVID-19 rebound after Paxlovid treatment. 2022 [internet publication].Full text
983. Malden DE, Hong V, Lewin BJ, et al. Hospitalization and emergency department encounters for COVID-19 after Paxlovid treatment: California, December 2021-May 2022. MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-3.Full text Abstract
984. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022 Feb 16 [Epub ahead of print].Full text Abstract
985. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe COVID-19 and mortality in high risk patients. Clin Infect Dis. 2022 Jun 2 [Epub ahead of print].Full text Abstract
986. Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022 Feb;198:105252.Full text Abstract
987. Merck. Merck and Ridgeback Biotherapeutics provide update on results from MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine, in at risk adults with mild-to-moderate COVID-19. 2021 [internet publication].Full text
988. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022 Feb 10;386(6):509-20.Full text Abstract
989. Caraco Y, Crofoot GE, Moncada PA, et al. Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults. NEJM Evid. 2021 Dec 16;1(2).Full text
990. Johnson MG, Puenpatom A, Moncada PA, et al. Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial. Ann Intern Med. 2022 Jun 7 [Epub ahead of print].Full text Abstract
991. Singh AK, Singh A, Singh R, et al. Molnupiravir in COVID-19: a systematic review of literature. Diabetes Metab Syndr. 2021 Oct 30;15(6):102329.Full text Abstract
992. European Medicines Agency. EMA recommends approval for use of Kineret in adults with COVID-19. 2021 [internet publication].Full text
993. National Institute for Health and Care Excellence. COVID 19 rapid evidence summary: anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis. 2020 [internet publication].Full text
994. Davidson M, Menon S, Chaimani A, et al. Interleukin-1 blocking agents for treating COVID-19. Cochrane Database Syst Rev. 2022 Jan 26;(1):CD015308.Full text Abstract
995. Kyriazopoulou E, Huet T, Cavalli G, et al. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021 Oct;3(10):e690-7.Full text Abstract
996. Barkas F, Ntekouan SF, Kosmidou M, et al. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology (Oxford). 2021 Dec 1;60(12):5527-37.Full text Abstract
997. Somagutta MKR, Lourdes Pormento MK, Hamid P, et al. The safety and efficacy of anakinra, an interleukin-1 antagonist in severe cases of COVID-19: a systematic review and meta-analysis. Infect Chemother. 2021 Jun;53(2):221-37.Full text Abstract
998. Reyes AZ, Hu KA, Teperman J, et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2021 May;80(5):550-7.Full text Abstract
999. Mikolajewska A, Fischer AL, Piechotta V, et al. Colchicine for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Oct 18;(10):CD015045.Full text Abstract
1000. Mehta KG, Patel T, Chavda PD, et al. Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials. RMD Open. 2021 Oct;7(3):e001746.Full text Abstract
1001. Dorward J, Yu L, Hayward G, et al. Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial. Br J Gen Pract. 2022 Mar 23 [Epub ahead of print].Full text
1002. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med. 2021 Dec;9(12):1419-26.Full text Abstract
1003. Humanigen. FDA has declined Humanigen’s emergency use authorization (EUA) request for lenzilumab in hospitalized COVID-19 patients. 2021 [internet publication].Full text
1004. Temesgen Z, Burger CD, Baker J, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2021 Dec 1 [Epub ahead of print].Full text Abstract
1005. Cremer PC, Abbate A, Hudock K, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jun;3(6):e410-8.Full text Abstract
1006. US Food and Drug Administration. FDA in brief: FDA updates emergency use authorization for COVID-19 convalescent plasma to reflect new data. 2021 [internet publication].Full text
1007. Medicines and Healthcare products Regulatory Agency. Convalescent plasma in the management of hospitalised patients with COVID-19. 2021 [internet publication].Full text
1008. Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. 2021 Sep 23;374:n2231.Full text Abstract
1009. Piechotta V, Iannizzi C, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 May 20;5(5):CD013600.Full text Abstract
1010. Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021 Mar 23;325(12):1185-95.Full text Abstract
1011. Gupta T, Kannan S, Kalra B, et al. Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): evidence-base for practise and implications for research. Transfus Med. 2021 Dec;31(6):409-20.Full text Abstract
1012. Klassen SA, Senefeld JW, Johnson PW, et al. The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis. Mayo Clin Proc. 2021 May;96(5):1262-75.Full text Abstract
1013. Wardhani SO, Fajar JK, Wulandari L, et al. Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. F1000Res. 2021 Feb 3;10:64.Full text Abstract
1014. Kloypan C, Saesong M, Sangsuemoon J, et al. Convalescent plasma for COVID-19: a meta-analysis of clinical trials and real-world evidence. Eur J Clin Invest. 2021 Aug 10:e13663.Full text Abstract
1015. Axfors C, Janiaud P, Schmitt AM, et al. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infect Dis. 2021 Nov 20;21(1):1170.Full text Abstract
1016. Troxel AB, Petkova E, Goldfeld K, et al. Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a meta-analysis. JAMA Netw Open. 2022 Jan 4;5(1):e2147331.Full text Abstract
1017. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021 May 29;397(10289):2049-59.Full text Abstract
1018. Sullivan DJ, Gebo KA, Shoham S, et al. Early outpatient treatment for Covid-19 with convalescent plasma. N Engl J Med. 2022 May 5;386(18):1700-11.Full text Abstract
1019. Park H, Tarpey T, Liu M, et al. Development and validation of a treatment benefit index to identify hospitalized patients with COVID-19 who may benefit from convalescent plasma. JAMA Netw Open. 2022 Jan 4;5(1):e2147375.Full text Abstract
1020. Xiang HR, Cheng X, Li Y, et al. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis. Int Immunopharmacol. 2021 Jul;96:107732.Full text Abstract
1021. ClinicalTrials.gov. Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus. 2020 [internet publication].Full text
1022. Wang J, Shi P, Chen D, et al. Research status of the safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-related pneumonia: a systematic review and meta-analysis. Stem Cells Dev. 2021 Oct 1;30(19):947-69. Abstract
1023. Li Y, Wei Z, Ma X, et al. Efficacy and safety of mesenchymal stromal cells therapy for COVID-19 infection: a systematic review and meta-analysis. Curr Stem Cell Res Ther. 2021 Dec 6 [Epub ahead of print]. Abstract
1024. Kirkham AM, Bailey AJM, Monaghan M, et al. Updated living systematic review and meta-analysis of controlled trials of mesenchymal stromal cells to treat COVID-19: a framework for accelerated synthesis of trial evidence for rapid approval - FASTER approval. Stem Cells Transl Med. 2022 Jun 27 [Epub ahead of print].Full text Abstract
1025. Mesoblast Limited. Mesoblast update on COVID-19 ARDS trial. 2020 [internet publication].Full text
1026. Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 Feb;9(2):196-206.Full text Abstract
1027. ClinicalTrials.gov. Interferon lambda for immediate antiviral therapy at diagnosis in COVID-19 (ILIAD). 2022 [internet publication].Full text
1028. Eiger BioPharmaceuticals. Eiger BioPharmaceuticals announces positive results of investigator sponsored randomized controlled trial at University of Toronto with peginterferon lambda in outpatients with mild to moderate COVID-19. 2020 [internet publication].Full text
1029. Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787.Full text Abstract
1030. Popp M, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 2021 Jul 28;(7):CD015017.Full text Abstract
1031. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021 Jun 21;28(4):e434-60.Full text Abstract
1032. Kory P, Meduri GU, Varon J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther. 2021 Apr 22;28(3):e299-318.Full text Abstract
1033. Zein AFMZ, Sulistiyana CS, Raffaelo WM, et al. Ivermectin and mortality in patients with COVID-19: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. Diabetes Metab Syndr. 2021 Jun 27;15(4):102186.Full text Abstract
1034. Kow CS, Merchant HA, Mustafa ZU, et al. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacol Rep. 2021 Oct;73(5):1473-9.Full text Abstract
1035. Padhy BM, Mohanty RR, Das S, et al. Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462-9.Full text Abstract
1036. Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021 Apr 26;373:n949.Full text Abstract
1037. Roman YM, Burela PA, Pasupuleti V, et al. Ivermectin for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials. Clin Infect Dis. 2021 Jun 28 [Epub ahead of print].Full text Abstract
1038. Deng J, Zhou F, Ali S, et al. Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. QJM. 2021 Dec 20;114(10):721-32.Full text Abstract
1039. Bitterman A, Martins CP, Cices A, et al. Comparison of trials using ivermectin for COVID-19 between regions with high and low prevalence of strongyloidiasis: a meta-analysis. JAMA Netw Open. 2022 Mar 1;5(3):e223079.Full text Abstract
1040. Azeez TA, Lakoh S, Adeleke AA, et al. Chemoprophylaxis against COVID-19 among health-care workers using ivermectin in low- and middle-income countries: a systematic review and meta-analysis. Indian J Pharmacol. 2021 Nov-Dec;53(6):493-8.Full text Abstract
1041. PRINCIPLE Trial Collaborative Group. Ivermectin to be investigated in adults aged 18+ as a possible treatment for COVID-19 in the PRINCIPLE trial. 2021 [internet publication].Full text
1042. Rossignol JF, Bardin MC, Fulgencio J, et al. A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19. EClinicalMedicine. 2022 Mar;45:101310.Full text Abstract
1043. Blum VF, Cimerman S, Hunter JR, et al. Nitazoxanide superiority to placebo to treat moderate COVID-19: a pilot prove of concept randomized double-blind clinical trial. EClinicalMedicine. 2021 Jun 27;100981.Full text Abstract
1044. Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021 Jul 8;58(1):2003725.Full text Abstract
1045. Sukhatme VP, Reiersen AM, Vayttaden SJ, et al. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021 Apr 20;12:652688.Full text Abstract
1046. Guo CM, Harari O, Chernecki C, et al. Fluvoxamine for the early treatment of COVID-19: a meta-analysis of randomized clinical trials. Am J Trop Med Hyg. 2022 Mar 9 [Epub ahead of print].Full text Abstract
1047. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022 Jan;10(1):e42-51.Full text Abstract
1048. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020 Dec 8;324(22):2292-300.Full text Abstract
1049. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021 Feb;8(2):ofab050.Full text Abstract
1050. Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021 Jul;9(7):763-72.Full text Abstract
1051. Baker JR, Mahdi M, Nicolau DV Jr, et al. Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. Lancet Respir Med. 2022 Apr 7 [Epub ahead of print].Full text Abstract
1052. Griesel M, Wagner C, Mikolajewska A, et al. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2022 Mar 9;(3):CD015125.Full text Abstract
1053. Yu LM, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021 Sep 4;398(10303):843-55.Full text Abstract
1054. Medicines and Healthcare products Regulatory Agency. COVID-19 therapeutic alert: antimicrobials (azithromycin and doxycycline) not beneficial in the management of COVID-19 (SARS-CoV-2) positive patients. 2021 [internet publication].Full text
1055. Popp M, Stegemann M, Riemer M, et al. Antibiotics for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Oct 22;(10):CD015025.Full text Abstract
1056. Mangkuliguna G, Glenardi, Susanto N, et al. Efficacy and safety of azithromycin for the treatment of COVID-19: a systematic review and meta-analysis. Tuberc Respir Dis (Seoul). 2021 Oct;84(4):299-316.Full text Abstract
1057. Ayerbe L, Risco-Risco C, Forgnone I, et al. Azithromycin in patients with COVID-19: a systematic review and meta-analysis. J Antimicrob Chemother. 2022 Feb 2;77(2):303-9.Full text Abstract
1058. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 Feb 13;397(10274):605-12.Full text Abstract
1059. Butler CC, Yu LM, Dorward J, et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respir Med. 2021 Sep;9(9):1010-20.Full text Abstract
1060. Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020 Apr 2;12(4).Full text Abstract
1061. McCartney DM, Byrne DG. Optimisation of vitamin D status for enhanced immuno-protection against Covid-19. Ir Med J. 2020 Apr 3;113(4):58.Full text Abstract
1062. Jakovac H. COVID-19 and vitamin D: is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E589.Full text Abstract
1063. Jolliffe DA, Camargo CA Jr, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol. 2021 May;9(5):276-92.Full text Abstract
1064. National Institute for Health and Care Excellence. COVID-19 rapid guideline: vitamin D. 2020 [internet publication].Full text
1065. Stroehlein JK, Wallqvist J, Iannizzi C, et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 May 24;(5):CD015043.Full text Abstract
1066. Shah K, Saxena D, Mavalankar D. Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis. QJM. 2021 May 19;114(3):175-81.Full text Abstract
1067. Pal R, Banerjee M, Bhadada SK, et al. Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis. J Endocrinol Invest. 2022 Jan;45(1):53-68.Full text Abstract
1068. Szarpak L, Filipiak KJ, Gasecka A, et al. Vitamin D supplementation to treat SARS-CoV-2 positive patients: evidence from meta-analysis. Cardiol J. 2021 Oct 13 [Epub ahead of print].Full text Abstract
1069. Tentolouris N, Samakidou G, Eleftheriadou I, et al. The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients: a systematic review, meta-analysis and meta-regression. Diabetes Metab Res Rev. 2022 May;38(4):e3517.Full text Abstract
1070. Shah K, Varna VP, Sharma U, et al. Does vitamin D supplementation reduce COVID-19 severity? A systematic review. QJM. 2022 Feb 15 [Epub ahead of print]. Abstract
1071. Hosseini B, El Abd A, Ducharme FM. Effects of vitamin D supplementation on COVID-19 related outcomes: a systematic review and meta-analysis. Nutrients. 2022 May 20;14(10):2134.Full text Abstract
1072. da Rocha AP, Atallah AN, Aldrighi JM, et al. Insufficient evidence for vitamin D use in COVID-19: a rapid systematic review. Int J Clin Pract. 2021 Jul 26:e14649.Full text Abstract
1073. Castillo ME, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020 Aug 29;105751.Full text Abstract
1074. Abioye AI, Bromage S, Fawzi W. Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis. BMJ Glob Health. 2021 Jan;6(1):e003176.Full text Abstract
1075. Tabatabaeizadeh SA. Zinc supplementation and COVID-19 mortality: a meta-analysis. Eur J Med Res. 2022 May 23;27(1):70.Full text Abstract
1076. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition. 2020 Apr 21:100190.Full text Abstract
1077. ClinicalTrials.gov. Vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia. 2020 [internet publication].Full text
1078. Rawat D, Roy A, Maitra S, et al. Vitamin C and COVID-19 treatment: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2021 Oct 28;15(6):102324.Full text Abstract
1079. Kwak SG, Choo YJ, Chang MC. The effectiveness of high-dose intravenous vitamin C for patients with coronavirus disease 2019: a systematic review and meta-analysis. Complement Ther Med. 2021 Dec 22;64:102797.Full text Abstract
1080. Roach A, Chikwe J, Catarino P, et al. Lung transplantation for Covid-19-related respiratory failure in the United States. N Engl J Med. 2022 Jan 26 [Epub ahead of print].Full text Abstract
1081. Kurihara C, Manerikar A, Querrey M, et al. Clinical characteristics and outcomes of patients with COVID-19-associated acute respiratory distress syndrome who underwent lung transplant. JAMA. 2022 Feb 15;327(7):652-61.Full text Abstract
1082. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2021 [internet publication].Full text
1083. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-8.Full text Abstract
1084. Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020 Nov;14(11):1149-63.Full text Abstract
1085. Dmytriw AA, Chibbar R, Chen PPY, et al. Outcomes of acute respiratory distress syndrome in COVID-19 patients compared to the general population: a systematic review and meta-analysis. Expert Rev Respir Med. 2021 Oct;15(10):1347-54.Full text Abstract
1086. de la Calle C, Lalueza A, Mancheño-Losa M, et al. Impact of viral load at admission on the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021 Jun;40(6):1209-16.Full text Abstract
1087. Elezkurtaj S, Greuel S, Ihlow J, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021 Feb 19;11(1):4263.Full text Abstract
1088. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020 Sep;188:109890.Full text Abstract
1089. Sumner MW, Kanngiesser A, Lotfali-Khani K, et al. Severe outcomes associated with SARS-CoV-2 infection in children: a systematic review and meta-analysis. Front Pediatr. 2022 Jun 9;10:916655.Full text Abstract
1090. Smith C, Odd D, Harwood R, et al; medRxiv. Deaths in children and young people in England following SARS-CoV-2 infection during the first pandemic year: a national study using linked mandatory child death reporting data [preprint]. 2021 [internet publication].Full text
1091. Qian Z, Lu S, Luo X, et al. Mortality and clinical interventions in critically ill patient with coronavirus disease 2019: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jul 23;8:635560.Full text Abstract
1092. Docherty AB, Mulholland RH, Lone NI, et al. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021 Jul;9(7):773-85.Full text Abstract
1093. Gray WK, Navaratnam AV, Day J, et al. COVID-19 hospital activity and in-hospital mortality during the first and second waves of the pandemic in England: an observational study. Thorax. 2021 Nov 24 [Epub ahead of print].Full text Abstract
1094. Asch DA, Sheils NE, Islam MN, et al. Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic. JAMA Intern Med. 2021 Apr 1;181(4):471-8.Full text Abstract
1095. Nguyen NT, Chinn J, Nahmias J, et al. Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers. JAMA Netw Open. 2021 Mar 1;4(3):e210417.Full text Abstract
1096. Finelli L, Gupta V, Petigara T, et al. Mortality among US patients hospitalized with SARS-CoV-2 infection in 2020. JAMA Netw Open. 2021 Apr 1;4(4):e216556.Full text Abstract
1097. Anesi GL, Jablonski J, Harhay MO, et al. Characteristics, outcomes, and trends of patients with COVID-19-related critical illness at a learning health system in the United States. Ann Intern Med. 2021 May;174(5):613-21.Full text Abstract
1098. Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID-19: an overview of systematic evaluations. Eur J Clin Invest. 2021 Mar 26:e13554.Full text Abstract
1099. Axfors C, Ioannidis JPA. Infection fatality rate of COVID-19 in community-dwelling populations with emphasis on the elderly: an overview [preprint]. 2021 [internet publication].Full text
1100. Rajgor DD, Lee MH, Archuleta S, et al. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020 Jul;20(7):776-7.Full text Abstract
1101. Ghayda RA, Lee KH, Han YJ, et al. Global case fatality rate of coronavirus disease 2019 (COVID-19) by continents and national income: a meta-analysis. J Med Virol. 2022 Jan 31 [Epub ahead of print].Full text Abstract
1102. Alimohamadi Y, Tola HH, Abbasi-Ghahramanloo A, et al. Case fatality rate of COVID-19: a systematic review and meta-analysis. J Prev Med Hyg. 2021 Jun;62(2):E311-20.Full text Abstract
1103. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 17;41(2):145-51.Full text Abstract
1104. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun;20(6):669-77.Full text Abstract
1105. Sorbello M, El-Boghdadly K, Di Giacinto I, et al. The Italian COVID-19 outbreak: experiences and recommendations from clinical practice. Anaesthesia. 2020 Jun;75(6):724-32.Full text Abstract
1106. Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2–associated deaths among persons aged <21 years: United States, February 12–July 31, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1324-9.Full text Abstract
1107. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 6;323(16):1574-81.Full text Abstract
1108. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020 Mar 19;323(16):1612-4.Full text Abstract
1109. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Global COVID-19 case fatality rates. 2020 [internet publication].Full text
1110. Mahase E. Covid-19: the problems with case counting. BMJ. 2020 Sep 3;370:m3374.Full text Abstract
1111. Centre for Evidence-Based Medicine; Spencer E, Jefferson T, Brassey J, et al. When is Covid, Covid? 2020 [internet publication].Full text
1112. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Reconciling COVID-19 death data in the UK. 2020 [internet publication].Full text
1113. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 May 12;323(18):1775-6.Full text Abstract
1114. Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020;15(11):e0241955.Full text Abstract
1115. Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One. 2021 Mar 4;16(3):e0247461.Full text Abstract
1116. Zhang L, Hou J, Ma FZ, et al. The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis. Arch Virol. 2021 Aug;166(8):2071-87.Full text Abstract
1117. Dumitrascu F, Branje KE, Hladkowicz ES, et al. Association of frailty with outcomes in individuals with COVID-19: a living review and meta-analysis. J Am Geriatr Soc. 2021 Sep;69(9):2419-29.Full text Abstract
1118. Bellou V, Tzoulaki I, van Smeden M, et al. Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis. Eur Respir J. 2022 Feb 3;59(2):2002964.Full text Abstract
1119. Santus P, Radovanovic D, Saderi L, et al. Severity of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a prospective observational multicentre study. BMJ Open. 2020 Oct 10;10(10):e043651.Full text Abstract
1120. Shi C, Wang L, Ye J, et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. BMC Infect Dis. 2021 Jul 8;21(1):663.Full text Abstract
1121. Javanmardi F, Keshavarzi A, Akbari A, et al. Prevalence of underlying diseases in died cases of COVID-19: a systematic review and meta-analysis. PLoS One. 2020 Oct 23;15(10):e0241265.Full text Abstract
1122. Shi Q, Wang Z, Liu J, et al. Risk factors for poor prognosis in children and adolescents with COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2021 Nov;41:101155.Full text Abstract
1123. Ramzi ZS. Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients: a systematic review and meta-analysis. Am J Emerg Med. 2022 Jan;51:267-79.Full text Abstract
1124. Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020 Dec 3;383(23):2291-3.Full text Abstract
1125. Lund LC, Hallas J, Nielsen H, et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. 2021 Oct;21(10):1373-82.Full text Abstract
1126. UK Health Security Agency. COVID-19: investigation and management of suspected SARS-CoV-2 reinfections. 2021 [internet publication].Full text
1127. Mattiuzzi C, Henry BM, Sanchis-Gomar F, et al. SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis. Acta Biomed. 2020 Sep 7;91(3):e2020014.Full text Abstract
1128. Azam M, Sulistiana R, Ratnawati M, et al. Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. Sci Rep. 2020 Nov 26;10(1):20692.Full text Abstract
1129. SeyedAlinaghi S, Oliaei S, Kianzad S, et al. Reinfection risk of novel coronavirus (COVID-19): a systematic review of current evidence. World J Virol. 2020 Dec 15;9(5):79-90.Full text Abstract
1130. Arafkas M, Khosrawipour T, Kocbach P, et al. Current meta-analysis does not support the possibility of COVID-19 reinfections. J Med Virol. 2021 Mar;93(3):1599-604.Full text Abstract
1131. Vibholm LK, Nielsen SS, Pahus MH, et al. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine. 2021 Jan 30;64:103230.Full text Abstract
1132. Mao YJ, Wang WW, Ma J, et al. Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. Chin Med J (Engl). 2021 Dec 13;135(2):145-52.Full text Abstract
1133. Helfand M, Fiordalisi C, Wiedrick J, et al. Risk for reinfection after SARS-CoV-2: a living, rapid review for American College of Physicians practice points on the role of the antibody response in conferring immunity following SARS-CoV-2 infection. Ann Intern Med. 2022 Jan 25 [Epub ahead of print].Full text Abstract
1134. Wang J, Kaperak C, Sato T, et al. COVID-19 reinfection: a rapid systematic review of case reports and case series. J Investig Med. 2021 Aug;69(6):1253-5.Full text Abstract
1135. Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA. 2020 Oct 6;324(13):1279-81.Full text Abstract
1136. World Health Organization. COVID-19 natural immunity: scientific brief. 2021 [internet publication].Full text
1137. Savage HR, Santos VS, Edwards T, et al. Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021 Jul 8;15(7):e0009551.Full text Abstract
1138. Arkhipova-Jenkins I, Helfand M, Armstrong C, et al. Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review. Ann Intern Med. 2021 Jun;174(6):811-21.Full text Abstract
1139. Flannery DD, Gouma S, Dhudasia MB, et al. Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. JAMA Pediatr. 2021 Jun 1;175(6):594-600.Full text Abstract
1140. Foley MK, Searle SD, Toloue A, et al. Centenarians and extremely old people living with frailty can elicit durable SARS-CoV-2 spike specific IgG antibodies with virus neutralization functions following virus infection as determined by serological study. EClinicalMedicine. 2021 Jun 27:100975.Full text Abstract
1141. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 Aug;26(8):1200-4.Full text Abstract
1142. Alfego D, Sullivan A, Poirier B, et al. A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States. EClinicalMedicine. 2021 May 24:100902.Full text Abstract
1143. Egbert ER, Xiao S, Colantuoni E, et al. Durability of spike immunoglobin G antibodies to SARS-CoV-2 among health care workers with prior infection. JAMA Netw Open. 2021 Aug 2;4(8):e2123256.Full text Abstract
1144. Alejo JL, Mitchell J, Chang A, et al. Prevalence and durability of SARS-CoV-2 antibodies among unvaccinated US adults by history of COVID-19. JAMA. 2022 Feb 3 [Epub ahead of print].Full text Abstract
1145. Centre for Evidence-Based Medicine; Plüddemann A, Aronson JK. What is the role of T cells in COVID-19 infection? Why immunity is about more than antibodies. 2020 [internet publication].Full text
1146. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5;371(6529):eabf4063.Full text Abstract
1147. Shrotri M, van Schalkwyk MCI, Post N, et al. T cell response to SARS-CoV-2 infection in humans: a systematic review. PLoS One. 2021;16(1):e0245532.Full text Abstract
1148. Tarke A, Sidney J, Methot N, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021 Jul 20;2(7):100355.Full text Abstract
1149. Redd AD, Nardin A, Kared H, et al. CD8+ T-cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. Open Forum Infect Dis. 2021 Jul;8(7):ofab143.Full text Abstract
1150. Guo L, Wang G, Wang Y, et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe. 2022 Mar 23 [Epub ahead of print].Full text Abstract
1151. Venet F, Gossez M, Bidar F, et al. T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19. EBioMedicine. 2022 Mar 26;78:103967.Full text Abstract
1152. Petráš M. Highly effective naturally acquired protection against COVID-19 persists for at least 1 year: a meta-analysis. J Am Med Dir Assoc. 2021 Nov;22(11):2263-5.Full text Abstract
1153. Chen Q, Zhu K, Liu X, et al. The protection provided by naturally acquired antibodies against subsequent SARS-CoV-2 infection: a systematic review and meta-analysis. Emerg Microbes Infect. 2022 Feb 23:1-44.Full text Abstract
1154. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021 Apr 17;397(10283):1459-69.Full text Abstract
1155. Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021 Mar 27;397(10280):1204-12.Full text Abstract
1156. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022 Mar 31;22(6):781-90.Full text Abstract
1157. Ridgway JP, Tideman S, Wright B, et al. Rates of COVID-19 among unvaccinated adults with prior COVID-19. JAMA Netw Open. 2022 Apr 1;5(4):e227650.Full text Abstract
1158. Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy. JAMA Intern Med. 2021 Oct 1;181(10):1407-8.Full text Abstract
1159. Doshi P. Covid-19: do many people have pre-existing immunity? BMJ. 2020 Sep 17;370:m3563.Full text Abstract
1160. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020 Dec 11;370(6522):1339-43.Full text Abstract
1161. Vacharathit V, Aiewsakun P, Manopwisedjaroen S, et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis. 2021 Oct;21(10):1352-4.Full text Abstract
1162. Shenai MB, Rahme R, Noorchashm H. Equivalency of protection from natural immunity in COVID-19 recovered versus fully vaccinated persons: a systematic review and pooled analysis. Cureus. 2021 Oct 28;13(10):e19102.Full text Abstract
1163. León TM, Dorabawila V, Nelson L, et al. COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis: California and New York, May – November 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-31.Full text Abstract
1164. Heesakkers H, van der Hoeven JG, Corsten S, et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. JAMA. 2022 Feb 8;327(6):559-65.Full text Abstract
1165. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020 Jul;18(7):1747-51.Full text Abstract
1166. Gendron N, Dragon-Durey MA, Chocron R, et al. Lupus anticoagulant single positivity during the acute phase of COVID-19 is not associated with venous thromboembolism or in-hospital mortality. Arthritis Rheumatol. 2021 Nov;73(11):1976-85.Full text Abstract
1167. Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021 Oct;76(10):970-9.Full text Abstract
1168. Zaffanello M, Piacentini G, Nosetti L, et al. Thrombotic risk in children with COVID-19 infection: a systematic review of the literature. Thromb Res. 2021 Jul 16;205:92-8.Full text Abstract
1169. Centre for Evidence-Based Medicine; Kernohan A, Calderon M. What are the risk factors and effectiveness of prophylaxis for venous thromboembolism in COVID-19 patients? 2020 [internet publication].Full text
1170. Cui LY, Cheng WW, Mou ZW, et al. Risk factors for pulmonary embolism in patients with COVID-19: a systemic review and meta-analysis. Int J Infect Dis. 2021 Aug 18;111:154-63.Full text Abstract
1171. van Nieuwkoop C. COVID-19 associated pulmonary thrombosis. Thromb Res. 2020 Jul;191:151.Full text Abstract
1172. Belen-Apak FB, Sarıalioğlu F. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. J Thromb Thrombolysis. 2020 Aug;50(2):278-80.Full text Abstract
1173. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-73.Full text Abstract
1174. Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. 2020 Aug 25;324(8):799-801.Full text Abstract
1175. Wang C, Zhang H, Zhou M, et al. Prognosis of COVID-19 in patients with vein thrombosis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):10279-85.Full text Abstract
1176. Sabatino J, De Rosa S, Di Salvo G, et al. Impact of cardiovascular risk profile on COVID-19 outcome: a meta-analysis. PLoS One. 2020 Aug 14;15(8):e0237131.Full text Abstract
1177. Jafari-Oori M, Moradian ST, Ebadi A, et al. Incidence of cardiac complications following COVID-19 infection: an umbrella meta-analysis study. Heart Lung. 2022 Jan 10;52:136-45.Full text Abstract
1178. Changal K, Veria S, Mack S, et al. Myocardial injury in hospitalized COVID-19 patients: a retrospective study, systematic review, and meta-analysis. BMC Cardiovasc Disord. 2021 Dec 31;21(1):626.Full text Abstract
1179. Creel-Bulos C, Hockstein M, Amin N, et al. Acute cor pulmonale in critically ill patients with Covid-19. N Engl J Med. 2020 May 21;382(21):e70.Full text Abstract
1180. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020 Apr 10;1-5.Full text Abstract
1181. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27;5(7):1-6.Full text Abstract
1182. Hua A, O'Gallagher K, Sado D, et al. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020 Jun 7;41(22):2130.Full text Abstract
1183. Singh S, Desai R, Gandhi Z, et al. Takotsubo syndrome in patients with COVID-19: a systematic review of published cases. SN Compr Clin Med. 2020 Oct 6:1-7.Full text Abstract
1184. Ammirati E, Lupi L, Palazzini M, et al. Prevalence, characteristics, and outcomes of COVID-19-associated acute myocarditis. Circulation. 2022 Apr 12;145(15):1123-39. Abstract
1185. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020 Jul 1;5(7):831-40.Full text Abstract
1186. Liu PP, Blet A, Smyth D, et al. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020 Jul 7;142(1):68-78.Full text Abstract
1187. Hendren NS, Drazner MH, Bozkurt B, et al. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020 Jun 9;141(23):1903-14.Full text Abstract
1188. Li X, Pan X, Li Y, et al. Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review. Crit Care. 2020 Jul 28;24(1):468.Full text Abstract
1189. Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020 May 14;41(19):1798-800.Full text Abstract
1190. Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022 Feb 7 [Epub ahead of print].Full text Abstract
1191. Raina R, Mahajan ZA, Vasistha P, et al. Incidence and outcomes of acute kidney injury in COVID-19: a systematic review. Blood Purif. 2021 Jun 15:1-14.Full text Abstract
1192. Cai X, Wu G, Zhang J, et al. Risk factors for acute kidney injury in adult patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Dec 6;8:719472.Full text Abstract
1193. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. 2021 [internet publication].Full text
1194. Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. 2021 [internet publication].Full text
1195. Taquet M, Dercon Q, Luciano S, et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021 Sep;18(9):e1003773.Full text Abstract
1196. Wildwing T, Holt N. The neurological symptoms of COVID-19: a systematic overview of systematic reviews, comparison with other neurological conditions and implications for healthcare services. Ther Adv Chronic Dis. 2021 Jan 28;12:2040622320976979.Full text Abstract
1197. Matta J, Wiernik E, Robineau O, et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med. 2022 Jan 1;182(1):19-25.Full text Abstract
1198. Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, et al. Frequency, signs and symptoms, and criteria adopted for long COVID: a systematic review. Int J Clin Pract. 2021 Oct;75(10):e14357.Full text Abstract
1199. Iqbal FM, Lam K, Sounderajah V, et al. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jun;36:100899.Full text Abstract
1200. Aminian A, Bena J, Pantalone KM, et al. Association of obesity with postacute sequelae of COVID-19). Diabetes Obes Metab. 2021 Sep;23(9):2183-8.Full text Abstract
1201. Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med. 2021 Oct;92:55-70.Full text Abstract
1202. Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021 Oct 1;4(10):e2128568.Full text Abstract
1203. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021 Apr;27(4):626-31.Full text Abstract
1204. Office for National Statistics. Technical article: updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. 2021 [internet publication].Full text
1205. Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021 Jul;9(7):747-54.Full text Abstract
1206. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021 Aug 28;398(10302):747-58.Full text Abstract
1207. Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022 May 11 [Epub ahead of print].Full text Abstract
1208. Havervall S, Rosell A, Phillipson M, et al. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. 2021 May 18;325(19):2015-6.Full text Abstract
1209. Augustin M, Schommers P, Stecher M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021 Jul;6:100122.Full text Abstract
1210. Stavem K, Ghanima W, Olsen MK, et al. Persistent symptoms 1.5 to 6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. 2020 Dec 3;76(4):405-7.Full text Abstract
1211. Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021 Mar;110(3):914-21.Full text Abstract
1212. Radtke T, Ulyte A, Puhan MA, et al. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. JAMA. 2021 Jul 15;326(9):869-71.Full text Abstract
1213. Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022 May 18;377:e069676.Full text Abstract
1214. Antonelli M, Pujol JC, Spector TD, et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022 Jun 18;399(10343):2263-4.Full text Abstract
1215. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep. 2022 Jun 23;12(1):9950.Full text Abstract
1216. Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026.Full text Abstract
1217. Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021 Sep;6(9):e005427.Full text Abstract
1218. Zhang X, Wang F, Shen Y, et al. Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Netw Open. 2021 Sep 1;4(9):e2127403.Full text Abstract
1219. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022 May;10(5):311-21.Full text Abstract
1220. Chopra V, Flanders SA, O'Malley M, et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021 Apr;174(4):576-8.Full text Abstract
1221. So M, Kabata H, Fukunaga K, et al. Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis. BMC Pulm Med. 2021 Mar 22;21(1):97.Full text Abstract
1222. Watanabe A, So M, Iwagami M, et al. One-year follow-up CT findings in COVID-19 patients: A systematic review and meta-analysis. Respirology. 2022 Jun 12 [Epub ahead of print].Full text Abstract
1223. Mandal S, Barnett J, Brill SE, et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021 Apr;76(4):396-8.Full text Abstract
1224. Hama Amin BJ, Kakamad FH, Ahmed GS, et al. Post COVID-19 pulmonary fibrosis: a meta-analysis study. Ann Med Surg (Lond). 2022 May;77:103590.Full text Abstract
1225. American Academy of Physical Medicine and Rehabilitation. Multidisciplinary quality improvement initiative. 2022 [internet publication].Full text
1226. Li G, Yang Y, Gao D, et al. Is liver involvement overestimated in COVID-19 patients? A meta-analysis. Int J Med Sci. 2021;18(5):1285-96.Full text Abstract
1227. Bzeizi K, Abdulla M, Mohammed N, et al. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. Sci Rep. 2021 May 19;11(1):10599.Full text Abstract
1228. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United European Gastroenterol J. 2020 Jun;8(5):509-19.Full text Abstract
1229. Sodeifian F, Seyedalhosseini ZS, Kian N, et al. Drug-induced liver injury in COVID-19 patients: a systematic review. Front Med (Lausanne). 2021 Sep 20;8:731436.Full text Abstract
1230. Wong GL, Wong VW, Thompson A, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):776-87.Full text Abstract
1231. Guerrero JI, Barragán LA, Martínez JD, et al. Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings. BMC Infect Dis. 2021 Jun 2;21(1):515.Full text Abstract
1232. Favas TT, Dev P, Chaurasia RN, et al. Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurol Sci. 2020 Dec;41(12):3437-70.Full text Abstract
1233. Sullivan BN, Fischer T. Age-associated neurological complications of COVID-19: a systematic review and meta-analysis. Front Aging Neurosci. 2021 Aug 2;13:653694.Full text Abstract
1234. Chua TH, Xu Z, King NKK. Neurological manifestations in COVID-19: a systematic review and meta-analysis. Brain Inj. 2020 Oct 19:1-20. Abstract
1235. Kubota T, Kuroda N. Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: a systematic review. Clin Neurol Neurosurg. 2020 Nov 1;106349.Full text Abstract
1236. Lu Y, Li X, Geng D, et al. Cerebral micro-structural changes in COVID-19 patients: an MRI-based 3-month follow-up study. EClinicalMedicine. 2020 Aug;25:100484.Full text Abstract
1237. LaRovere KL, Riggs BJ, Poussaint TY, et al. Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol. 2021 May 1;78(5):536-47.Full text Abstract
1238. Lu Y, Zhao JJ, Ye MF, et al. The relationship between COVID-19's severity and ischemic stroke: a systematic review and meta-analysis. Neurol Sci. 2021 Jul;42(7):2645-51.Full text Abstract
1239. Yamakawa M, Kuno T, Mikami T, et al. Clinical characteristics of stroke with COVID-19: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2020 Aug 29;29(12):105288.Full text Abstract
1240. Nannoni S, de Groot R, Bell S, et al. Stroke in COVID-19: a systematic review and meta-analysis. Int J Stroke. 2021 Feb;16(2):137-49.Full text Abstract
1241. Valencia-Enciso N, Ortiz-Pereira M, Zafra-Sierra MP, et al. Time of stroke onset in coronavirus disease 2019 patients around the globe: a systematic review and analysis. J Stroke Cerebrovasc Dis. 2020 Sep 18;29(12):105325.Full text Abstract
1242. Tu TM, Seet CYH, Koh JS, et al. Acute ischemic stroke during the convalescent phase of asymptomatic COVID-2019 infection in men. JAMA Netw Open. 2021 Apr 1;4(4):e217498.Full text Abstract
1243. Ntaios G, Michel P, Georgiopoulos G, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry. Stroke. 2020 Sep;51(9):e254-8.Full text Abstract
1244. Qureshi AI, Abd-Allah F, Alsenani F, et al. Management of acute ischemic stroke in patients with COVID-19 infection: report of an international panel. Int J Stroke. 2020 Jul;15(5):540-54.Full text Abstract
1245. Palaiodimou L, Stefanou MI, Katsanos AH, et al. Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis. Eur J Neurol. 2021 Oct;28(10):3517-29.Full text Abstract
1246. Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021 Apr;268(4):1133-70.Full text Abstract
1247. Siow I, Lee KS, Zhang JJY, et al. Encephalitis as a neurological complication of COVID-19: a systematic review and meta-analysis of incidence, outcomes, and predictors. Eur J Neurol. 2021 Oct;28(10):3491-502.Full text Abstract
1248. Nabizadeh F, Balabandian M, Sodeifian F, et al. Autoimmune encephalitis associated with COVID-19: a systematic review. Mult Scler Relat Disord. 2022 Apr 6;62:103795.Full text Abstract
1249. Hayek SS, Brenner SK, Azam TU, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ. 2020 Sep 30;371:m3513.Full text Abstract
1250. Khan DSA, Hamid LR, Ali A, et al. Differences in pregnancy and perinatal outcomes among symptomatic versus asymptomatic COVID-19-infected pregnant women: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2021 Dec 1;21(1):801.Full text Abstract
1251. Sun S, Savitz DA, Wellenius GA. Changes in adverse pregnancy outcomes associated with the COVID-19 pandemic in the United States. JAMA Netw Open. 2021 Oct 1;4(10):e2129560.Full text Abstract
1252. Huntley BJF, Mulder IA, Di Mascio D, et al. Adverse pregnancy outcomes among individuals with and without severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a systematic review and meta-analysis. Obstet Gynecol. 2021 Apr 1;137(4):585-96.Full text Abstract
1253. Stowe J, Smith H, Thurland K, et al. Stillbirths during the COVID-19 pandemic in England, April-June 2020. JAMA. 2021 Jan 5;325(1):86-7.Full text Abstract
1254. DeSisto CL, Wallace B, Simeone RM, et al. Risk for stillbirth among women with and without COVID-19 at delivery hospitalization: United States, March 2020 – September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640-5.Full text Abstract
1255. Dhir SK, Kumar J, Meena J, et al. Clinical features and outcome of SARS-CoV-2 infection in neonates: a systematic review. J Trop Pediatr. 2021 Jul 2;67(3):fmaa059.Full text Abstract
1256. Allotey J, Chatterjee S, Kew T, et al. SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis. BMJ. 2022 Mar 16;376:e067696.Full text Abstract
1257. Meng X, Zhu K, Wang J, et al. Can SARS-CoV-2 positive pregnant women affect the hearing of their newborns: a systematic review. Am J Otolaryngol. 2022 Jun 2;43(5):103523.Full text Abstract
1258. Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, et al. Coronavirus disease 2019 as cause of viral sepsis: a systematic review and meta-analysis. Crit Care Med. 2021 Dec 1;49(12):2042-57.Full text Abstract
1259. Song JC, Wang G, Zhang W, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020 Apr 20;7(1):19.Full text Abstract
1260. Zhou X, Cheng Z, Luo L, et al. Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thromb Res. 2021 Feb 17;201:23-9.Full text Abstract
1261. Levi M, Iba T. COVID-19 coagulopathy: is it disseminated intravascular coagulation? Intern Emerg Med. 2021 Mar;16(2):309-12.Full text Abstract
1262. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 Jun 4;135(23):2033-40.Full text Abstract
1263. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-9.Full text Abstract
1264. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. Pediatrics. 2020 Jun;145(6):e20200702.Full text Abstract
1265. Jain S, Khanna P, Sarkar S. Comparative evaluation of ventilator-associated pneumonia in critically ill COVID- 19 and patients infected with other corona viruses: a systematic review and meta-analysis. Monaldi Arch Chest Dis. 2021 Sep 28;92(2).Full text Abstract
1266. Singh A, Singh Y, Pangasa N, et al. Risk factors, clinical characteristics, and outcome of air leak syndrome in COVID-19: a systematic review. Indian J Crit Care Med. 2021 Dec;25(12):1434-45.Full text Abstract
1267. Que Y, Hu C, Wan K, et al. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol. 2021 Feb 22;1-14.Full text Abstract
1268. Kunal S, Ish P, Sakthivel P, et al. The emerging threat of multisystem inflammatory syndrome in adults (MIS-A) in COVID-19: a systematic review. Heart Lung. 2022 Mar 14;54:7-18.Full text Abstract
1269. Melgar M, Haston J, DeCuir J, et al. Multisystem inflammatory syndrome in adults (MIS-A): case finding through systematic review of electronic medical records. Clin Infect Dis. 2022 Apr 20 [Epub ahead of print]. Abstract
1270. Abrams JY, Godfred-Cato SE, Oster ME, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review. J Pediatr. 2020 Aug 5;226:45-54.Full text Abstract
1271. Royal College of Paediatrics and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. 2020 [internet publication].Full text
1272. Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). 2020 [internet publication].Full text
1273. Yousaf AR, Cortese MM, Taylor AW, et al. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health. 2022 May;6(5):303-12.Full text Abstract
1274. Ouldali N, Bagheri H, Salvo F, et al. Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study. Lancet Reg Health Eur. 2022 Apr 29:100393.Full text Abstract
1275. Kildegaard H, Lund LC, Højlund M, et al. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study. BMJ. 2022 Apr 11;377:e068898.Full text Abstract
1276. Yasuhara J, Watanabe K, Takagi H, et al. COVID-19 and multisystem inflammatory syndrome in children: a systematic review and meta-analysis. Pediatr Pulmonol. 2021 May;56(5):837-48.Full text Abstract
1277. Rhedin S, Lundholm C, Horne A, et al. Risk factors for multisystem inflammatory syndrome in children: a population-based cohort study of over 2 million children. Lancet Reg Health Eur. 2022 Jun 22 [Epub ahead of print].Full text
1278. Abrams JY, Oster ME, Godfred-Cato SE, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health. 2021 May;5(5):323-31.Full text Abstract
1279. Shaiba LA, More K, Hadid A, et al. Multisystemic inflammatory syndrome in neonates: a systematic review. Neonatology. 2022 May 5:1-13.Full text Abstract
1280. Haghighi Aski B, Manafi Anari A, Abolhasan Choobdar F, et al. Cardiac abnormalities due to multisystem inflammatory syndrome temporally associated with Covid-19 among children: a systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2021 Mar 22:100764.Full text Abstract
1281. Zou H, Lu J, Liu J, et al. Characteristics of pediatric multi-system inflammatory syndrome (PMIS) associated with COVID-19: a meta-analysis and insights into pathogenesis. Int J Infect Dis. 2021 Jan;102:319-26.Full text Abstract
1282. Levy N, Koppel JH, Kaplan O, et al. Severity and incidence of multisystem inflammatory syndrome in children during 3 SARS-CoV-2 pandemic waves in Israel. JAMA. 2022 Jun 28;327(24):2452-4.Full text Abstract
1283. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3. Arthritis Rheumatol. 2022 Apr;74(4):e1-20.Full text Abstract
1284. Davies P, du Pré P, Lillie J, et al. One-year outcomes of critical care patients post-COVID-19 multisystem inflammatory syndrome in children. JAMA Pediatr. 2021 Dec 1;175(12):1281-3.Full text Abstract
1285. Penner J, Abdel-Mannan O, Grant K, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. Lancet Child Adolesc Health. 2021 Jul;5(7):473-82.Full text Abstract
1286. Bilotta C, Perrone G, Adelfio V, et al. COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis. Front Immunol. 2021 Nov 29;12:729251.Full text Abstract
1287. Waqar U, Ahmed S, Gardezi SMHA, et al. Thrombosis with thrombocytopenia syndrome after administration of AZD1222 or Ad26.COV2.S vaccine for COVID-19: a systematic review. Clin Appl Thromb Hemost. Jan-Dec 2021 Jan-Dec;27:10760296211068487.Full text Abstract
1288. Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021 Oct 28;385(18):1680-9.Full text Abstract
1289. World Health Organization. Interim statement of the COVID-19 subcommittee of the WHO global advisory committee on vaccine safety on AstraZeneca COVID-19 vaccine. 2021 [internet publication].Full text
1290. National Institute for Health and Care Excellence. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT). 2022 [internet publication].Full text
1291. Palaiodimou L, Stefanou MI, Katsanos AH, et al. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: a systematic review and meta-analysis. Neurology. 2021 Nov 23;97(21):e2136-47. Abstract
1292. Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, et al. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination: a systematic review. J Neurol Sci. 2021 Aug 3;428:117607.Full text Abstract
1293. Salih F, Schönborn L, Kohler S, et al. Vaccine-induced thrombocytopenia with severe headache. N Engl J Med. 2021 Nov 25;385(22):2103-5.Full text Abstract
1294. Cascio Rizzo A, Giussani G, Agostoni EC. Ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia following COVID-19 vaccine: a case report with systematic review of the literature. Cerebrovasc Dis. 2022 May 5:1-13. Abstract
1295. Kolahchi Z, Khanmirzaei M, Mowla A. Acute ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia post COVID-19 vaccination; a systematic review. J Neurol Sci. 2022 Jun 20;439:120327.Full text Abstract
1296. British Society for Haematology. Guidance from the expert haematology panel (EHP) on Covid-19 vaccine-induced immune thrombocytopenia and thrombosis (VITT). 2021 [internet publication].Full text
1297. American Society of Hematology. Vaccine-induced immune thrombotic thrombocytopenia. 2022 [internet publication].Full text
1298. Furie KL, Cushman M, Elkind MSV, et al; American Heart Association/American Stroke Association Stroke Council Leadership. Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia. Stroke. 2021 Jul;52(7):2478-82.Full text Abstract
1299. International Society on Thrombosis and Haemostasis. The ISTH releases interim guidance on vaccine-induced immune thrombotic thrombocytopenia (VITT). 2021 [internet publication].Full text
1300. Hwang J, Park SH, Lee SW, et al. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score. Eur Heart J. 2021 Oct 14;42(39):4053-63.Full text Abstract
1301. Mitaka H, Kuno T, Takagi H, et al. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. Mycoses. 2021 Sep;64(9):993-1001.Full text Abstract
1302. Wang J, Yang Q, Zhang P, et al. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit Care. 2020 Jun 5;24(1):299.Full text Abstract
1303. Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022 Jan 25 [Epub ahead of print].Full text Abstract
1304. Muthu V, Agarwal R, Patel A, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. Lancet Infect Dis. 2022 Apr 4 [Epub ahead of print].Full text Abstract
1305. Muthu V, Rudramurthy SM, Chakrabarti A, et al. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia. 2021 Dec;186(6):739-54.Full text Abstract
1306. Dulski TM, DeLong M, Garner K, et al. Notes from the field: COVID-19-associated mucormycosis – Arkansas, July–September 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1750-1.Full text Abstract
1307. Pal R, Singh B, Bhadada SK, et al. COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses. 2021 Dec;64(12):1452-9.Full text Abstract
1308. Singh AK, Singh R, Joshi SR, et al. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021 May 21;15(4):102146.Full text Abstract
1309. Indian Council of Medical Research. Evidence based advisory in the time of COVID-19 (screening, diagnosis and management of mucormycosis). 2021 [internet publication].Full text
1310. Arora N, Gudipati A, Kundu R, et al. Post-COVID-19 mucormycosis presenting as chest wall cellulitis with mediastinitis. Lancet Infect Dis. 2021 Nov;21(11):1611.Full text Abstract
1311. Kumar A. Mucormycosis in COVID-19 recovered patients. J Med Virol. 2022 Apr;94(4):1272-3.Full text Abstract
1312. Pruthi H, Muthu V, Bhujade H, et al. Pulmonary artery pseudoaneurysm in COVID-19-associated pulmonary mucormycosis: case series and systematic review of the literature. Mycopathologia. 2022 Feb;187(1):31-7.Full text Abstract
1313. Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 associated pulmonary aspergillosis (CAPA): from immunology to treatment. J Fungi (Basel). 2020 Jun 24;6(2):91.Full text Abstract
1314. Prestel C, Anderson E, Forsberg K, et al. Candida auris outbreak in a COVID-19 specialty care unit: Florida, July – August 2020. MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):56-7.Full text Abstract
1315. Gangneux JP, Dannaoui E, Fekkar A, et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2022 Feb;10(2):180-90.Full text Abstract
1316. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1;159(1):367-70.Full text Abstract
1317. Mutneja HR, Bhurwal A, Arora S, et al. Acute pancreatitis in patients with COVID-19 is more severe and lethal: a systematic review and meta-analysis. Scand J Gastroenterol. 2021 Dec;56(12):1467-72. Abstract
1318. Yang F, Huang Y, Li T, et al. Prevalence and outcomes of acute pancreatitis in COVID-19: a meta-analysis. Gut. 2021 Oct 20 [Epub ahead of print].Full text Abstract
1319. Gubatan J, Levitte S, Patel A, et al. Prevalence, risk factors and clinical outcomes of COVID-19 in patients with a history of pancreatitis in Northern California. Gut. 2021 Feb;70(2):440-1.Full text Abstract
1320. Babajide OI, Ogbon EO, Adelodun A, et al. COVID-19 and acute pancreatitis: a systematic review. JGH Open. 2022 Apr;6(4):231-5.Full text Abstract
1321. Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med. 2020 Sep 19:1-11.Full text Abstract
1322. Aemaz Ur Rehman M, Farooq H, Ali MM, et al. The association of subacute thyroiditis with COVID-19: a systematic review. SN Compr Clin Med. 2021 Apr 29:1-13.Full text Abstract
1323. Tutal E, Ozaras R, Leblebicioglu H. Systematic review of COVID-19 and autoimmune thyroiditis. Travel Med Infect Dis. 2022 Mar 18;47:102314.Full text Abstract
1324. El Moheb M, Naar L, Christensen MA, et al. Gastrointestinal complications in critically ill patients with and without COVID-19. JAMA. 2020 Sep 24;324(18):1899-901.Full text Abstract
1325. Ojha V, Mani A, Mukherjee A, et al. Mesenteric ischemia in patients with COVID-19: an updated systematic review of abdominal CT findings in 75 patients. Abdom Radiol (NY). 2021 Nov 10;1-38.Full text Abstract
1326. Keshavarz P, Rafiee F, Kavandi H, et al. Ischemic gastrointestinal complications of COVID-19: a systematic review on imaging presentation. Clin Imaging. 2020 Dec 8;73:86-95.Full text Abstract
1327. Patel S, Parikh C, Verma D, et al. Bowel ischemia in COVID-19: a systematic review. Int J Clin Pract. 2021 Oct 4:e14930.Full text Abstract
1328. Marasco G, Maida M, Morreale GC, et al. Gastrointestinal bleeding in COVID-19 patients: a systematic review with meta-analysis. Can J Gastroenterol Hepatol. 2021 Sep 1;2021:2534975.Full text Abstract
1329. Chen J, Hang Y. Characteristics, risk factors and outcomes of gastrointestinal hemorrhage in COVID-19 patients: a meta-analysis. Pak J Med Sci. 2021 Sep-Oct;37(5):1524-31.Full text Abstract
1330. Hussain N, Agarwala P, Iqbal K, et al. A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation. J Med Virol. 2022 Apr;94(4):1391-401.Full text Abstract
1331. Christensen RE, Jafferany M. Association between alopecia areata and COVID-19: a systematic review. JAAD Int. 2022 Jun;7:57-61.Full text Abstract
1332. Raschke RA, Agarwal S, Rangan P, et al. Discriminant accuracy of the SOFA score for determining the probable mortality of patients with COVID-19 pneumonia requiring mechanical ventilation. JAMA. 2021 Apr 13;325(14):1469-70.Full text Abstract
1333. George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020 Nov;75(11):1009-16.Full text Abstract
1334. Shah AS, Wong AW, Hague CJ, et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021 Apr;76(4):402-4.Full text Abstract
1335. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2021 Jul-Aug;27(4):328-37.Full text Abstract
1336. Chen M, Liu J, Peng P, et al. Dynamic changes of pulmonary diffusion capacity in survivors of non-critical COVID-19 during the first six months. EClinicalMedicine. 2022 Jan;43:101255.Full text Abstract
1337. Fan G, Tu C, Zhou F, et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. Eur Respir J. 2020 Sep 10;56(3):2002113.Full text Abstract
1338. Zou X, Li S, Fang M, et al. Acute physiology and chronic health evaluation II score as a predictor of hospital mortality in patients of coronavirus disease 2019. Crit Care Med. 2020 May 1;48(8):e657-65.Full text Abstract
1339. Ji D, Zhang D, Xu J, et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. Clin Infect Dis. 2020 Sep 12;71(6):1393-99.Full text Abstract
1340. van Klaveren D, Rekkas A, Alsma J, et al. COVID outcome prediction in the emergency department (COPE): using retrospective Dutch hospital data to develop simple and valid models for predicting mortality and need for intensive care unit admission in patients who present at the emergency department with suspected COVID-19. BMJ Open. 2021 Sep 16;11(9):e051468.Full text Abstract
1341. Liang W, Liang H, Ou L, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020 Aug 1;180(8):1081-9.Full text Abstract
1342. Fumagalli C, Rozzini R, Vannini M, et al. Clinical risk score to predict in-hospital mortality in COVID-19 patients: a retrospective cohort study. BMJ Open. 2020 Sep 25;10(9):e040729.Full text Abstract
1343. Berenguer J, Borobia AM, Ryan P, et al. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax. 2021 Sep;76(9):920-9.Full text Abstract
1344. Department of Health and Social Care. New technology to help identify those at high risk from COVID-19. 2021 [internet publication].Full text
1345. Wongvibulsin S, Garibaldi BT, Antar AAR, et al. Development of severe COVID-19 adaptive risk predictor (SCARP), a calculator to predict severe disease or death in hospitalized patients with COVID-19. Ann Intern Med. 2021 Jun;174(6):777-85.Full text Abstract
1346. Chua F, Vancheeswaran R, Draper A, et al. Early prognostication of COVID-19 to guide hospitalisation versus outpatient monitoring using a point-of-test risk prediction score. Thorax. 2021 Jul;76(7):696-703.Full text Abstract
1347. Yadaw AS, Li YC, Bose S, et al. Clinical features of COVID-19 mortality: development and validation of a clinical prediction model. Lancet Digit Health. 2020 Oct;2(10):e516-25.Full text Abstract
1348. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. BMJ. 2020 Sep 9;370:m3339.Full text Abstract
1349. Knight SR, Gupta RK, Ho A, et al. Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO clinical characterisation protocol. Thorax. 2022 Jun;77(6):606-15.Full text Abstract
1350. Corrao G, Rea F, Carle F, et al. Stratification of the risk of developing severe or lethal Covid-19 using a new score from a large Italian population: a population-based cohort study. BMJ Open. 2021 Nov 18;11(11):e053281.Full text Abstract
1351. Banerjee A, Pasea L, Manohar S, et al. 'What is the risk to me from COVID-19?': public involvement in providing mortality risk information for people with 'high-risk' conditions for COVID-19 (OurRisk.CoV). Clin Med (Lond). 2021 Nov;21(6):e620-8.Full text Abstract
1352. Centers for Disease Control and Prevention. Animals and COVID-19. 2022 [internet publication].Full text
1353. Salman D, Vishnubala D, Le Feuvre P, et al. Returning to physical activity after covid-19. BMJ. 2021 Jan 8;372:m4721.Full text Abstract
1354. Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the Big Ten COVID-19 Cardiac Registry. JAMA Cardiol. 2021 Sep 1;6(9):1078-87.Full text Abstract
Use of this content is subject to our disclaimer